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Abstract 
Background. Clostridium difficile infections (CDI) account for 20-30% of healthcare-acquired 
infections, resulting in serious patient and economic burdens. CDI incidence has grown rapidly 
due to overuse of antibiotics and an aging population, posing a significant public health threat. 
Fecal microbiota transplantation (FMT) using donor stool has demonstrated clinical efficacy 
rates up to 94% and long-term restoration of a healthy intestinal microbiome. Challenges with 
donor screening, lack of research about optimal stool donor characteristics and intestinal 
microbiome composition, and a poorly fit screening model, create barriers to the availability of 
FMT. 
Purpose. This study aimed to generate essential information about FMT donor characteristics 
predictive of passing the screening and donor intestinal microbiome compositions associated 
with FMT clinical efficacy. The primary aims were to 1) identify previously unstudied 
characteristics of prospective FMT donors that are predictive of passing a stool bank’s screening 
process; and 2) determine whether donor intestinal microbial diversity is related to FMT clinical 
efficacy in preventing recurrent CDI.  
Methods. This study was conducted as a secondary analysis on a cohort of previously screened 
donors (n=770). Aim 1 was tested through a logistic regression of donor characteristics (gender, 
age, body mass index, frequency of bowel movements, diet, tobacco and alcohol use, and 
 
 
seasonality) with screening outcomes. Aim 2 was tested through a simple regression evaluating 
donor intestinal microbial diversity and rates of FMT clinical efficacy. 
Results. One donor characteristic in the logistic regression, frequency of bowel movements (p = 
0.018), was significantly predictive of whether a donor passed the screening. Specifically, donors 
who had fewer than two bowel movements per day were more likely to pass. All other 
characteristics were not predictive. Similarly, the linear regression evaluating alpha diversity and 
FMT clinical efficacy was not significantly predictive of clinical efficacy (p = 0.140). 
Conclusion. Findings were used to support recommendations for improving prospective donor 
screening that nurses and other clinicians can implement to decrease challenging logistics, 
reduce costs and barriers, and potentially increase FMT clinical efficacy.
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Chapter 1. Statement of the Problem 
Clostridium difficile infections (CDI) are a global concern and the primary cause of 
diarrhea and colitis in industrialized countries. Over the past decade, the incidence of CDI has 
increased significantly because of factors that reduce the number and diversity of commensal 
intestinal bacteria that normally keep Clostridium difficile in check. The overuse of antibiotics 
that alter the normal intestinal microbiome composition is a well-known contributor to CDI, and 
the problem is compounded by the demographic shift toward older people, whose intestinal 
microbiomes are less diverse than in younger people (Dubberke & Olsen, 2012; Lessa, Winston, 
& McDonald, 2015; McNabb-Baltar, Yaghoobi, O'Byrne, Soulellis, & Trinh, 2013).  
Fecal microbiota transplantation (FMT) utilizing human stool donors has emerged as a 
viable treatment option for recurrent CDI, demonstrating clinical cure in up to 94% of recipients 
(Kassam, Lee, Yuan, & Hunt, 2013; van Nood, Vrieze, et al., 2013) and long-term restoration of 
a recipient’s commensal bacteria and intestinal microbiome composition (Broecker et al., 2013). 
Fecal transplant material from healthy donors with diverse intestinal microbiomes effectively 
inhibits CDI through the recolonization of a patient recipient’s intestines with commensal 
bacteria, thus preventing Clostridium difficile overgrowth and restoring patient health. Despite 
the documented success of FMT, the inability of nurses and other clinicians to expeditiously 
evaluate prospective donors to procure fecal material from healthy donors with consistently high 
rates of clinical efficacy continues to be a major barrier to patient access. As the demand for 
FMT treatments has increased, so has the need to generate knowledge about optimal prospective 
FMT donor characteristics and ideal intestinal microbiome compositions.  
Information about FMT donor characteristics such as gender, diet, and body mass index 
is collected by nurses under the donor screening program currently utilized by the largest 
STOOL DONOR CHARACTERISTICS 
 
2 
international public stool bank located in the United States (U.S.), OpenBiome in Somerville, 
Massachusetts. Despite its availability, this information has not been adequately evaluated for its 
potential impact on the donor screening process, which may contribute to the notably low donor 
acceptance rate of 4%-10% encountered under existing screening programs (L. J. Burns et al., 
2015; Paramsothy et al., 2015). Furthermore, the relationship between the level of bacterial 
diversity of the donor’s intestinal microbiome (as measured by 16S ribosomal ribonucleic acid 
[rRNA] sequencing) that is transplanted during the FMT and clinical efficacy has not been 
examined in sufficiently robust stool donor cohorts. This gap may explain why the clinical 
efficacy of FMT, although high (van Nood, Vrieze, et al., 2013; Youngster et al., 2014), falls 
below 100%. Robust donor screening guidelines that address currently underutilized donor 
characteristics and information about the 16S rRNA level of bacterial diversity of the donor stool 
microbiome have the potential to improve and expedite the FMT donor screening process and 
increase clinical efficacy. These advances could contribute to the goal of reducing patient 
suffering and threats to overall public health posed by CDI.  
The Intestinal Microbiome and Clostridium difficile Infections 
The collective bacteria that live in the human intestines are known as the intestinal 
microbiome. Bacteria that comprise the intestinal microbiome in healthy individuals use various 
strategies to compete for scarce energy resources and maintain a balance in their population 
levels to prevent dominant colonization by any one bacterial species, a phenomenon known as 
colonization resistance. Colonization resistance is an effective protective mechanism that 
prevents overpopulation of disease-causing opportunistic bacteria such as Clostridium difficile. 
However, when perturbations to the intestinal microbiome occur, as when antibiotics eliminate 
critical normal flora, colonization resistance fails and pathogenic bacteria such as Clostridium 
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difficile can thrive and cause disease. Restoring colonization resistance through FMT can be an 
effective strategy for combatting intestinal diseases caused by opportunistic bacteria. 
Fecal Microbiota Transplant as a Potentially Effective Solution 
Fecal microbiota transplantation is an emerging medical intervention where fecal material 
from healthy donors is collected, minimally processed, and then transplanted into patients with 
recurrent CDI who have significantly suppressed intestinal bacteria. Clinically, fecal preparations 
are often infused by physicians either directly into the large intestine via colonoscopy or to the 
small intestine through upper endoscopy. With the recent availability of capsules, fecal 
preparations may now be dispensed for oral delivery under nursing or clinician supervision 
(Samuel, Crumb, & Duba, 2014).  
Although the exact mechanism for how FMT prevents CDI recurrence is not entirely 
understood, transplantation of fecal material from healthy donors is believed to restore the 
intestinal microbiome by preemptively repopulating a CDI patient’s intestines with diverse 
commensal bacteria (Broecker et al., 2013). The bacteria introduced into the patient’s intestines 
via the donor fecal material restore colonization resistance and collectively out-compete and 
exclude pathogenic Clostridium difficile bacteria, thus preventing re-colonization, imbalances in 
the microbiota (called dysbiosis), and disease recurrence. Although the procedure is not new to 
medicine, recent randomized controlled clinical trials have demonstrated resolution rates of 
recurrent CDI in upwards of 94% of patients after one or two FMT treatments utilizing healthy 
donor derived fecal material (van Nood, Vrieze, et al., 2013; Youngster et al., 2014). 
Statement of the Problem  
The recent emergence of a hypervirulent Clostridium difficile strain BI/NAP1/027, an 
aging population at greater risk for intestinal dysbiosis and medical interventions, and continued 
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overuse of antibiotics have led to a rapid increase in demand for safe and efficacious donor fecal 
material to treat recurrent CDI (Borgia, Maraolo, Foggia, Buonomo, & Gentile, 2015; Khoruts & 
Weingarden, 2014). Despite the clinical efficacy of FMT supported within the literature and a 
permissive regulatory environment (Center for Biologics Evaluation and Research, 2013), 
significant barriers to access continue to exist. Impediments to patient access consistently 
reported by nurses and other clinicians are the procedures and costs associated with finding and 
screening suitable donors (Paramsothy et al., 2015). Although basic guidelines for evaluating 
donors for infectious and communicable diseases exist, pertinent donor characteristics purported 
in the literature to directly influence an FMT donor’s health and potentially FMT clinical 
efficacy such as gender, diet, age, and microbiome diversity, have not been well explored and 
thus are not currently evaluated during the prospective FMT screening process. The dearth of 
information, largely precipitated by the lack of sufficiently robust donor cohorts, has created a 
notable patient barrier to safe and efficacious donor fecal material, FMT treatment, and CDI 
cure.  
Significance of the Problem 
Prior to the emergence of the first public stool bank in 2013 in the U.S., FMT donor 
screenings were solely conducted on a one-off basis by nurses and clinicians using a directed 
donor approach with the focus on minimizing the risk of transmitting infectious or 
communicable diseases. Under directed donations, prospective FMT donors are sourced for a 
one-time treatment donation from within the patient’s friends and family network. In the absence 
of consensus guidelines about relevant donor information, prospective donor screening is non-
cohesive and differs notably among clinicians and across institutions. Coupled with clinician and 
patient concerns about the distasteful aspects of the procedure and fear associated with handling 
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fecal material, institutional adoption of FMT has been slow. For these reasons, it has been 
difficult to generate the data needed to make inferences about donor characteristics that would 
support robust guidelines and reduce screening costs.  
With the introduction of the first public stool bank, OpenBiome, the number of donors 
screened has increased dramatically. Despite this increase in donor data, few improvements have 
been made to the current conservative and logistically challenging donor screening approach, 
which continues to be time intensive, conducted over multiple in-person nursing and other 
clinician visits, and requires extensive laboratory screening for infectious and transmissible 
diseases (Bakken et al., 2011). The process, which takes several weeks to complete, has a 
reported 4-10% donor pass rate and deferral rates between 90-96% (L. J. Burns et al., 2015; 
Paramsothy et al., 2015). Additionally, despite the increasing access and affordability of 
microbiome-based genetic sequencing technologies, there is a paucity of current research on the 
intestinal microbiome and the characteristics of the microbiome of transplanted fecal material 
that may predict clinical efficacy of FMT. Thus, evidence to support the clinical utility of 
incorporating information about the donor intestinal microbiome diversity using 16S rRNA 
sequencing analysis during the prospective FMT donor screening process is lacking. Due to this 
lack of exploration of pertinent donor characteristics, such as age, gender, and intestinal 
microbiome, the prospective FMT donor screening approach has not evolved despite indications 
that such knowledge could lead to program tailoring, efficient donor targeting and recruitment, 
and reductions in program costs and treatment delays.  
The current demanding and time-consuming approach to FMT donor screening has a 
negative impact on patient psychosocial well-being and quality of life (Pakyz, Moczygemba, 
VanderWielen, & Edmond, 2016). Patients who choose to use a directed donor approach take on 
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the entire burden of finding a suitable donor. However, under the current approach, ten or more 
prospective donors on average need to be identified by patients and subsequently screened by 
nurses and other clinicians in order to find one that is suitable (Paramsothy et al., 2015). This 
presents practical social and ethical challenges to patients who must disclose their private health 
information to individuals who might not otherwise be aware of the patient’s health status. 
Similarly, FMT donors face social and ethical dilemmas from having to disclose their private 
health and lifestyle information. Anxiety resulting from the discovery of asymptomatic 
communicable diseases or from needing to provide a fecal sample is common among FMT 
donors (Paramsothy et al., 2015). Under these circumstances, finding a suitable family member, 
friend, or acquaintance to donate fecal material can be challenging and have a profound impact 
on CDI patients, requiring more counseling and other time-intensive nursing interventions. 
Once a prospective donor has volunteered, out-of-pocket patient costs associated with 
donor testing and FMT treatment can increase rapidly, creating significant health disparities 
(Pakyz et al., 2016). Laboratory costs alone may surpass $500 per screening and are not 
reimbursable (Helwick, 2015). In cases where pre-screened, anonymous FMT donors from 
public stool banks are used, the patient’s effort to find a suitable donor is reduced. However, 
while public stool banks attempt to minimize the costs of donor recruitment and fecal 
procurement, they encounter the same logistical challenges. Because the costs of finding and 
monitoring FMT donors are absorbed within the operational costs of the public stool bank, any 
inefficiency in donor screening directly impacts the prices public stool banks charge for 
anonymous fecal material. Currently there are no dedicated billing codes to cover fecal material 
from public stool banks or the FMT procedure. As such, patient out of pocket costs for one FMT 
treatment may cost upwards of $10,000 per treatment (Petrof & Khoruts, 2014). This further 
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shifts the burden of living with CDI disease to socially disadvantaged patients who lack 
sufficient economic resources to access FMT as a treatment for CDI. 
Although patients suffering from recurrent CDI tend to be open and receptive to FMT, on 
average, patients wait approximately 7.2 months after diagnosis before receiving an FMT (Pakyz 
et al., 2016). This delay places a significant burden on both the healthcare system and the 
patients who undergo multiple and sometimes continuous long-term antibiotic treatment to avoid 
disease recurrence and mitigate disease progression. The overall cost of treating CDI with 
vancomycin for ten days, the current standard of care, is estimated to be $12,306 per recurrence 
and increases with each recurrence, length of antibiotic treatment, and CDI severity (Stranges, 
Hutton, & Collins, 2013). Recurrent CDI also negatively impacts a patient’s pre-existing 
comorbidities and increases the complexity of disease-appropriate healthcare delivery. As such, 
approximately 29,000 deaths in the U.S. each year are attributed to complications arising from 
CDI infection (Lessa et al., 2015). Further, recurrent CDI has been shown to increase length of 
stay by 2.3 days on average and contribute to an additional 30-60% increase in healthcare costs 
(Dubberke & Olsen, 2012). Delays in access to FMT and CDI cure have a direct and cumulative 
financial and health impact on patients. 
Most notably, the length of time that a patient suffers from CDI poses a significant public 
health threat. When a patient is diagnosed with CDI, the healthcare facility, nurses, and other 
clinicians must initiate stringent isolation and contact precautions, as well as enhanced infectious 
disease control measures to reduce contamination and carriage of Clostridium difficile spores that 
could lead to a CDI outbreak. While patients with CDI invariably spend some time in a hospital 
setting for treatment, much of CDI treatment has shifted to outpatient treatment in primary care 
settings and within the community. The incidence of community-acquired CDI is now estimated 
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to represent 20-40% of all CDI cases (Gupta & Khanna, 2014; Khanna et al., 2012). While 
hospital-acquired CDI tends to affect older patients with significant pre-existing comorbidities, 
the population affected by community-acquired CDI tends to be younger and have lower 
comorbidity scores (Khanna et al., 2012). The ability of CDI to effectively transition over the 
past decade into a new setting and population previously thought to be protected against CDI 
illustrates the challenges that nurses and other clinicians face in combating this robust 
communicable disease in the community and healthcare settings.  
Delays in receiving FMT arising from challenges associated with sourcing suitable 
donors, a lack of safe donor fecal material availability, and high out of pocket medical costs lead 
to significant health and economic burdens for patients, the healthcare industry, and overall 
public welfare. The identification of optimal FMT donor characteristics could provide the 
information needed to improve the prospective FMT donor screening approach and allow for 
better targeting of prospective donors by nurses and other clinicians, thus significantly increasing 
the pass rate and reducing costs associated with recruitment and screening. Knowledge about 
donor 16S rRNA intestinal microbiome bacterial diversity and its relationship with FMT clinical 
efficacy could support the incorporation of intestinal microbiome sequencing as a biomarker 
during prospective FMT donor screening. In turn, the adoption of this technology could help to 
reduce out of pocket screening costs, shorten laboratory testing delays, and increase overall 
clinical efficacy of FMT. Combined, these improvements in the recruitment and screening of 
prospective FMT donors could reduce overall costs and barriers to institutional adoption, 
expedite patient access to FMT treatments, and ultimately reduce the incidence of CDI.  
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Purpose of the Study 
The first purpose of this study was to identify additional, previously unstudied 
characteristics of prospective FMT donors that are predictive of passing a public stool bank’s 
current screening process. FMT donor characteristics included in this analysis were donor’s 
gender, age, body mass index, frequency of bowel movements, diet, alcohol and tobacco use, and 
seasonality based on the screening date. This study also characterized the 16S rRNA intestinal 
microbiome composition of stool from FMT donors that passed from the prospective to the 
active donor phase of the stool bank’s FMT screening program. Hence, the second purpose of 
this study was to determine whether the microbial diversity of active FMT donor stool, as 
measured by 16S ribosomal ribonucleic acid, is related to FMT clinical efficacy, as measured by 
the recipient’s clinical cure. The data for these analyses were on file and sourced from 
OpenBiome and were made available to the researcher.  
Specific Aims 
The specific aims of this secondary data analysis were to:  
1. Identify additional, previously unstudied characteristics of prospective FMT 
donors that are predictive of passing a public stool bank’s current screening 
process. 
2. Determine whether the microbial diversity of active FMT donor stool, as 
measured by 16S ribosomal ribonucleic acid, is related to FMT clinical efficacy, 
as measured by the recipient’s clinical cure.  
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Definition of Terms 
The following section clarifies important terms that were relevant to the implementation 
of this study. Theoretical and operational definitions for prospective FMT donor characteristics 
used for this study are defined in the methods section. 
Prospective Donor. An individual who has expressed interest in donating fecal material 
for use in FMT and has demonstrated a willingness to complete the FMT donor screening 
process (World Health Organization, 2012).  
Deferred Donor. A prospective donor who was postponed from donating material due to 
not passing at least one component of the FMT donor screening program, during either the health 
assessment or laboratory screening, and was deemed ineligible to donate fecal material to treat 
recurrent CDI at the time of screening (World Health Organization, 2012). 
Active Donor. A prospective donor who has passed all the criteria of the donor screening 
program, including both the health assessment and laboratory screening, and has been deemed 
eligible to donate fecal material to treat recurrent CDI at the time of screening. Active donors are 
assumed to have a low risk of transmitting diseases and have been cleared to contribute 
biological tissue for transfusion or transplantation (World Health Organization, 2012). 
Microbiota. The collection of microorganisms that colonize a particular environment, 
such as the intestinal microbiota (Eloe-Fadrosh & Rasko, 2013).  
Microbiome. The collective genetic make-up of the bacterial inhabitants or microbiota 
that constitute a particular habitat or ecosystem, such as the intestinal microbiome (Eloe-Fadrosh 
& Rasko, 2013). 
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Phylum. A top level taxonomic rank or relative level for bacteria in the biological 
classification system. Immediately follows the Bacteria/Eubacteria kingdom and is above 
bacterial class (Tyler, Smith, & Silverberg, 2014). 
Species. The basic unit or taxonomic rank for bacteria in the biological classification 
system based on a microbe’s 16S ribosomal ribonucleic acid (rRNA) sequence (Tyler et al., 
2014).  
16S Ribosomal Ribonucleic Acid (rRNA). The highly conserved molecular genetic 
sequence component of the 30S ribosome that allows bacteria to be to identified and categorized 
into their representative phylogenetic classifications (Tyler et al., 2014).  
Alpha Diversity (a.k.a. Microbial Diversity, Bacterial Diversity, Diversity). The mean 
diversity of the microbiome within a sample as measured by the richness and evenness of the 
microbiota (Tyler et al., 2014). 
Beta Diversity. The degree of bacterial differentiation within the intestinal microbiome 
as measured by ratios, principal coordinates, and analysis plots (Tyler et al., 2014). 
Dysbiosis. Defined as an imbalance in the microbiota resulting in diminished 
colonization by commensal bacteria that are normally present and an overabundance in 
colonization by potentially pathogenic non-commensal bacteria (Eloe-Fadrosh & Rasko, 2013). 
Clinical Efficacy. The clinical efficacy in terms of recurrent CDI is the overall measure 
in percent of how effective an active donor’s FMT material is at preventing CDI recurrence 
within the eight weeks post-intervention. The rate is most frequently provided as an overall 
percentage for all FMT treatments or as an individual percentage by FMT donor (Osman et al., 
2016).  
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Clinical Cure. Clinical cure in the case of recurrent CDI is defined as the complete 
resolution of recurrent CDI symptoms for at least eight weeks post-procedure. Clinical cure is 
defined as a yes or no dichotomous outcome variable and established during the 8-week post-
procedure physician follow-up assessment (Cohen et al., 2010; Surawicz et al., 2013). 
Assumptions Based on Existing Knowledge 
The following assumptions underpin this study: 
1. Prospective FMT donors accurately reported demographic and clinical data and 
accurately answered the screening questions.  
2. Active FMT donors who passed the prospective FMT screening program donated the 
fecal material collected. 
3. The 16S rRNA methodology used to characterize the intestinal microbiome of FMT 
donors was the best technological option for differentiating between bacterial species 
within the FMT donor fecal material.  
4. The FMT donor data were accurately recorded in the stool bank data repositories by the 
study staff.  
5. The current approach used by the public stool bank for screening FMT donors effectively 
selected donors with safe and efficacious fecal material. 
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Chapter 2. Conceptual Framework and Review of the Literature 
 The previous chapter illustrated the significance of Clostridium difficile infections (CDI) 
and described how this study aimed to build knowledge that would improve the efficiency of 
treating this serious patient and public health problem. The following chapter presents the 
theoretical and conceptual framework as proposed by Eloe-Fadrosh and Rasko (2013) that was 
used to guide this study. Attention is placed on explaining the relationships among the human 
host, environment, and microbiota as they are expressed in healthy patients and in patients 
suffering from recurrent Clostridium difficile infections. The rationale for choosing this 
conceptual framework will be illustrated through its application within the pathophysiological 
process observed before and after fecal microbiota treatment (FMT) delivery in patients suffering 
from recurrent CDI. This chapter also aims to provide an overview of the existing literature and 
evolution of FMT as they relate to the variables of interest in this study. The literature review 
will highlight areas where the research currently falls short both conceptually and 
methodologically and how this study aimed to address these gaps. 
Conceptual Framework  
The theoretical and conceptual underpinnings for this study were drawn from a 
conceptual framework presented by Eloe-Fadrosh and Rasko (2013), which explains the 
relationships among host, environmental, and microbiota features (Figure 1). This ecologically 
based framework provides a model for explaining how the characteristics of donors of FMT 
material, along the donor’s environment and intestinal microbiome, interact and influence each 
other to promote a symbiotic and homeostatic intestinal fecal microbiome conducive to host 
health. This model also explains how colonization by Clostridium difficile bacteria perpetuates 
host disease in affected patients and presents a plausible framework for how fecal transplant 
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material from healthy donors is likely to be effective in preventing the recurrence of CDI in 
patient recipients.  
Figure 1.  
Conceptual underpinnings 
 
Figure 1. Framework demonstrating interactions among host, environmental, and 
microbiota features that promote patient health or lead to disease. Adapted from Eloe-
Fadrosh, E. A., & Rasko, D. A. (2013). The human microbiome: From symbiosis to 
pathogenesis. Annual Review of Medicine, 64, 145-163. doi:10.1146/annurev-med-
010312-133513. 
 
Interactions among Host, Environmental, and Microbiota Features. Emerging 
research in ecology and medicine has demonstrated how the perspective of the host as the 
dominant influence in health and disease has evolved to view the host as one of several active 
participants. Equally important are environmental and microbiota features that collaboratively 
interact and work together with the host in a complex ecosystem to promote health or influence 
disease development (Costello, Stagaman, Dethlefsen, Bohannan, & Relman, 2012). Rather than 
view each feature independently, the ecological perspective perceives all features as having a 
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collective role in promoting host health or disease that is uniquely shaped by the factors that 
impact each of them directly. 
The host’s environment provides frequent exposure to factors that influence the 
composition of the intestinal microbiome on a daily basis. Host diet and nutrient consumption in 
particular, play an important role in defining microbial exposure and nutritional state. What the 
host consumes is further influenced by factors including the availability and accessibility of food 
and nutrients. In turn, these factors shape the intestinal ecosystem by providing microbial 
exposure and nutrient support that results in a tailored intestinal microbiome. Researchers are 
finding that colonization of the human host intestinal microbiome is not solely dependent on the 
environment and not entirely stochastic (Christian, Whitaker, & Clay, 2015; Costello et al., 
2012). Alternatively, host specific factors, including genetics, gender, and stress influence the 
intestinal ecosystem and promote colonization by certain microbes to a much greater extent than 
previously perceived.  
The host, environment, and microbiota features interact holistically to contribute to host 
health and disease prevention. One of the primary ways in which this complex ecosystem helps 
promote host health is by facilitating intestinal colonization resistance. Homeostatic community 
assemblage of the intestinal microbiome creates bacterial interference, which allows resident 
microbiota to hinder localized growth by potentially infectious exogenous microorganisms. The 
process of developing intestinal colonization resistance is highly influenced by the host, 
environment, and microbiota features. 
Establishment of Intestinal Colonization Resistance. The intestinal microbiota is most 
recognized for helping to facilitate digestion and nutrition. However, research has shown that 
these intestinal microbes also play a critical role in health promotion and infectious disease 
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prevention through the development of colonization resistance (Tourneur & Chassin, 2013). 
Colonization resistance is established during community assemblage as intestinal bacteria 
interact with the human host to trigger immune mediated responses. This bi-directional 
communication leads to either host recognition of commensal bacteria or a host mediated 
immune response to pathogens. In turn, this process facilitates an intestinal ecosystem that 
promotes optimal colonization by microbes capable of independently mounting a localized 
competitive bacterial response and providing interference against invasive foreign organisms 
(Tourneur & Chassin, 2013).  
Community assemblage of the intestinal microbiome is most pronounced during birth 
when newborns are exposed through the environment to a significant number of microbes. These 
microorganisms shape the newborn intestinal microbiome and are influenced by whether the 
birth was vaginal or by cesarean section (Dominguez-Bello et al., 2010). While the intestinal 
microbiome continues to fluctuate during infancy in response to distinct events, such as 
development related changes in diet, the intestinal microbiome generally stabilizes by two years 
of age to reflect an adult-like composition (Eloe-Fadrosh & Rasko, 2013). After that, 
colonization resistance is generally stable but continues to be influenced by aberrations in 
microbiome, host, and environmental interactions that directly impact host health.  
The intestinal microbiome promotes colonization resistance throughout the host’s life by 
utilizing several bacterial interference approaches. In addition to triggering the host’s innate 
immune system in response to new or foreign pathogens (Corthesy, Gaskins, & Mercenier, 
2007), bacteria that typically comprise the intestinal microbiome of healthy individuals compete 
directly with foreign microbes for scarce energy, resources, and space (Bernet-Camard et al., 
1997). These processes skew the intestinal ecosystem toward an environment that impedes 
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colonization by opportunistic microbes (Chan, Reid, Irvin, Bruce, & Costerton, 1985). 
Commensal bacteria are also known to produce bactericidal proteins within the intestinal lumen 
that act locally to prevent colonization by competing bacteria (Brook, 1999). Once a healthy 
homeostatic intestinal ecosystem is in place, the symbiotic intestinal relationship between host 
and microbiome promotes a competitive and diverse microecosystem comprised of over 1,000 
different species and dominated by bacteria from several different phyla including Firmicutes, 
Bacteroides, and Actinobacteria (Tuddenham & Sears, 2015). This diversity makes it 
challenging for any single potentially antagonistic organism to predominate and cause 
symptomatic intestinal disease in healthy hosts (Falagas, Rafailidis, & Makris, 2008).  
In general, intestinal microbiome colonization and immune system development and 
function are robust to environmental insult. Symbiotic interactions among host, environment, and 
microbial features are designed to support intestinal colonization by a diverse microbiome, 
which in turn leads to colonization resistance and bacterial interference against potentially 
infectious pathogens. However, when disruptions to the symbiotic intestinal ecosystem occur, 
intestinal homeostasis and immune expression are hindered and can result in intestinal dysbiosis 
and disease development. Factors such as phenotypic expression of heritable diseases, extreme 
changes in diet, or recent use of antibiotics can lead to perturbations in the intestinal microbiome. 
These factors can also trigger a cascade of disruptions that span host, environment, and microbial 
features resulting in intestinal dysbiosis and increased susceptibility to disease. For example, a 
tooth abscess in the host may impact nutritional intake and require antibiotic intervention leading 
to disruption in intestinal colonization resistance. Sufficient perturbations to the intestinal 
microbiome, such as those observed with antibiotic use, may result in suboptimal bacterial 
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interference. This in turn places the host at an increased risk for colonization by opportunistic 
pathogens and disease development, such as Clostridium difficile related infections.  
Application of Conceptual Framework to Clostridium difficile Infections 
The Clostridium difficile bacterium is a pernicious pathogen that leads to infectious 
diarrhea and colitis. Although infections caused by the Clostridium difficile bacterium are not 
new to healthcare, the incidence and severity of CDI have increased over the past decade (Borgia 
et al., 2015; Khoruts & Weingarden, 2014). Each year, over 453,000 new cases of CDI are 
diagnosed in the United States (U.S.), of which approximately 83,000 are repeat occurrences due 
to failed antibiotic treatment (Lessa et al., 2015). Primary risk factors for CDI include 
physiological states or medical interventions that decrease intestinal bacterial diversity, such as 
antimicrobial use (Khanna et al., 2012). These risk factors impact host immune response, reduce 
bacterial interference, and present an opportunity for colonization by potentially pathogenic 
Clostridium difficile spores.  
 At any point in time, approximately 1-3% of the adult population is colonized by 
Clostridium difficile microbes (Ozaki et al., 2004). However, as an opportunistic bacterium, 
Clostridium difficile bacteria do not typically cause disease in healthy adults with intact 
colonization resistance (Rea et al., 2012). Bacterial interference mounted by resident microbes in 
a healthy and diverse intestinal ecosystem hampers active colonization by Clostridium difficile 
bacteria and its ability to multiply and cause a disease state. In spore form however, Clostridium 
difficile is resistant to intestinal bacterial interference, antibiotics, and most hospital disinfectants. 
This allows Clostridium difficile spores to reside dormant in the intestines and on surfaces for 
prolonged periods of time, in wait for an environment that is conducive to growth (Khan & 
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Cheesbrough, 2003). Figure 2 provides an overview of the cycle of CDI infection and recurrence 
within the context of intestinal microbiome colonization resistance.  
Figure 2.  
Cycle of Clostridium difficile infection and recurrence 
 
Figure 2. Repeated antibiotic use alters the patient’s intestinal microbiome, setting up an 
environment that is permissive to colonization and repeat infection by Clostridium 
difficile. Adapted from Britton and Young (2014). Role of the intestinal microbiota in 
resistance to colonization by Clostridium difficile. Gastroenterology, 146(6), 1547-1553. 
doi:10.1053/j.gastro.2014.01.059 
 
Disruption of the normal intestinal microbiome as a result of medical interventions, such 
as antibiotics, creates dysbiosis of the intestinal microbiota. This breakdown in colonization 
resistance places the host at increased risk for colonization by opportunistic pathogens. 
Clostridium difficile, a bacillus shown to survive in spore form for up to three months on 
surfaces, is transmitted via the fecal-oral route and is capable of surviving the acidity of the 
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stomach. Infectious diarrhea and colitis occur when Clostridium difficile spores that have been 
ingested by an individual encounter a perturbed intestinal microbiome where bacterial 
interference is compromised. Under this opportune condition, the Clostridium difficile spores 
germinate and quickly colonize the large intestine with little resistance. Clostridium difficile 
begins producing endotoxins that further skew the intestinal environment toward its benefit, 
creating an environment unfavorable to colonization by commensal bacteria. The resulting 
infection can range from mild diarrhea and abdominal pain to severe pseudomembranous colitis, 
toxic megacolon, sepsis, and death.  
For 94% of inpatient and 78% of outpatient CDI cases, exposure to antibiotics occurs 
within the 90 days prior to diagnosis (Weissman & Coyle, 2012). Despite the association, 
antibiotics have remained one of the few available options for treating infections caused by 
Clostridium difficile bacteria. The aim of antibiotic use is to suppress the growth of Clostridium 
difficile bacteria and reduce the production of endotoxins that produce localized inflammation 
and exacerbate CDI. For approximately 80% of patients with a first episode of CDI, antibiotics 
are successful at eradicating the disease (Kelly, de Leon, & Jasutkar, 2012). However, antibiotics 
also indiscriminately target critical commensal intestinal bacteria, making it difficult for the host 
to restore colonization resistance. Because antibiotics are not capable of clearing residual 
Clostridium difficile spores, these spores remain dormant in the intestines and convert into the 
disease-causing vegetative state once the antibiotic has been cleared from the patient’s system. 
This allows the Clostridium difficile bacterium to take advantage of the sustained dysbiotic 
intestinal environment and cause recurrence before commensal bacteria can repopulate and 
restore colonization resistance (McFarland, 2012). For the remaining 20% of first episode CDI 
patients treated with antibiotics, recurrence of disease occurs within eight weeks after antibiotic 
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treatment and is associated with a notably higher 40% chance of recurrence driven by prolonged 
intestinal dysbiosis (Kelly et al., 2012). The risk for recurrence rises further to over 60% for 
patients who fail two or more rounds of CDI antibiotic based interventions.  
Use of repetitive and continuous antibiotic regimens to treat recurrent CDI leads to a 
notable loss of intestinal microbial diversity and colonization resistance. After repeated use, 
patients treated with antibiotics for recurrent CDI develop an intestinal microbiome that is 
perpetually reduced in overall intestinal microbial richness and diversity. Most notably, 
commensal bacteria from the Bacteroides and Firmicutes phyla that are usually plentiful in a 
healthy intestinal ecosystem are significantly reduced as a group in patients with recurrent CDI 
(Chang et al., 2008). As a result, repetitive use of antibiotics to treat recurrent CDI irreparably 
perturbs overall microbial density and alters the entire intestinal ecosystem long-term (Vincent & 
Manges, 2015), hindering the ability of the host to restore colonization resistance and 
perpetuating the cycle of recurrence observed with CDI.  
Restoration of Intestinal Colonization Resistance by Fecal Transplants. Although 
fecal material has been used for centuries to treat intestinal related diseases (Zhang, Luo, Shi, 
Fan, & Ji, 2012), the use of human fecal material to successfully cure pseudomembranous colitis 
associated with CDI was first reported in the medical literature in 1958 (Eiseman, Silen, Bascom, 
& Kauvar, 1958). More recently, with the advent of genetics sequencing technologies and 
increased knowledge about the human intestinal microbiome, FMT has emerged as a viable 
restorative treatment for patients who experience recurrent CDI. The primary aim of FMT is to 
impede Clostridium difficile reinfection by quickly restoring intestinal colonization resistance 
post-antibiotic treatment. Fecal transplants encompass the infusion of homogenized and 
unfiltered human fecal material from either directed donors i.e., a donor known to the patient, or 
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anonymous donors. The fecal transplant preparation is infused directly into the colon or 
delivered to the small intestines through upper endoscopy or capsules within two to three days 
after completion of antibiotics.  
Post-transplant, the recipient’s intestinal microbiome quickly repopulates and begins to 
resemble a diverse community composed of both the recipient and donor’s microbiome (Seekatz 
et al., 2014). By 14 days post-transplant, bacteria from the Bacteroides phylum and butyrate 
producing bacteria known to be associated with intestinal health are found to dominate the 
intestines (Khoruts, Dicksved, Jansson, & Sadowsky, 2010). Corresponding with intestinal re-
colonization, recipients report gradual improvement and subsequent resolution in diarrhea, 
bloating, and abdominal pain within one to four weeks of FMT treatment (Brandt et al., 2012). 
Recipients that experienced fatigue, anorexia, and loss of appetite during active CDI report 
improvement in energy, the restoration of appetite, and resumption of a normal diet, all of which 
further support overall well-being and host health. The competitive commensal microbes 
introduced by fecal material from donors restore colonization resistance and inhibits the growth 
of Clostridium difficile bacteria and prevent reinfection. In association with the restoration of 
overall host well-being and environmental features that promote host health, commensal 
microbes restore long-term intestinal microbial stability that results in symptom resolution and 
clinical cure.  
Review of the Literature 
Clinical Efficacy of Fecal Microbiota Transplant. Since 1958, several case series, 
meta-analyses, and two randomized controlled clinical trials have published evidence supporting 
the clinical efficacy of FMT in preventing recurrent CDI (Brandt et al., 2012; Kassam et al., 
2013). More recently in 2013, van Nood and colleagues presented results from one of two 
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randomized controlled trials comparing the clinical efficacy of fresh fecal microbiota 
preparations from anonymous donors with the current standard of care antibiotic treatment for 
recurrent CDI. Interim data analysis suggested resolution rates of up to 94% in the FMT 
intervention group, compared to 31% or less in the standard of care groups, prompting early 
termination of the clinical trial (van Nood, Vrieze, et al., 2013). In 2014, Youngster and 
colleagues utilized frozen fecal material from anonymous donors to successfully treat patients 
with recurrent CDI demonstrating a clinical efficacy rate of 90% (Youngster et al., 2014). 
Smaller randomized controlled studies performed in notoriously difficult to treat population 
subgroups, such as immunocompromised or severe-complicated recurrent CDI, similarly 
reported high levels of clinical efficacy (Kelly et al., 2014).  
While the rates of clinical efficacy for FMT reported in the literature can be high, FMT 
has been found to fail to prevent the recurrence of CDI in anywhere from 2.1% to 35.7% of 
patient cases (Fischer et al., 2016; Kassam et al., 2013). In a smaller percentage of patients, FMT 
is entirely ineffectual in preventing CDI despite repeated treatments (Fischer et al., 2016). The 
explanation for the less than 100% clinical efficacy rate of FMT in preventing CDI recurrence is 
uncertain and published literature that purports to explain this finding is limited. However, 
clinicians and researchers postulate that the rationale for the failure may be multifactorial, 
whereby donor features such as intestinal microbiome composition may be influential. In a 
retrospective cohort study of 201 subjects conducted in the U.S. in which 12.4% patients 
experienced CDI recurrence post procedure, FMT failure was found to be positively correlated 
with the number of FMTs received. This finding indicated that as the number of FMT treatments 
increased, the higher the likelihood of CDI recurrence (Meighani et al., 2016). This finding 
prompted the investigators to advise that a second FMT using an alternative donor be considered 
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in the case of FMT failure. Other smaller studies have similarly found that a second FMT 
treatment utilizing material from a donor presumably possessing a different intestinal microbial 
composition has resulted in CDI cure in patients where recurrence of CDI occurred post-
procedure (van Nood, Dijkgraaf, & Keller, 2013). Findings presented by Fischer and colleagues 
(2016) identified a number of patient recipient factors that appeared to be predictive of FMT 
failure, including the patient’s severity of CDI and FMT performed as an inpatient. However, no 
donor characteristics were considered as part of this study, which was noted by the investigators 
to be a limitation. Although the findings of these studies were informative to clinical practice, 
neither FMT donor characteristics nor the intestinal microbiome composition of the donor were 
evaluated to assess their potential impact on the clinical efficacy of FMT.  
Despite the suggestions in the literature that donor intestinal microbiome composition 
and diversity may increase the clinical efficacy of FMT, little research has been done to address 
this gap in knowledge. The difficulty in fully understanding potential contributors to FMT failure 
was echoed in Kassam and colleagues’ meta-analysis on the use of FMT in the treatment of 
recurrent CDI (Kassam et al., 2013). While the review found no clinical difference in overall 
clinical efficacy rates between anonymous versus directed donors, the authors did find 
significant disparity in the donor screening approach used by clinicians and noted that this may 
account for the lower clinical efficacy rates observed in some studies. As part of the conclusion, 
the investigators reiterated the need for guidance and greater standardization of donor screening 
to ensure the maximum likelihood of procuring both safe and efficacious donor fecal material.  
 Introduction of Fecal Microbiota Donor Screening Programs. Because of the high 
rates of FMT clinical efficacy and clinical expert testimony demonstrating patient need for FMT, 
in 2013 the U.S. Food and Drug Administration (FDA) chose to take an enforcement discretion 
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approach to regulating the use of FMT despite the U.S. FDA’s classification of FMT as an 
experimental drug. The policy effectively allows clinicians to administer FMT for recurrent CDI 
as long as the patient is properly consented. As the use of FMT has grown under this permissive 
regulatory environment, so has the importance of finding suitable, healthy FMT donors that can 
contribute clinically efficacious fecal material. However, the process to implement such a 
program by healthcare facilities, public stool banks, and clinicians has been difficult and 
unpredictable.  
The inconsistencies encountered among FMT donor screening programs create a 
significant impediment to FMT for both clinicians and patients. Nurses have an important role in 
the execution of many of the FMT donor screening program operational procedures and FMT 
delivery. These activities include championing institutional adoption, facilitating donor 
assessments and laboratory screenings, reviewing donor eligibility, procuring fecal material, and 
assisting in endoscopy or providing patient treatment directly through enema or capsules 
(Samuel et al., 2014). A recent study by Brumbaugh and colleagues (2017) presented the 
findings of a successful implementation of a nurse-led intragastric pediatric FMT program, 
demonstrating both economic benefits and efficacious FMT outcomes in line with the literature.  
Because FMT is a relatively new procedure, however, most healthcare facilities lack the 
protocols needed to handle the donor screening and procurement of fecal material. The 
challenges with implementing FMT as a treatment option were elucidated by a nurse who 
chronicled the steps she went through to facilitate the first FMT within her hospital (Myers, 
2015). Among several barriers identified, a knowledge deficit about effective donor screening 
criteria and burdensome U.S. FDA recommendations were highlighted. As a result, the methods 
utilized by healthcare facilities, researchers, and stool banks to develop FMT donor screening 
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programs have varied widely from simple clinician-guided individual donor screenings to full 
ethics board approved investigational drug research protocols (Bafeta, Yavchitz, Riveros, 
Batista, & Ravaud, 2017). Referred to as “heterogeneity in FMT protocols,” Brumbaugh and 
colleagues acknowledged this phenomenon as a significant gap in clinical care and opportunity 
for improvement (Brumbaugh et al., 2017).  
Adoption of a Risk Reduction Based Approach to Donor Screening. Much of the 
uncertainty and disparity across FMT programs has been driven by a lack of informative research 
on donor features, such as donor age or the donor microbiome, that are most pertinent to assess 
during the screening process. A recently published systematic review by Bafeta and colleagues 
(2017) on FMT donor screening approaches utilized by FMT clinical research trials substantiated 
the persistent lack of description of methodological components in sourcing fecal material (up to 
89% of studies reviewed) and general guidance on donor screening methods (up to 98%). To 
address the gap in guidance, in 2011 the American Gastroenterology Association (AGA) FMT 
Working Group, in collaboration with the U.S. FDA, published a document outlining suggested 
minimum criteria to utilize in the screening of donors and administration of FMT within clinical 
practice (Bakken et al., 2011). The group suggested the adoption of a risk reduction approach to 
donor screening, similar to the approached presently utilized by blood banks (Center for 
Biologics Evaluation and Research, 2007) and in compliance with the U.S. FDA Title 21 Code 
of Federal Regulations (CFR). Under Title 21 CFR, subpart 1271, clinicians that screen 
biological material donors, such as blood and stool, must ensure that only material that is free of 
infectious and communicable disease is used. As such, donors are required to be healthy, at low 
risk for infectious disease, and demonstrate no clinical disease symptoms (Department of Health 
and Human Services, 2017). Noting the lack of data to support the recommendation for 
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considering other donor factors in the screening process, such as donor fecal microbiome 
composition and diversity, the American Association of Blood Bank’s (AABB) Donor Health 
Questionnaire (DHQ) and laboratory based testing protocols were proposed as a template to 
evaluate prospective FMT donors (Bakken et al., 2011).  
The primary rationale for utilizing a risk reduction approach to screening prospective 
FMT donors is to provide a way for nurses and other clinicians to identify as early as possible 
any risks for transmitting an infectious disease through donor stool. To accomplish this goal, 
clinicians are advised to select donors that are in good health and demonstrate a near zero risk for 
infectious disease. As such, every step in the risk reduction based prospective FMT donor 
screening program is designed to test donor characteristics against an exclusionary criterion. For 
example, like the blood donor risk reduction model, specific social and lifestyle behaviors that 
may indicate a donor has a higher risk for infectious or communicable disease, such as recent 
travel to countries where communicable diseases are prevalent, use of illicit drugs, and high-risk 
sexual behaviors, are also considered exclusionary under the FMT donor screening program.  
Prospective FMT donors however, undergo more extensive in-person screenings than 
blood donors and meet with multiple clinicians, including nurses, who assist in making the 
determination as to the suitability of the donor’s fecal material. For example, FMT donors with 
gastrointestinal issues (i.e., recurrent diarrhea or constipation) or recent clinical interventions that 
are known to perturb the intestinal microbiome (i.e., recent use of antibiotics) are excluded. 
Although long-term correlational data about the role of the intestinal microbiome on health and 
disease is limited, there is evidence to suggest that a dysbiotic intestinal microbiome is 
associated with certain chronic diseases, such as inflammatory bowel disease (IBD), intestinal 
malignancy, and obesity (Penders, Stobberingh, van den Brandt, & Thijs, 2007; D. A. Peterson, 
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Frank, Pace, & Gordon, 2008; Turnbaugh & Gordon, 2009). As such, prospective FMT donors 
with any history or clinical evidence for chronic gastrointestinal diseases are excluded based on 
the assumption that the dysbiotic fecal material may trigger the development of these chronic 
diseases in the recipient of the transplant material (Turnbaugh, Backhed, Fulton, & Gordon, 
2008). Upon completion of the stool bank DHQ, clinicians perform in-person health exams and 
clinical interviews to ensure the accuracy of the donor’s answers to the stool bank DHQ. Once a 
prospective FMT donor passes the risk assessment portion of the screening, prospective FMT 
donors undergo serological and stool laboratory testing (described in more detail in Chapter 3) 
for infectious diseases that may be transmissible through stool.  
Fecal Donor Screening Pass and Deferral Rates. While the proposed risk reduction 
model, Blood Bank DHQ, and blood bank laboratory testing protocols provided a starting point 
for screening prospective FMT donors, the FMT screening program quickly became overly 
burdensome and inefficient for nurses and other clinicians to utilize due to the inherent risks 
associated with transplanting unprocessed fecal material. The use of this highly conservative, 
expansive, and logistically challenging risk reduction approach for assessing the suitability of 
prospective FMT donors is time-consuming, conducted over multiple in-person visits, requires 
completion of extensive laboratory testing, and takes several weeks to complete (Bakken et al., 
2011). Ultimately, the increased complexity of the FMT donor screening programs when applied 
to the general population reports donor pass rates between 4-10%, and deferral rates between 90-
96% (L. J. Burns et al., 2015; Paramsothy et al., 2015). While the risk reduction approach was 
important to provide a process for screening out infectious diseases for which suitable tests are 
not available, the result is a significant reduction in the qualified FMT donor pool. Despite this 
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situation, no research has been conducted to identify the predictors of FMT donor passage and 
failures to improve the process for finding healthy stool donors.  
Using Blood Banks as a Model to Improve FMT Donor Pass Rates. Since adoption of 
the risk reduction based approach, blood banks continue to utilize and improve the model to 
ensure the safety of blood transfusion material (World Health Organization, 2012). However, the 
deferral and pass rates for blood donors is notably lower at 12.8%, with an 87.2% pass rate, 
compared to fecal donor pass rates (Zou et al., 2008). To keep this deferral rate low, blood banks 
regularly monitor and analyze prospective donor characteristics that may be predictive of passing 
or deferral. This information is subsequently used to improve the recruitment, tailor the blood 
donor screening processes, and increase donor pass rates when implemented.  
In addition to data on deferral rationales, donation frequency, and donor attrition, blood 
banks regularly monitor various prospective donor factors to inform and target donor 
recruitment. These include factors such as gender, age, blood type, and time of donation, as well 
as certain health and lifestyle factors, such as dietary habits, body mass index, and drug and 
alcohol use (World Health Organization, 2012). Data collected about prospective blood donor 
characteristics, behaviors, and outcomes are analyzed and used to support continuous 
improvement in operations, monitor adherence to standard operating procedures, and ensure the 
clinical efficacy of blood transfusions. For example, an evaluation of European blood donors by 
Bani and Giussani (2010) demonstrated that gender had a significant impact on prospective 
donor motivation, deferral, and donor related adverse events. These findings prompted tailoring 
of the prospective blood donor recruitment and screening programs to properly evaluate 
prospective female donors for specific risk factors. Female donors found to have a higher risk of 
deferral from whole blood donations were directed to alternative types of donations that were 
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more suitable with their hematological parameters. In turn, these operational changes reduced 
deferral rates and costs associated with screening prospective blood donors. Ultimately, donor 
data allow blood banks to efficiently recruit donors who are more likely to pass the screening and 
minimize the cost and delays resulting from donor deferrals. 
Challenges with Improving Fecal Donor Screening Programs. Despite its limitations 
in screening FMT donors, the blood banks’ risk reduction model has remained the principal 
method for screening prospective FMT donors (Kapel et al., 2014; Kelly et al., 2012). Further, 
very little research has been conducted to date to improve the FMT donor screening process. The 
primary challenge of studying prospective FMT donor characteristics, 16S ribosomal ribonucleic 
acid (rRNA) intestinal microbiome composition, and related clinical efficacy rates to improve 
the procurement of suitable fecal material has been the limited pool of information about 
qualifying donors. Because the directed donor approach requires only one donor and one 
universal FMT donor can treat many patients, sufficient aggregation of data to support 
meaningful inquiry has been limited. Further, despite reductions in the cost of genetic 
sequencing technologies, microbiome sequencing adds to the already high out-of-pocket 
procedural costs associated with screening FMT donors. Because the use of microbiome 
sequencing is not currently supported by the literature, physicians and stool banks are reluctant 
to incorporate it into donor screening despite its potential to improve the clinical efficacy of 
FMT in patient recipients. As a result, these barriers have hindered progress and process 
improvements to the FMT donor screening programs currently utilized by clinicians and stool 
banks.  
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Variables of Interest to this Study 
FMT donor characteristics that impact the host, environment, and microbiota features 
presented within the ecological based conceptual framework by Eloe-Fadrosh and colleagues 
(2013) were evaluated as part of this study to assess whether this information can be utilized to 
improve the FMT donor screening process to better identify healthy donors. Specific FMT donor 
characteristics of concern to this study were: 1) donor host factors including gender, age, body 
mass index (BMI), and frequency of bowel movements; 2) environmental factors including diet, 
alcohol and tobacco use and seasonality based on screen date; and 3) 16S rRNA based intestinal 
microbiome diversity. The aforementioned variables have been supported by the literature to 
influence an individual’s health and microbiome composition and are thus potentially predictive 
of donor pass rates and FMT clinical efficacy. The following section outlines the current state of 
the science as it pertains to each of the FMT donor characteristics of interest to this study.  
Host Features. 
Gender. Although research supporting an interaction between gender-related hormones 
and intestinal microbial composition is still emerging, there is strong evidence to suggest that 
gender-related differences in health and the intestinal microbiome exist. The difference is 
thought to be due in part to the bi-directional modulation of sex hormones by the host and 
intestinal microbiome (Garcia-Gomez, Gonzalez-Pedrajo, & Camacho-Arroyo, 2013). The 
evolving maternal intestinal microbiome during pregnancy demonstrates how rising estrogen 
levels during the third trimester lead to a distinct and less diverse intestinal microbiome 
independent of health status and dominated by Proteobacteria and Actinobacteria (Koren et al., 
2012). More recently, a study looking at gender differences in intestinal microbiome within the 
context of BMI demonstrated that the intestinal microbiome between matched subjects differed 
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by gender at the bacterial phyla, genus, and species levels (Haro et al., 2016). Despite the lack of 
a clear causal explanation between gender and intestinal microbiome mediated disease, the 
research provides evidence to suggest that gender driven differences in the intestinal microbiome 
exist and that these differences uniquely shape 16S rRNA microbiome composition and host 
health.  
No research to date has been conducted to assess whether one particular gender 
demonstrates a higher frequency in passing the FMT donor screening, possesses a distinct 16S 
rRNA intestinal microbiome, or offers better clinical efficacy rates in treating recurrent CDI. 
Alternatively, female donors who are either pregnant or breastfeeding are generally excluded 
from donating due to the observed changes in 16S rRNA intestinal microbiome composition 
associated with fluctuations in hormone levels. The female gender has also been associated with 
a higher risk for certain functional gastrointestinal disorders including irritable bowel syndrome 
(IBS), recurrent diarrhea and constipation (Bakken et al., 2011; Houghton et al., 2016), and 
celiac disease (Lo, Sano, Lebwohl, Diamond, & Green, 2003), suggesting that female FMT 
donors may be less likely to pass the FMT donor screening. Because individuals with symptoms 
consistent with gastrointestinal disorders may also present with a perturbed intestinal 
microbiome in the absence of a formal diagnosis, these FMT donors are consequentially 
excluded from donating fecal material. In general, the risk reduction approach excludes certain 
health related factors that appear to affect women disproportionately. As such, there is the 
possibility that female FMT donors may be less represented in the FMT donor pool and that the 
16S rRNA intestinal microbiome composition for female FMT donors that do pass may be 
significantly different from that of male FMT donors. As such, this study postulated that 
identifying any gender related influences could provide valuable and pertinent information that 
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may improve FMT donor recruitment logistics, decrease screening costs, and promote 
consistency in donor microbiome diversity and FMT clinical efficacy rates.  
Age. Studies on the intestinal microbiome in elderly individuals have demonstrated that 
as people age, there is a shift in colonization toward a less diverse microbiome composition 
(O'Toole & Jeffery, 2015). More specifically, elderly individuals tend to have higher relative 
proportions of Bacteroidetes (Hopkins, Sharp, & Macfarlane, 2002) when compared to young 
adults who are predominantly colonized with higher proportions of Firmicutes (Cresci & 
Bawden, 2015; Mariat et al., 2009; Nagao-Kitamoto, Kitamoto, Kuffa, & Kamada, 2016). While 
an exact mechanism or explanation for this shift in intestinal microbiome composition is not 
fully understood, the gradual evolution in microbiome composition is associated with an 
increasing risk for immunosenescence and declining cognitive function as one ages (Biagi et al., 
2013; Guigoz, Dore, & Schiffrin, 2008; O'Sullivan et al., 2013). This shift in diversity also 
impacts colonization resistance over time, resulting in suboptimal bacterial interference in older 
individuals and thus increasing one’s risk for opportunistic infections. In particular, Clostridium 
difficile related infections have been shown to disproportionately affect the elderly population in 
spite of one’s health status (Loo et al., 2011).  
While intestinal microbiome variability among individual adults has been found to differ, 
there is still uncertainty as to whether aging plays a role in 16S rRNA intestinal microbiome 
composition within the healthy adult population. This has led to the assumption that the intestinal 
microbiome composition and colonization of young to middle aged adults do not differ. Because 
intestinal microbiome related research has predominantly focused on the extreme ends of the age 
spectrum, namely the very young and elderly, there are few studies looking at within group age-
related differences in the intestinal microbiome of healthy adults. However, a recent cohort study 
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of Japanese community dwelling individuals aimed to illustrate the evolution of the intestinal 
microbiome across different decades of life from infancy to elderly. That study demonstrated that 
the microbiome composition of the adult population as a group remained fairly stable (Odamaki 
et al., 2016). However, intestinal microbial diversity gradually decreased upon adulthood after 
eighteen years of age and with each decade of life. 
FMT donors of advanced age are generally excluded from donating based on the 
increased risk for dysbiosis and disease found to be associated with the elderly. Due to differing 
interpretations of what constitutes advanced age within the context of health and intestinal 
microbiome related disease, FMT donors as young as 50 years of age may be excluded from 
donating fecal material. Further, the various demands and constraints inherent in the FMT donor 
risk reduction approach and logistics of donating fecal material such as in-person health 
assessments, multiple laboratory-based screenings, and on-site or time-sensitive donations, may 
favor enrollment by a younger subset of the healthy adult population. Because the compositional 
stability of young to middle aged adults and the timing at which intestinal microbiome diversity 
evolves are not entirely understood within the context of host physiology and health, this study 
postulated that evaluating whether age is predictive of passing the FMT donor screening process 
could prove to be informative.  
Body Mass Index. Healthcare providers routinely measure a person’s BMI as a proxy for 
total body adiposity and disease risk. A healthy BMI is thought to range from 18kg/m2 to less 
than 25kg/m2, while a BMI between 25kg/m2 and less than 30kg/m2 is considered overweight. 
Generally, individuals with a BMI of 30kg/m2 or greater are considered obese and have 
significantly elevated odds of prematurely developing chronic diseases, such as metabolic and 
cardiovascular related disease (Mokdad et al., 2003; Nuttall, 2015). Risk factors for a high BMI 
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include a sedentary lifestyle, poor dietary habits and nutrition, genetics, and certain medical 
conditions (Centers for Disease Control and Prevention, 2017a). Of concern in developed 
countries is the increase in sedentary lifestyles and poor dietary habits that are driving a growth 
in obesity rates. When caloric consumption is not offset with an increase in caloric expenditure, 
the host’s increased access to nutrients allows cells to process and store greater amounts of 
energy as fat cells, resulting in excessive weight gain and increasing one’s risk for obesity. While 
the health issues in obese individuals are more apparent, individuals who fall within the 
overweight category (BMI between 25 and 30kg/m2) are also generally perceived to be at a 
heightened risk for long-term development of obesity related chronic diseases. 
 Recent research has proposed that diets high in fat and calories may lead to a dysbiotic 
intestinal ecosystem colonized by microbes that are conducive to weight gain (Ley et al., 2005). 
Using a humanized mouse model, Turnbaugh and colleagues (2008) were able to transplant fecal 
material from obese humans and replicate the diet-induced obesity effects of a high caloric, high 
fat diet on the mouse model. Upon introduction of the high caloric, high fat diet, mice 
transplanted with dysbiotic fecal material gained weight and continued to do so despite caloric 
reductions. Subsequent research on obesity conducted in human twins found reduced intestinal 
microbial diversity and phylum level dysbiosis in obese twins when compared with their lean 
counterparts (Turnbaugh et al., 2009). This difference was found to be significant and 
independent of innate host or environmental factors. The research suggests that intestinal 
colonization by a distinct set of microbes inherent in obese individuals may be the impetus for 
further sensitization of host metabolic pathways (Cox & Blaser, 2013) and result in further 
weight gain over time.  
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 High caloric, high fat diets promote a shift in the intestinal ecosystem causing it to 
perpetuate the intestinal microbial dysbiosis that results in weight gain. Referred to as efficient 
harvesters, the intestinal microbes associated with obesity may serve as biomarkers and 
precursors for obesity-related chronic diseases. Because individuals with a BMI of 30kg/m2 or 
greater are generally understood to have a heightened risk for intestinal dysbiosis and exhibit a 
host of disease symptoms, including diabetes, hypertension, and high cholesterol, FMT donors 
with a BMI of 30kg/m2 or greater are excluded from donating fecal material. However, the risks 
for disease and intestinal dysbiosis in overweight individuals with BMI between 25kg/m2 and 
less than 30kg/m2 are not as well understood and less apparent. Because the BMI metric is an 
imperfect measure of host health, some individuals with a BMI between 25kg/m2 and 30kg/m2 
may not accurately be classified as overweight or at risk for intestinal dysbiosis. Evaluating FMT 
donor data to assess for a BMI-related impact on deferral status would be valuable to help 
identify whether certain individuals are more likely to pass based on their BMI. Alternatively, 
overweight individuals may already possess an asymptomatic dysbiotic intestinal microbiome or 
present with mild obesity related symptoms that don’t yet meet strict exclusion criteria. As such, 
this study postulated that evaluating the donor BMI with passing the prospective donor screening 
program, may provide a metric that would be more efficient at identifying healthy FMT donors 
earlier in the screening process.  
Frequency of Bowel Movements. Transit time of fecal material through the intestines 
and fecal consistency have been shown to directly impact the type of microbiota that colonize the 
intestinal tract through access to nutrients and bacterial clearance (Tigchelaar et al., 2016; 
Vandeputte et al., 2016). Although abnormally pronounced during infectious diseases, healthy 
stool frequency, which serves as a proxy for intestinal transit time, can vary from as few as three 
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stools per week to three stools per day. In the absence of disease, frequency of bowel movements 
affects the length of time that fecal material remains in the intestines where nutrient breakdown 
and water absorption by the host and microbial inhabitants occur. Accelerated transit of fecal 
material can produce nutritional scarcity and disproportionately impair colonization by certain 
microbes. In a recent study, rapid fecal transit was found to selectively skew intestinal 
colonization toward fast growing bacteria, such as Ruminococcaceae and Bacteroides 
(Vandeputte et al., 2016). These bacteria were found to be capable of utilizing available nutrients 
more effectively allowing for greater colonization. As a result, intestinal microbial composition 
can differ markedly depending on the length of time that intestinal microbes have access to 
nutrients. 
Depending on the fecal transit time, differentiated ecosystems may emerge that support 
colonization by distinct bacteria and influence microbiome composition and colonization 
resistance. Accelerated fecal transit increases bacterial clearance and washout. This hinders the 
ability of certain bacteria to adhere to and colonize the intestines. As a result, bacteria with a 
higher degree of intestinal wall adherence capabilities, such as that seen with Prevotella, are 
more likely to avoid bacterial washout (Vandeputte et al., 2016) and disproportionately colonize 
the intestines. Of concern is the finding that the intestinal microbiome of individuals with 
Clostridium difficile related infection and non-infectious diarrhea in healthy adults was found to 
be remarkably similar and indistinguishable in diversity (Schubert et al., 2014). These 
microbiome findings were in contrast to non-diarrheal healthy controls that maintained 
significantly different intestinal microbiomes. In particular, the Clostridium difficile bacterium is 
known to adhere well to intestinal epithelial cells. As such, the intestinal microbiome of 
individuals with more frequent bowel movements may be comprised of a dysbiotic intestinal 
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microbiome composition and reduced colonization resistance that places them at greater risk for 
infection by Clostridium difficile.  
Despite the findings in the literature, transit time and stool consistency are not taken into 
consideration as potential influencers of the intestinal microbiome or host health during the FMT 
prospective donor screening process. Stool frequency and consistency, as measured by the 
Bristol Stool Scale, are collected as part of the FMT donor screening process. However, the aim 
of screening stool characteristics is to reduce the risk for a perturbed microbiome due to an 
infectious cause and uncover donors who have a history of chronic diarrhea or constipation 
related to an undiagnosed gastrointestinal disorder. Due to the lack of research in FMT donors, 
neither transit time nor stool consistency are currently utilized as exclusion criteria or potential 
predictors of target FMT donors with a diverse intestinal microbiome and potentially higher 
FMT clinical efficacy. As such, this study postulated that investigating the donor frequency of 
bowel movements could prove to be informative.  
Environmental Features. 
Diet. One of the beneficial functions of intestinal bacteria is the ability of these microbes 
to breakdown undigested foods and promote access and absorption to important nutrients 
(Turnbaugh & Gordon, 2009). The type of diet one consumes directly shapes the intestinal 
ecosystem and bacteria that inhabit the intestines long-term by promoting colonization by 
bacteria capable of digesting the nutrients that are consumed as part of the diet. This influence 
can be observed in the intestinal microbiome among individuals who consume animal-based 
versus predominantly carbohydrate- or plant-based diets. Diets of individuals who consume 
plant-based foods and exclude all animal products, referred to as vegetarians, tend to be higher in 
carbohydrates and fiber and lead to lower stool pH and lower counts of Bifidobacterium, 
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Bacteroides, Escherichia coli and Enterobacteriaceae (Zimmer et al., 2012). Escherichia coli 
and Enterobacteriaceae species are known to survive better in protein-rich, high pH intestinal 
ecosystems. As such, these bacteria tend to be more predominant in individuals that consume 
animal proteins. Whereas, individuals who consume primarily carbohydrate- or plant-based diets 
are predominantly colonized by the Prevotella enterotype (De Filippo et al., 2010; Wu et al., 
2011).  
Similar trends have been observed in individuals who follow non-traditional diets, which 
have gained in popularity over the past decade regardless of the rationale or health need, such as 
gluten-free diets. Research on individuals who adopted gluten-free diets for a four-week period 
found significant reductions in Veillonellaceae throughout the intervention period corresponding 
with a shift in intestinal microbial activity (Bonder et al., 2016). For extreme diets, animal 
models have provided an opportunity to study the impact that extreme alterations in diet have on 
the intestinal microbiome and demonstrate shifts in both 16S rRNA intestinal microbiome and 
microbial physiology. For example, mice fed a diet high in fat for a 12-week period experienced 
significant weight gain corresponding with a significant increase in Rikenellaceae, a microbe 
recently found to be associated with the development of type II diabetes (Daniel et al., 2014; Qin 
et al., 2012). Similarly, the consumption of a high-fat, high-sugar diet within a humanized mouse 
model resulted in a notable increase in adiposity that was successfully transplantable and 
replicable via fecal material transplant to recipient gnotobiotic mice (Turnbaugh & Gordon, 
2009). The aforementioned studies help to support the theory that intestinal microbial 
composition can be influenced by diet.  
Despite one’s existing intestinal microbes, rapid shifts in the intestinal microbiome occur 
in response to alterations in diet, further demonstrating the ability of diets to regulate intestinal 
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microbiome composition on a day-to-day basis. Analysis of the 16S rRNA intestinal microbiome 
of individuals who alternated between animal- and plant-based diets observed a significant shift 
in microbes within 24 hours after a different diet was introduced (David et al., 2014). Most 
notably, the animal-based diet induced a significant increase in colonization by bile-tolerant 
microorganisms i.e., Bacteroides and decreased colonization by microbes that metabolize plant 
polysaccharides i.e., Firmicutes within 24 hours (David et al., 2014). Similar changes in the 
microbiome were observed within 24 hours of individuals shifting from a high-fat, low-fiber diet 
to a low-fat, high-fiber diet (Wu et al., 2011) over a 10-day period.  
The ability of one’s diet to selectively and rapidly alter intestinal microbiome 
composition is an important consideration in host health and intestinal microbiome composition. 
Because the baseline adult intestinal ecosystem is established by three years of age, periodic 
fluctuations in the diets of healthy adults are unlikely to significantly hinder overall colonization 
resistance of the gut to the point of causing disease. However, long-term trends in microbiome 
colonization associated with specific diets demonstrate how diet uniquely shapes the 16S rRNA 
intestinal microbiome and thus the potential for colonization resistance. Because of this, the 
current FMT donor screening process recommends deferral of individuals who choose to adopt 
diets that are considered extreme, such as gluten-free or high-protein based diets, regardless of 
the rationale. However, FMT donors that follow a balanced and traditional diet, such as animal- 
or plant-based diets, are allowed to donate fecal material. In spite of the role of diet in shaping 
the intestinal microbiome, little long-term data exist to support whether any particular diet is 
associated with optimal donor host health and passing the donor screening process. This study 
postulated that such data would be valuable to help determine whether certain FMT donors, 
based on diet, were more likely to pass the donor screening. 
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Alcohol Use. Similar to host diet, the use of alcohol has been shown to influence the 
intestinal microbiome. However, unlike research into the effects of diet on the intestinal 
microbiome, research on alcohol use and the composition of the intestinal microbiome is limited 
and has been primarily conducted in animal models with a focus on advanced human disease 
states such as alcoholic liver disease and cirrhosis. Within the available research literature there 
is a general consensus that chronic alcohol abuse results in a significant increase in bacterial 
overgrowth throughout the gastrointestinal tract (Bode, Bode, Heidelbach, Durr, & Martini, 
1984). The degree of this overgrowth has been found to correlate with the presence of alcohol in 
the gut and worsens with increasing severity of alcohol-induced disease (P. Chen & Schnabl, 
2014). Because certain intestinal microbes can metabolize alcohol, individuals who chronically 
abuse alcohol tend to experience intestinal dysbiosis marked by a significant increase in 
Proteobacteria and decrease in Bacteroidetes when compared to a healthy human microbiome 
(Y. Chen et al., 2011; Mutlu et al., 2012). While the underlying mechanism between intestinal 
dysbiosis and pathogenic alcohol-induced disease remains unclear, trials on the use of probiotics 
in individuals with alcohol-induced disease have demonstrated reductions in disease symptoms 
suggesting that the intestinal microbiome is likely associated with disease expression to some 
degree. 
FMT donor screening programs that exclude donors based on alcohol consumption due to 
health related reasons generally follow guidelines provided by U.S. Dietary Guidelines (Centers 
for Disease Control and Prevention, 2017c). Based on these guidelines, donors who report 
regular weekly consumption of alcohol greater than or equal to seven drinks per week for women 
or fourteen drinks for men are excluded from donating. Although research on the impact of 
alcohol on the 16S rRNA intestinal microbiome has not been conducted in disease-free healthy 
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adults who consume low to moderate levels of alcohol, the intestinal microbiome has been 
shown to rapidly evolve based on the nutrients made available through dietary consumption. 
Low to moderate weekly consumption of alcohol is therefore likely to have an influence on the 
intestinal microbiome much like that of other dietary or nutrient intake in otherwise healthy FMT 
donors. As such, varying levels of alcohol intake may result in dysbiosis or altered levels of 
intestinal resident microbes. Based on this information, this study postulated that further 
exploration of the relationship between alcohol use and donor passage of the FMT screening 
program was warranted as it may subsequently influence the microbiome diversity of donor fecal 
material and clinical efficacy of FMT.  
Tobacco Use. The impact of tobacco use on individual health has been well documented 
over several decades of research. Long-term tobacco use has been shown to negatively impact 
nearly every part of the human body, increasing one’s risk for chronic disease, susceptibility to 
cancers, disease morbidity, and mortality (Centers for Disease Control and Prevention, 2017c). 
Regardless of the delivery route, the use of tobacco has also been asserted to increase 
susceptibility to certain gastrointestinal related disorders, such as Crohn’s disease (X. C. Morgan 
et al., 2012) and colorectal cancers (Giovannucci, 2001; Giovannucci & Martinez, 1996) and 
places one at increased risk for tobacco related medical complications. In a recent study on the 
impact of smoking on patients with IBD, researchers found that current smokers with Crohn’s 
diseases were at increased risk of requiring surgery and former smokers with ulcerative colitis 
were more likely to undergo a colectomy than never smokers (Kuenzig et al., 2016).  
 Tobacco use has also been shown to induce changes in the intestinal microbiome. In a 
study on the impact of tobacco use in individuals with IBD, researchers found that the abundance 
of a specific bacteria from the Firmicutes phylum, Anaerostipes, was significantly decreased by 
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greater than 60% in current and former smokers (Cosnes, 2004). This finding was further 
supported in a more recent study looking at the evolution of the intestinal microbiome after 
smoking cessation, which demonstrated that reduced intestinal levels of Firmicutes and 
Actinobacteria rebounded upon complete cessation of smoking (Biedermann et al., 2013). The 
significant increase in diversity in the intestinal microbiome of these individuals occurred within 
four weeks after smoking cessation and was maintained at the eight-week follow-up visit. Most 
notably, the use of tobacco appears to significantly impact butyrate producing microbiota 
(Biedermann et al., 2013; Cosnes, 2004; Nagao-Kitamoto et al., 2016), which are important in 
overall intestinal health.  
 Tobacco’s impact on the intestinal microbiome is not surprising given the existing 
research findings on tobacco use and multisystem disease. As such, for programs that incorporate 
tobacco use during their screening, FMT donors are asked to quantify their past and current 
smoking history during the in-person screening and are classified according to the terminology 
set forth by the Centers for Disease Control (CDC) (Centers for Disease Control and Prevention, 
2017b). Donors who meet the definition of daily smokers as defined by the CDC as one cigarette 
or more per day are typically deferred from donating fecal material. However, clear deferral 
exclusions do not exist for FMT donors who smoke less than one cigarette per day or former 
smokers, so these donors may be allowed to donate fecal material. While a recent study was 
unable to find a difference between the 16S rRNA intestinal microbiome of non-smokers and 
smokers (Tu et al., 2017), the study did not distinguish between current and former smokers who 
were grouped together categorically. Further, the Biedermann study (2013) demonstrated that the 
intestinal microbiome is capable of effectively and rapidly restoring a diverse intestinal 
ecosystem upon complete cessation of tobacco use, suggesting a difference may exist between 
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former smokers and current or intermittent smokers who, for example, smoke infrequently or 
during social events alone. Despite the plasticity of the intestinal microbiome, little information 
exists about the impact of infrequent or intermittent use of tobacco on the intestinal microbiome. 
As such, this study postulated that further evaluation of the impact of varying degrees of tobacco 
use on FMT deferral rates could provide valuable information to improve the FMT screening 
process and clinical efficacy rates for donor fecal material.  
Seasonality. In infectious disease medicine, seasonality refers to a “periodic surge in 
disease incidence” that corresponds with different seasons across one full calendar year (Fisman, 
2007). Although the rationale is not entirely understood, seasonal changes have been observed 
for both respiratory and gastrointestinal infectious diseases. In particular, the incidence of 
respiratory illnesses, such as rhinovirus, tends to increase with the resumption of the fall 
academic school year and remain elevated through early spring (Monto, 2002). The emergence 
of influenza tends to be slightly delayed with cases occurring more often during the winter and 
spring seasons (Monto, 2002). Certain gastrointestinal related infectious diseases, such as 
rotavirus, also tend to follow a similar pattern with a peak incidence observed in the U.S. during 
the winter months (Cook, Glass, LeBaron, & Ho, 1990). Because the risk reduction approach 
aims to defer individuals with an increased risk for transmitting infectious and communicable 
diseases, the rate of donor deferral may vary significantly from one season to the next. This 
challenge is further complicated due to asymptomatic carriage, which may be higher during 
periods of peak incidence (Pickering, Bartlett, Reves, & Morrow, 1988). As such, an 
unanticipated variable in the donor screening process may be the varying rates of donor deferral 
during different seasons due to fluctuations in infectious disease occurrence and risk.  
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In order to accurately gauge the impact of seasonality on the intestinal microbiome, 
researchers must control for many variables that may confound the results. For example, one’s 
diet naturally changes according to the nutrients available during different seasons. Because diet 
has been shown to have a notable and rapid impact on the intestinal microbiome, it can be 
difficult for researchers to corroborate changes in the intestinal microbiome to seasonality alone 
and thus few published studies exist. However, one study conducted on 60 members of an 
indigenous group attempted to associate changes in the intestinal microbiome with the different 
seasons. While a distinct and clear association among all phylum levels of the 16S rRNA 
intestinal microbiome was observed with seasonality, the researchers were admittedly not able to 
entirely control for the effects of diet, which differed markedly between seasons based on the 
availability of fresh produce (Davenport et al., 2014). A similar study conducted in Japan also 
observed a change in microbiome composition with seasonality, specifically Bifidobacterium and 
Lactobacillus. Interestingly, the researchers suggested that the significant change in 
Bifidobacteria could be associated with changes in fermented milk consumption during different 
seasons (Hisada, Endoh, & Kuriki, 2015). However, the researchers were not able to attribute the 
change in Lactobacillus with diet or fermented milk consumption, suggesting that seasonal 
variation may have contributed to this difference.  
While research has been done to evaluate the impact of infectious gastroenteritis on the 
intestinal microbiome, there is little information available regarding acute respiratory diseases 
and their impact on the intestinal microbiome. Because of the risk reduction approach to 
infectious disease, FMT donors who exhibit active symptoms for any infectious disease are 
deferred from donating fecal material. The FMT donor screening further reduces this risk by 
excluding donors found to be asymptomatically affected with infectious diseases during the 
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laboratory screening. Despite these efforts, several theories purport the impact of seasonality on 
host health and the intestinal microbiome independent of infectious disease prevalence, which 
may be predictive of passing the FMT donor screen and microbiome composition. These include 
changes in atmospheric conditions, different light/dark periods, and cyclical variations in host 
immune function (Dowell, 2001). While seasonality may be found to contribute to the cyclical 
appearance of infectious disease outbreaks, because of the bidirectional relationship between the 
host immune system and intestinal microbiome, it is possible seasonality may also potentially 
skew intestinal colonization resistance. As such, this study postulated that evaluating for a 
seasonal variation in FMT donor deferral could allow stool banks and providers to proactively 
plan in advance for potential FMT donor shortages or target recruitment to ensure the collection 
of fecal material with more optimal intestinal microbiome composition diversity.  
Microbiome Features. 
Fecal Microbiome Diversity. The value of understanding how the intestinal microbiome 
evolves and maintains a mature homeostatic and symbiotic ecosystem becomes evident when 
consideration is given to the impact that the microbiome has in shaping the intestinal ecosystem, 
influencing microbial inhabitants, and supporting host defenses against infectious disease. When 
significant alterations to the natural ecosystem occur, intestinal homeostasis and immune 
expression can be negatively impacted and result in diseases such as those caused by pathogenic 
Clostridium difficile bacteria. However, systematic review of the literature has demonstrated 
FMT clinical efficacy rates of up to 94% in the treatment of CDI recurrence (Kassam et al., 
2013; Sha et al., 2014) suggesting that re-colonization of the perturbed intestinal microbiome 
with healthy donor fecal material can prevent disease recurrence.  
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Prior to the emergence of stool banks, FMT donors were utilized on a once or twice basis 
making it difficult to meaningfully study the critical components of the intestinal microbiome in 
treating recurrent CDI. As such, most research conducted on FMT donor 16S rRNA intestinal 
microbiome composition has focused on clinical efficacy rates in the prevention of CDI 
recurrence. Research has begun to emerge evaluating FMT donor characteristics and 16S rRNA 
intestinal microbiome composition with clinical efficacy in preventing CDI recurrence. In 2016, 
researchers evaluating the clinical efficacy rates of four FMT donors in an enema treatment of 34 
cases of recurrent CDI did not find a significant difference in the FMT clinical efficacy rates 
among the donors (Ray & Jones, 2016). However, neither FMT donor characteristics nor their 
16S rRNA intestinal microbiome composition were evaluated as part of this study. More 
recently, a pilot study on 35 FMT donors looking at the impact of diet, alcohol, and tobacco 
intake on 16S rRNA intestinal microbiome composition and FMT clinical efficacy was 
inconclusive (Tu et al., 2017). However, the finding may be attributed to limitations in the study 
design, such as the use of overly inclusive definitions for predictor variables and a delayed time 
span between the completion of the food frequency questionnaire and collection of the fecal 
sample for 16S rRNA microbiome evaluation. Interestingly, a recent study by Budree and 
colleagues (2017) compared the 16S rRNA intestinal microbiome of FMT donors with superior 
clinical efficacy rates (greater than 90%) with FMT donors demonstrating anticipated or normal 
clinical efficacy rates of 80% to less than 90% and found that 16S rRNA intestinal microbiome 
diversity did not differ significantly between the groups. No additional FMT donor 
characteristics were considered or analyzed as part of that study.  
  




Prospective FMT donor selection and screening continue to vary significantly across 
institutions (Kump, Krause, Allerberger, & Hogenauer, 2014). The variability observed in 
prospective FMT donor screening programs is most notable with the direct donor approach. The 
first public stool bank opened in 2013 has screened over 1,000 FMT donors and provides 
clinician access to FMT material from multiple anonymous donors. Despite the availability of 
this donor information, little research has been conducted evaluating donor factors that may 
improve passage of the FMT donor screening program. As such, few improvements have been 
made to the prospective FMT donor screening process, which remains logistically challenging 
for both stool banks and individual physicians and hospitals that continue to use the directed 
donor approach.  
To date, no specific microbes or 16S rRNA based intestinal microbiome levels of 
diversity have been correlated with consistently providing optimal clinical efficacy in preventing 
CDI recurrence. Further, research looking at 16S rRNA intestinal microbiome composition and 
FMT clinical efficacy has been limited. Intestinal ecosystem diversity is a critical component 
required for the sustainability of colonization resistance and ecosystem stability in patients with 
recurrent CDI. Knowledge of the 16S rRNA microbiome composition and level of diversity of 
optimal FMT donors could serve to validate the 16S rRNA microbiome-based biomarker and 
improve prospective donor screening and FMT clinical cure.  
While a relatively new occurrence, the emergence of public stool banks has eased some 
of the logistical barriers to the preparation of FMT material and introduced greater consistency in 
prospective FMT donor screening and stool processing. However, in a survey of infectious 
disease physicians, the complexity and cost of donor screening was cited as the second most 
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common reason for not offering FMT (Bakken, Polgreen, Beekmann, Riedo, & Streit, 2013). 
The barriers to FMT have driven some patients to search for alternative options including 
unsupervised at home self-administration utilizing unscreened donor fecal material that could 
carry infectious or microbiome mediated diseases (Smith, Kelly, & Alm, 2014). As such, there is 
a clear need for improvement in the prospective FMT donor screening process and clear 
guidelines on the optimal intestinal microbiome composition for prospective FMT donors.  
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Chapter 3. Study Design and Methodological Approach 
Overview of Study Design 
This study was conducted as a secondary analysis of data collected from a cohort of fecal 
microbiota transplant (FMT) donors screened by OpenBiome, a public stool bank. The 
hypothesis for Aim 1 examined the association between previously unstudied donor 
characteristics and environmental influences on the donor’s likelihood of passing the company’s 
current screening regimen. That regimen categorized prospective donors as “passed” or 
“deferred” through a multistep process that included prescreening, clinical, and laboratory 
analysis phases. This study used logistic regression to determine whether additional donor host 
(gender, age, body mass index [BMI], and frequency of bowel movements) and environmental 
(diet, alcohol use, tobacco use, and seasonality based on screen date) factors affected the 
likelihood of passing the screening. Donors who passed the screening and provided stool for 
transplant into a patient had the microbial diversity of their stool quantified, but the relationship 
between that diversity and the clinical efficacy of the procedure has not been studied. As such, 
the hypothesis for Aim 2 used a simple linear regression to determine whether the microbial 
diversity of the donor stool predicted the rate of clinical cure.  
Hypotheses 
1. There is a statistically significant association between one or more characteristics of 
prospective FMT donors i.e., donor gender, age, BMI, frequency of bowel movements, 
diet, alcohol use, tobacco use, or seasonality based on screen date (predictor variables) 
and passing the FMT donor screening program (outcome variable).  
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2. There is a statistically significant association between the intestinal microbiome alpha 
diversity of active FMT donors (predictor variable) and Clostridium difficile infection 
(CDI) clinical efficacy (outcome variable). 
Site and Sampling 
This study was conducted as a secondary analysis of FMT donor clinical and microbiome 
related data collected at OpenBiome, a not-for-profit stool bank located in the United States 
(U.S.) in Somerville, Massachusetts. The town of Somerville is located within the Greater 
Boston Metropolitan area. OpenBiome recruited and collected FMT donor data between August 
2013 and December 2016 under a Massachusetts Institute of Technology (MIT) Human Subjects 
approved research protocol titled “Building a repository of healthy stool samples for fecal 
microbiota transplantation.” The aim of the study was to facilitate the collection of healthy donor 
stool for use as FMT material to prevent recurrent CDI and to promote research on the human 
microbiome. FMT donors who enrolled in the study were over 18 years of age and lived within 
close proximity of less than one hour’s travel distance to the stool bank donation location. For 
the purpose of testing the hypotheses presented by this research proposal, data for all FMT 
donors recruited between August 2013 and December 2016 were assessed for inclusion in this 
study. 
The following sections provide details regarding the operating procedures for 
OpenBiome that were used to collect the donor data to be utilized by this study. This study was 
conducted as a retrospective analysis of existing data already collected and stored in 
OpenBiome’s data repositories. As such, all laboratory testing, stool sample processing, and 16S 
ribosomal ribonucleic acid (rRNA) intestinal microbiome analyses were conducted under 
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OpenBiome’s approved research protocol. No additional laboratory or sample processing were 
required or conducted as part of this research study. 
Stool Bank Operating Procedures. Standard operating procedures for OpenBiome’s 
donor screening program included interacting with prospective FMT donors beginning at initial 
online contact during the pre-screening, in-person prospective FMT screening which included 
nursing and physician clinical assessment and laboratory based testing, and ending with final 
collection of stool samples for 16S rRNA intestinal microbiome analysis. Data generated during 
these procedures were stored in data repositories managed and controlled by OpenBiome.  
Pre-Screening. Prospective FMT donors were recruited through flyers and by word of 
mouth. Individuals who expressed interest in donating their stool were directed to register and 
complete the online pre-screening survey. The survey included questions about demographics, 
logistics, and health status. Health related questions were extracted directly from the Stool Donor 
Health Questionnaire (DHQ), the instrument used in the more comprehensive clinical assessment 
phase of the screening process described below. The survey took approximately ten minutes to 
complete online. Once submitted, a trained nurse and a physician study staff member as needed 
reviewed each prospective FMT donor’s answers to the questions to determine whether or not 
the prospective FMT donor met the inclusion criteria and could continue on to the in-person 
clinical assessment portion of the FMT donor screening program. Prospective FMT donors who 
met inclusion criteria were contacted to schedule an appointment for a clinical assessment and 
submit biological samples for laboratory screening.  
Clinical Assessment. The aims of the clinical assessment and laboratory screens were to 
evaluate the prospective FMT donor’s health, behavioral, and social history for presupposed 
risks for infectious diseases and hypothesized microbiome-mediated health conditions that may 
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be transmissible via stool. In-person clinical assessments were conducted by a nurse or physician 
study staff member and were overseen by the study’s Internal Medicine Physician Investigator.  
Prior to participating, the study staff member reviewed the purpose of the study in detail 
with the prospective FMT donor and answered any questions about participation. If the 
prospective FMT donor was interested in participating, informed consent utilizing OpenBiome’s 
MIT Human Subjects Approved consent form was obtained. The prospective FMT donor and the 
study staff member signed two copies of the consent form, one copy was provided to the 
prospective FMT donor and the second retained at OpenBiome. 
During the clinical assessment, prospective FMT donors were asked to complete 
OpenBiome’s full Stool DHQ in-person while at the stool bank. The Stool DHQ was developed 
by a clinical advisory board of twelve thought leaders and industry experts in infectious disease 
and gastroenterology with additional guidance from the U.S. Food and Drug Administration 
(FDA). Questions were based on the U.S. FDA recognized full-length American Association of 
Blood Bank’s DHQ. The Stool DHQ consists of over 100 closed- and open-ended questions 
aimed at obtaining a comprehensive health, behavioral, and social assessment of the prospective 
FMT donor’s risk factors for infectious or microbiome mediated diseases.  
Once completed, answers on the Stool DHQ were reviewed with the prospective FMT 
donor by a nurse or physician during the clinical interview. When needed, additional inquiry was 
requested to ensure accuracy of the response and clarify any uncertainty in the reported answers. 
As part of the clinical assessment, relevant vital signs were obtained by a nurse or physician 
including height, weight, and BMI. The entire in-person clinical assessment lasted approximately 
60 minutes. If any apparent risk factors were identified from answers on the Stool DHQ, 
prospective FMT donors were deferred temporarily or permanently from donating. Prospective 
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FMT donors with no apparent risks for infectious or communicable diseases were asked to 
submit a stool sample for pathology testing and blood sample for laboratory based serological 
testing.  
Laboratory Screening. Stool and serological laboratory tests were selected from the 
standard screening guidelines utilized by Blood Banks and further recommended by 
OpenBiome’s clinical advisory board in collaboration with feedback from the FDA. Prospective 
FMT donors were provided with a stool collection kit and received training in safe and sterile 
stool sample collection techniques. Prospective FMT donors were asked to collect a stool sample 
at home or provide a sample on site and deliver a fresh stool sample within less than one hour of 
passage to the stool bank for processing. Upon receipt, OpenBiome’s laboratory technicians 
placed aliquots of the prospective FMT donor’s stool sample into the proper collection 
containers and sent the samples to a Clinical Laboratory Improvement Amendments (CLIA) 
approved laboratory for comprehensive screening for stool transmissible pathogens.  
Additionally, a nurse or physician provided prospective FMT donors with a laboratory 
requisition for serological based screening to assess general prospective FMT donor health and 
to screen for transmissible infectious diseases. Prospective FMT donors were then provided with 
a list of local CLIA approved laboratories and asked to take the requisition to have their blood 
drawn for testing. Trained phlebotomist professionals employed by the CLIA approved 
laboratory conducted the phlebotomy and blood collection procedures and submitted the samples 
to the CLIA approved laboratories for testing.  
Upon receipt of the stool and serological based test results, a nurse and physician 
reviewed all laboratory results to assess whether the prospective FMT donor met inclusion 
criteria. Results were subsequently communicated with the prospective FMT donors. Any 
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abnormal result was deemed an exclusion criteria and the prospective FMT donor was either 
temporarily or permanently deferred from further participation in the study. 
Stool Collection and Preparation. Donors who met all inclusion criteria after completing 
the prospective FMT donor screening process were enrolled into OpenBiome’s stool donation 
program as active FMT donors. Active FMT donors were provided with stool collection kits and 
asked to donate stool samples for use as FMT transplant material for clinical treatment to prevent 
recurrent CDI. In return, active FMT donors received remuneration of $40 per accepted stool 
donation. Institutions that requested and utilized active FMT donor material voluntarily returned 
de-identified clinical efficacy data to the stool bank utilizing OpenBiome’s FMT Follow-up 
Form. 
During the donation period, an active FMT donor’s stool sample was selected and 
utilized to conduct 16S rRNA intestinal microbiome sequencing. Upon delivery of the sample to 
the stool bank laboratory by the active FMT donor, a member of the research team processed and 
placed aliquots of the stool sample into microtubules for freezer storage at -80° Celsius. Because 
concurrent sample sequencing reduces the risk for systematic bias between runs, stool samples 
from multiple active FMT donors were stored until a sufficient number of stool samples were 
collected. Once this amount was reached, the batch of active FMT donor stool samples was sent 
to a laboratory specializing in conducting intestinal microbiome molecular characterization using 
a 16S rRNA microbiome platform.  
16S rRNA Microbiome Sequencing. Stools samples collected for microbiome analysis 
underwent standard 16S rRNA intestinal microbiome genetic sequencing. Power Mag 
Microbiome kit with glass beads was used for repeated bead-beating cycles. DNA extracts that 
were not used immediately were stored at -20°C until further use. DNA extracts were then 
STOOL DONOR CHARACTERISTICS 
 
56 
amplified targeting the V4 region of the bacterial 16S ribosomal gene (Caporaso et al., 2011; 
Kozich, Westcott, Baxter, Highlander, & Schloss, 2013). Resulting amplicons were cleaned and 
quantified, pooled equimolarly, and then paired end sequenced on the Illumina MiSeq platform 
according to manufacturer’s instructions. 
Prior to data analysis, raw sequencing data were filtered and processed according to the 
UPARSE operational taxonomic unit (OTU) pipeline to create sequence clusters at various 
identity thresholds. Taxonomic identity assignment was based on review of the Greengenes 
reference database at a clustering at 97% identity or greater and RDP classifier. Results of the 
donor stool microbiome sequencing were stored as raw reads and processed taxonomic data in 
OpenBiome’s Microbiome Data Repository. 
Stool Bank Inclusion and Exclusion Criteria. The following OpenBiome stool bank 
determined inclusion and exclusion criteria were applied during the pre-screening and clinical 
assessment stages of the prospective FMT donor screening program. OpenBiome utilized a step 
approach to evaluating study inclusion due to the effort and costs associated with conducting in-
person clinical assessments and laboratory screenings. Only upon passing all inclusion criteria 
during the pre-screening and clinical assessment stages was the prospective FMT donor allowed 
to actively donate stool for FMT transplantation. As such, 16S rRNA intestinal microbiome and 
clinical efficacy data are available only for active FMT donors who passed all pre-donation study 
inclusion criteria.  
Pre-Screening. Adults 18 years of age or older with access to the Internet were directed 
to complete the Stool Bank Registry online. Prospective FMT donors were deferred during the 
pre-screening process if their answers included any of the following exclusion criteria:  
• Under 18 years of age or greater than 50 years of age 
• BMI of 30 or greater 
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• Tobacco use of three cigarettes per week or greater 
• Use of antibiotics, antifungals, or antivirals within the past three months 
• Vaccination with a live attenuated virus within the past two months 
• Travel within the past 12 months to an International SOS (ISOS) identified high risk 
country 
• Unable or unwilling to travel to the stool bank facility  
• Unable or unwilling to donate stool samples in person 4 times or more per week 
• Earning cash as the sole motivation for donating  
 
Clinical Assessment. Prospective FMT donors that underwent an in-person clinical 
assessment and laboratory screening were temporarily or permanently deferred from the study if 
they met any of the exclusion criteria specified on the Stool DHQ. In addition to reassessing the 
pre-screening exclusion criteria, prospective FMT donors whose daily commute to the stool bank 
was determined to be greater than one hour were excluded from participating. The one-hour time 
limit was imposed by OpenBiome to ensure the integrity of the intestinal microbiome in the stool 
donation. For proprietary reasons and to protect the continued integrity of OpenBiome’s Stool 
DHQ, broad exclusion categories have been provided. Prospective FMT donors with a 
remarkable health or medical history in any of the following areas were deferred either 
temporarily or permanently from donating:  
• Atopy, asthma, or allergies 
• Autoimmune conditions 
• Cancer history 
• Cardiovascular and Metabolic conditions 
• Current health status 
• Diet and exercise 
• Family history 
• Gastrointestinal conditions 
• Infectious disease history 
• Medications and supplements 
• Mental health and well-being 
• Musculoskeletal conditions 
• Neurological conditions 
• Sexual behavior and history 
• Social history 
• Surgical and other medical history 
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• Travel history 
• Women’s health 
• Vital signs 
 
Laboratory Screening. Upon completion and passing of the Stool DHQ and in-person 
clinical assessment, prospective FMT donors were asked to submit biological samples for 
serological and stool-based testing for infectious and communicable diseases. Complete blood 
count and liver function tests were also conducted to assess overall prospective FMT donor 
health status. Prospective FMT donors that received a positive infectious or communicable 
disease result or abnormal result for any of the serological laboratory tests listed below were 
deferred either temporary or permanently from donating fecal material:  
• Complete blood count 
• Liver function panel 
• Adenovirus 
• Campylobacter 
• Carbapenemase producing gram-negative rods 
• Clostridium difficile 
• Cryptosporidium 
• Escherichia coli O157 
• Extended spectrum beta-lactamase (ESBL) producing organisms 
• Giardia with reflex to ova and parasites 
• Helicobacter pylori 
• Hepatitis A, B, and C  
• Human immunodeficiency virus antibodies types 1 and 2 
• Human T-cell lymphotropic viruses types 1 and 2 
• Isospora and Cyclospora 
• Listeria monocytogenes 





• Treponema pallidum 
• Vancomycin-resistant Enterococci 
• Vibrio 
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Stool Bank Data Repositories. The data for this study were extracted from three 
different OpenBiome stool bank data repositories including the Stool Donor Registry, Clinical 
Assessment and Safety (CAS) Database, and Microbiome Data Repository.  
Stool Donor Registry. The Stool Donor Registry was created to assist during the online 
pre-screening of prospective FMT donors. This data repository contains information on healthy 
adults over 18 years of age who expressed interest in donating fecal material to OpenBiome and 
who completed the online survey. The registry contains data for over 8,000 prospective FMT 
donors including limited biodemographic information, motivation and logistics, and answers to a 
subset of questions taken directly from the Stool DHQ. Donor pass or deferral status from the 
pre-screening is also noted for each prospective FMT donor included in the database.  
Clinical Assessment and Safety Database. The Clinical Assessment and Safety (CAS) 
Database consists of data from a subset of prospective FMT donors that were recruited from the 
Stool Donor Registry. These prospective FMT donors met study inclusion criteria during the pre-
screening step and travelled to OpenBiome where they underwent an in-person clinical 
assessment and laboratory screening i.e., stool pathogen and serological testing, to verify 
eligibility and safety of their stool samples. The database contains clinical data for over 700 
prospective FMT donors including answers to the entire Stool DHQ and results of prospective 
FMT donor stool pathology and serological laboratory screening tests conducted on prospective 
FMT donors to determine eligibility to donate fecal material for clinical use. Donor pass or 
deferral status at each step of the clinical screening process is noted for every prospective FMT 
donor. Additionally, clinical efficacy rates of active FMT donor fecal material in preventing CDI 
recurrence were recorded in the database for active FMT donor fecal material utilized as part of 
clinical care fecal transplants. 
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Microbiome Data Repository. The Microbiome Data Repository contains raw 16S rRNA 
taxonomic microbiome data from active FMT donors who passed the clinical screening and 
donated stool samples to OpenBiome. The database contains 16S rRNA intestinal microbiome 
sequencing data for over 50 donors. This information is stored separately due to the large data 
storage capacity required to store the microbiome data files.  
Study Sample Size 
Based on power analysis performed using G*power© statistical analysis software, a 
minimum of 568 prospective FMT donors was required for the multiple variable logistic 
regression analysis (Aim 1) to reduce the chance of type I and type II statistical errors and to 
attain adequate power (0.80). Prospective FMT donor data required for the multiple variable 
logistic regression portion of this study was collected on all prospective FMT donors in the CAS 
Database who were recruited between August 2013 and December 2016, totaling over 750 
prospective FMT donors. Although prospective FMT donor recruitment by OpenBiome 
continued after December 2016, the donor population recruited after this date was performed 
under a clinical study approved by a different ethics board. The prospective FMT donor 
population recruited through December 2016 was deemed sufficient to that ensure power was 
achieved and to account for any unexpected challenges with data integrity.  
Intestinal 16S rRNA microbiome and clinical efficacy data were collected for a subset of 
active FMT donors who passed OpenBiome’s prospective FMT donor screening program and 
donated fecal material for clinical use. All active FMT donors with available microbiome 16S 
rRNA and clinical efficacy data were evaluated for inclusion in the analyses and dependent on 
the availability of active FMT donor data. 
  




Aim 1. Identify additional, previously unstudied characteristics of prospective FMT 
donors that are predictive of passing a public stool bank’s current screening process. A 
multiple variable logistic regression model was utilized as part of Aim 1 to test the hypothesis 
that there is a statistically significant association between one or more characteristics of 
prospective FMT donor characteristics (predictor variables) and passing the FMT donor 
screening program (outcome variable). Theoretical and operational definitions for the 
prospective FMT donor characteristics tested as part of the statistical analysis portion of the 
predictive analysis are provided in Table 1.  
Table 1.  
Donor characteristics of interest for prospective FMT donors 
Outcome 




• Final determination of 
prospective FMT donor’s 
eligibility to donate stool 
samples based on results 
from the clinical 
screening process. 
• The prospective FMT donor’s eligibility to 
donate stool will be assigned to one of the 
following values: 
o 0= defer (Donor not able to donate 
temporarily or permanently) 
o 1= pass (Donor able to donate 
immediately) 
Predictor 
Variable Theoretical Definition Operational Definitions 
Gender 
(dichotomous) 
• Physiological sex of FMT 
donor 
• Confirmed through donor self-report and 
assigned to one of the following values: 
o 1= male 
o 2= female 
Age (discrete) • Age of FMT donor at the 
time of study 
participation 
• Recorded as a discrete numerical value of 
years that the donor self-reports he/she has 




• A numerical estimate of 
body fat composition 
• Donor weight measured with a digital scale 
and recorded by the stool bank clinician in 
kilograms divided by the square of the 
body height measured by the clinician with 
a height rod in meters. Universally written 
as a three-digit number rounded to the first 
decimal and expressed in terms of kg/m2 
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Table 1 (continued) 
Predictor 





• An estimate of the 
average number of bowel 
movements or stools a 
person passes per day 
• The average number of bowel movements a 
donor self-reports as passing each day, 
rounded to the first decimal.  
Diet (categorical) • A specific course of food 
to which one restricts 
oneself, either to lose 
weight or for medical or 
ethical reasons 
• Type of diet regularly followed as self-
reported by the donors and categorized as 
follows: 
o 1= Diets that include meats 
o 2= Diets that exclude animal-based 
meats i.e., vegetarian, pescatarian, 
vegan 
o 3= Diet not specified 
Alcohol Use 
(continuous) 
• An estimate of the 
current alcohol intake on 
a weekly basis, measured 
by the number of 
servings equal to 0.6 fluid 
ounces or 14 grams of 
alcohol 
• An average of the prospective FMT 
donor’s self-reported weekly consumption 
of alcoholic beverages, rounded to the first 
decimal place.  
Tobacco Use 
(categorical) 
• Estimate of one’s 
historical and current 
direct (excluding 
secondary) exposure to 
tobacco through cigars or 
cigarettes, pipe smoking, 
or other tobacco-based 
products such as 
smokeless chewing 
tobacco, hookah, kreteks, 
e-cigarette, vaping, etc.  
• Prospective FMT donor’s self-reported 
history of direct exposure only to tobacco 
based on one of the following categories: 
o 1= Never smoker (An adult who has 
never smoked, or who has smoked 
less than 100 cigarettes in his or her 
lifetime) 
o 2= Former smoker (An adult who has 
smoked at least 100 cigarettes in his 
or her lifetime but who had quit 
smoking at the time of interview) 
o 3= Current Smoker (An adult who 




• Clinical assessment date 
conducted within the four 
meteorological seasonal 
cycles contained within 
one calendar year 
• Date of the prospective FMT donor’s 
clinical assessment categorized into one of 
the following groups: 
o 1= Winter (December 1 to February 
28 or 29 in leap years) 
o 2= Spring (March 1 to May31) 
o 3= Summer (June 1 to August 31) 
o 4= Fall (September 1 to November 
30) 
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Outcome Variable. The primary outcome of interest for the predictive multiple variable 
logistic regression was FMT donor status defined as pass or deferral. FMT donor deferral is 
defined as the non-acceptance of a prospective FMT donor upon conclusion of the prospective 
FMT donor screening process. Prospective FMT donors who pass all screens and are approved to 
donate fecal material for clinical treatments are referred to as active donors within the transplant 
industry. This study utilized the FMT donor status outcome variable to develop a model that 
identified previously unstudied FMT donor characteristics that are most predictive of becoming 
active donors upon completion of the prospective FMT donor screening process.  
Predictor Variables. The choice of variables utilized in the predictive analysis were 
guided by the conceptual framework. The selected predictor variables were considered 
influential factors in health and disease of prospective FMT donors and supported by the 
research literature as potentially associated with variations in the intestinal microbiome and 
colonization resistance. Specific prospective FMT donor characteristics that were of concern in 
this study were FMT donor host factors including gender, age, BMI, and frequency of bowel 
movements, and environmental factors including diet, alcohol and tobacco use, and seasonality 
based on screen date. These predictor variables were included to assess the association and 
significance of prospective FMT donor characteristics with passing the FMT donor screening.  
Aim 2. Determine whether the microbial diversity of active FMT donor stool, as 
measured by 16S rRNA, is related to FMT clinical efficacy, as measured by the recipient’s 
clinical cure. A simple linear regression analysis was utilized to test the hypothesis that there is 
a statistically significant association between active FMT donor intestinal microbiome 16S 
rRNA based alpha diversity (predictor variable) and FMT clinical efficacy (outcome variable). 
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Theoretical and operational definitions for the variables tested as part of this statistical analysis 
are provided in Table 2. 
Table 2.  
Donor characteristics of interest for prospective FMT donors 
Outcome 
Variable Theoretical Definition Operational Definitions 
Clinical efficacy 
(continuous) 
• The proportion of cases 
classified as cured by the 
donor’s fecal material 
• The total number of cases reported as cured 
divided by the total number of cases and 
reported as a whole proportion.  
Predictor 
Variable Theoretical Definition Operational Definitions 
Alpha Diversity 
(continuous) 
• A numerical measure of 
richness and evenness of 
the microbiota in a 
specific ecosystem based 
on the presence of 
bacterial 16S rRNA, 
a.k.a. Shannon’s diversity 
index.  
• The total sum of bacteria after dividing the 
number of individual species found in a 
sample by the number of all species, 
multiplied by its natural log. Both 
microbial richness and evenness of the 
community increase Shannon’s diversity 
index.  
 
Outcome Variable. The primary outcome of interest utilized in the simple linear 
regression analysis for Aim 2 was the clinical efficacy of FMT in CDI patient recipients of FMT 
donor fecal material. Clinical efficacy rates were collected from the FMT donor database. The 
clinical efficacy rate is a proportional value calculated for each active FMT donor and represents 
the percentage of clinical cure. The clinical efficacy rate was determined by dividing the total 
number of recurrent CDI cases identified as clinically cured by the total number of cases where 
the active FMT donor’s material was used. Clinical efficacy data was provided by treating 
physicians and collected prior to or during the eight-week follow-up visit. 
Predictor Variable. The primary predictive variable considered in the simple linear 
regression analysis was 16S rRNA based intestinal microbiome alpha diversity as represented by 
the Shannon diversity index. Alpha diversity provides an estimate of the mean phylogenetic 
diversity found within an active FMT donor’s intestinal ecosystem (Tyler et al., 2014). This 
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mean estimate is calculated by using multiple reads of an active FMT donor’s fecal sample to 
identify the number of different 16S rRNA sequences within a specific fecal sample and is 
represented by the Shannon diversity index measure.  
Data Collection Procedures and Strategies 
A data collection tool was used to record information from the data repositories about 
specific biodemographic, behavioral, and physiological variables to be used as part of this study. 
The data collection tool was created and managed in REDcap, a research electronic data capture 
tool and a Microsoft Excel© spreadsheet for upload into the statistical software program, IBM® 
Statistical Package for the Social Sciences (SPSS), where the data were analyzed upon 
completion of data collection. On rare occasions where data about a variable were not readily 
available within the data repositories, the data were imputed through a review of the source 
documents. Access to and collection of data was done in a de-identified manner using the 
anonymous derived donor identification number. No FMT donor identifiers were viewed or 
recorded as part of this study.  
Data Analysis Plan 
Data were entered into an IBM® SPSS statistical software program for analysis purposes. 
A significance level (p value) of 0.05 (5%) was used as the threshold to determine whether the 
independent predictor variables should be retained in the final models. 
Descriptive Analyses. Descriptive statistics including, but not limited to, mean, 
frequencies and measures of central tendency and dispersion were used to summarize the 
demographics of the overall prospective FMT donor population and outcomes of OpenBiome’s 
FMT donor screening program. Descriptive statistics were conducted using prospective FMT 
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donor characteristics collected during the pre-screening and clinical assessment stages, such as 
gender, age, and BMI, to describe the donor population and sample used in this study.  
Descriptive statistics were utilized to provide an overview of the donor screening 
outcomes for OpenBiome’s entire FMT donor screening program and at each step of the 
program. Prospective FMT donors were broken down by donor pass and deferral for the overall 
screening program and at each step in the screening i.e., pre-screening, clinical assessment, and 
laboratory investigation. The rationale for prospective FMT donor deferral was also available 
and was summarized at each step in the screening and for the program overall. Summarizing the 
rationale for deferral was used to provide an overview of donor outcomes and a descriptive 
breakdown of the most common reasons for donor deferral.  
Aim 1 Statistical Analyses. A predictive modeling analysis utilizing multiple variable 
logistic regression was used to test the hypothesis that one or more prospective FMT donor 
characteristics are predictive of passing the FMT donor screening process. The dependent 
outcome variable was defined as a dichotomous categorical variable identifying whether the 
prospective FMT donor passed the screening process or was deferred from donating stool to be 
used as fecal transplant material.  
Prior to analysis, categorical predictor variables established a priori were summarized 
into proportions. Correlations among the categorical variables were assessed through a chi-
square analysis. Continuous variables were summarized using means, standard deviations, and t-
tests to identify any pre-existing differences in the groups. A significance level (p value) of 0.05 
(5%) was used as the threshold to determine whether the variables should be reevaluated or 
reconsidered for inclusion in the final multiple variable logistic regression analysis.  
STOOL DONOR CHARACTERISTICS 
 
67 
Statistical assumptions underlying the multiple variable logistic regression method were 
tested to verify that study data met the criteria required for a logistic regression analysis. 
Scatterplots for each individual predictor variable against the outcome variable were constructed 
and evaluated to provide a preliminary assessment of the relationship between the variables, 
identify potential outliers, assess for nonlinearity in the data, and verify independence of the 
error. Data points were evaluated to assess whether they were outside the +/-3.0 standard 
deviation cut-off and considered for exclusion as potential outliers. 
Assumption of linearity was assessed through a plot of the residuals versus the predicted 
values. Scatterplots for studentized residuals of each predictor variable and probability P-P plots 
of the standardized residuals were produced to evaluate for constant variance across the model. 
Additionally, normality of the residuals and skewness for continuous variables were assessed 
through visual evaluation of the Standardized Residual histogram and assessed for the need for 
log transformation. Fischer’s measure of skewness was calculated to assess the significance of 
any observed skewness in the variables. If required, recoding of the data and collapsing of 
categories was considered to ensure an equal distribution of the data across groups.  
Multicollinearity between two variables is a concern with multiple variable regression 
analyses. As such, a correlation matrix of the variables, using Pearson correlation, was produced 
and assessed for collinearity among the variables. Linear regression analysis and collinearity 
diagnostics were run to further explore the correlational structure between the variables. A 
finding of multicollinearity among the predictor variables suggested that an interaction might be 
present, and warranted further evaluation and hypothesis testing of variables that may moderate 
one another.  
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Prior to conducting the analysis, the sample was assessed for missing values through 
frequency statistics and cross tabulation tables. Variables were assessed for inherent differences 
or patterns in the missing data. Sensitivity analysis on the missing data was conducted to 
evaluate the randomness of the missing values. An application for dealing with missing data i.e., 
listwise and case wise removal, was considered and performed. Descriptive statistics were run to 
assess the impact of data removal on the variables.  
A stepwise multiple variable logistic regression with backward elimination was 
performed to test the predictors for significance. The Goodness of Fit test was evaluated to see 
how well the data fit the model. The likelihood ratio and Wald statistic were evaluated to assess 
how well the variables in the model predicted the baseline outcome. Using the significant 
predictors determined by this analysis, the data were fit to a final multiple variable logistic 
regression model that identified the prospective FMT donor characteristics most associated with 
passing the FMT donor screening program. Odds ratios for each variable identified by the 
multiple variable logistic regression model as significantly predictive of the outcome were 
calculated and summarized.  
Aim 2 Statistical Analyses. Standard microbiome descriptive analyses were performed 
to describe and assess the composition of the intestinal microbiome of active FMT donors who 
pass OpenBiome’s FMT donor screening program. The OTU table identified through 16S rRNA 
sequencing was utilized to create a taxonomy bar plot to illustrate the relative abundance for the 
ten most abundant bacterial taxa distributed at the phylum level. Limiting the analysis to the ten 
most abundant bacterial taxa allows researchers to accurately identify and capture the major 
microbial phyla present in the fecal material providing a more informative description of the 
microbiome composition (Tyler et al., 2014). The data from cases were also utilized to build a 
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heatmap to provide a visual distribution of the taxa by the most and least abundant bacterial at 
the phylum level. Distance matrices were used to measure beta diversity supported with partial 
mantel and multiple matrix regression with randomization to evaluate and explain variations in 
the data. Ordination plots, or Principal Coordinates Analysis (PCoA), were utilized to visualize 
the data present in the beta diversity index.  
16S RNA based alpha diversity of the intestinal microbiome for each active FMT donor 
was calculated and represented by Shannon’s diversity index. Generalized linear models were 
used to evaluate and explain any variations in the data if apparent. A box and whisker plot was 
created utilizing the Shannon’s diversity index to compare the relative differences in alpha 
diversity among the active FMT donor characteristics found to be predictive of passing the FMT 
donor screening process.  
A simple linear regression model was performed to test the hypothesis that active FMT 
donor 16S rRNA intestinal microbiome alpha diversity is significantly associated with FMT 
clinical efficacy. Prior to analysis, statistical assumptions underlying the simple regression model 
were tested to verify the data met the criteria for regression analysis. A scatterplot of alpha 
diversity, the predictor variable, against clinical efficacy, outcome variable, was constructed to 
provide a preliminary assessment of the relationship between the two variables. Additionally, 
outliers, nonlinearity, and independence of the error were evaluated and considered for 
compliance with the model. Data points were evaluated to assess whether they were outside the 
+/-3.0 standard deviation cut-off and were considered for exclusion as potential outliers. 
Assumption of linearity was assessed through a plot of the residuals versus the predicted 
values. Scatterplots for studentized residuals of alpha diversity and probability P-P plots of the 
standardized residuals were produced to evaluate for constant variance. Additionally, normality 
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of the residuals and skewness for alpha diversity were assessed through visual evaluation of the 
standardized residual histogram and assessed for the need for log transformation. Fischer’s 
measure of skewness was calculated to assess the significance if skewness was observed. 
Because the model for Aim 2 included only one predictor, multicollinearity was not evaluated.  
Prior to conducting the analysis, the sample was assessed for missing values through 
frequency statistics and cross tabulation tables. Variables were assessed for inherent differences 
or patterns in the missing data. An application for dealing with missing data i.e., listwise and 
case wise removal, was considered and performed. Descriptive statistics were run to assess the 
impact of any data removal on the variables.  
A simple linear regression was performed to test the predictor, alpha diversity, for 
significance with the outcome variable, efficacy rate. The regression model correlation 
coefficient and associated model statistics were evaluated to assess whether alpha diversity 
predicted the outcome. Results of the simple linear regression were evaluated through an analysis 
of variance (ANOVA) and standard error of the regression coefficients. Goodness of Fit was 
assessed through evaluation of the coefficient of determinant (R Square) to see how well the 
predictor data fit the model. Likelihood ratio (F statistic) was evaluated to assess how well alpha 
diversity predicts the outcome. Odds ratios were calculated and summarized for variables 
included in the final model. 
Limitations and Threats to Validity 
 A benefit of conducting regression analyses utilizing retrospective data is that this 
approach allows the researcher to examine variables already present in the situation without 
having to prospectively control or manipulate the process (N. Burns & Grove, 2001). However, 
this approach is limited to analyses based on associations only and not causality. Additional 
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research would be needed in order to test for any causality between FMT donor characteristics 
and passing the FMT donor screening processes and 16S rRNA intestinal microbiome 
composition and FMT clinical efficacy of donor fecal material in treating recurrent CDI. The 
presence of collinearity and interactions between predictors present additional challenges to 
utilizing logistic regression to evaluate the effects of multiple independent predictors on the 
outcome, donor status. Despite these limitations, statistical steps were taken to validate 
associations as much as possible by minimizing alternative explanations due to bias, potential 
confounding factors, or random error.  
As with all quasi-experimental studies, issues inherent in the sampling process may lead 
to selection biases. While the flexibility of these study types offers researchers options when 
faced with challenges related to subject recruitment, inherent differences between the groups 
may emerge in in substantive ways. Efforts were taken to reduce incomplete documentation and 
missing data by reviewing source documentation and confirming with the nursing and physician 
study staff. Although measures were taken to reduce sample bias, descriptive and statistical 
analyses were done to identify and acknowledge any inherent differences within in the study 
sample.  
Protection of Human Subjects 
 Ethics board approval for the OpenBiome’s research protocol was obtained from MIT on 
July 18, 2013. All approved study staff interacting with FMT donors received training in 
conducting ethical research studies and completed the online Human Subjects Research 
protection certification course offered through the Collaborative Institutional Training Initiative 
(CITI). Informed consent was obtained from prospective FMT donors who completed the FMT 
donor screening process and prior to donating stool for fecal transplant. During the informed 
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consent process, study procedures were carefully explained to each prospective FMT donor and 
the donor was asked to read the entire informed consent form. The study staff or investigator 
answered any questions presented by prospective FMT donors. Prospective FMT donors were 
reminded that they could choose to voluntarily withdraw from the study at any time for any 
reasons. Consent was reviewed again with the prospective FMT donors, prior to and throughout 
the intervention as needed. Participation in the study was open to adults regardless of gender and 
ethnicity and no harmful or hazardous procedures were conducted on the prospective FMT 
donors. Ethics board approval for this secondary analysis of previously collected, de-identified 
data was obtained on March 9, 2018 from the Boston College institutional review board for the 
protection of human subjects. Written documentation of permission to work with OpenBiome’s 
study data was also obtained prior to conducting the study. 
Data Protection 
The research records used in this study are the property of OpenBiome. To protect 
participant confidentiality, the stool bank assigned prospective FMT donors with a random code 
upon enrollment in the study. Subsequently, all source data was referenced using the random 
donor number only. The key to this code linking subject identification with the random number 
is stored separately from the source documentation and databases. No identifying information 
about the FMT donors were received or used within this study. The database containing the data 
for this analysis were entirely de-identified and kept on a password protected computer.  
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Chapter 4. Results 
This chapter summarizes the data collected on the subjects and results of the data 
analysis. The chapter is divided into two primary sections with the first addressing the analysis 
and results for Aim 1 and the second addressing the analysis and results for Aim 2.  
Aim 1 Description of Sample and Results of Analysis 
 Data were collected from a total of 782 prospective donors who completed OpenBiome’s 
prospective fecal microbiota transplantation (FMT) donor screening program between August 16, 
2013 and December 30, 2016. Data collection was conducted using the methodology outlined 
within the chapter on study methods. Upon completion, data for the regression analyses were 
entered directly into an IBM® Statistical Package for the Social Sciences (SPSS) version 25 
database from the Microsoft Excel© data collection tool. Once entered, the data were cleaned 
and reviewed for accuracy. During review of the data, 12 donors (1.5%) were found to not meet 
inclusion criteria and thus not eligible to participate in OpenBiome’s prospective donor screening. 
Of the 12 excluded donors, nine donors (75.0%) were excluded based on a body mass index 
(BMI) of 30.0 or greater and three donors (25.0%) were excluded based on age. Data from these 
donors were removed from the database, bringing the final number of eligible prospective donors 
who met enrollment criteria and had data collected for this study to a total of 770 subjects.  
 Prior to conducting the analysis, the data were evaluated for any missing values. A 
descriptive frequency analysis demonstrated that there were a total of 54 (0.9%) missing data 
points affecting 26 unique prospective donors (3.4%). Results of the frequency analysis of 
missing data demonstrated that 15 of the prospective donors (1.9%) had no more than one 
missing data point, while 11 of the prospective donors (1.4%) were missing two or more data 
points. Cross tabulation tables were created to evaluate for inherent differences and any patterns 
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in the missing data. Review of the tables demonstrated that the missing values were not related to 
any particular variable and were missing completely at random.  
Based on the analysis, the decision was made to adopt a listwise deletion approach to the 
missing data. This decision was supported by the observation that the missing data appeared to 
occur completely at random, the sample size was sufficiently large to maintain adequate power, 
and the number of prospective donors that contributed to the missing data represented a small 
portion of the total sample size (n=26, 3.4%). As such, removing these prospective donors would 
be unlikely to have a significant impact on the analyses and overall regression model.  
Descriptive statistics were calculated for both continuous (Appendix A) and categorical 
variables (Appendix B) prior to and post listwise removal of the data to evaluate for any patterns. 
Comparison of the tables found similar results between the pre- and post-removal groups, 
supporting the decision to use a listwise deletion approach. Upon completion of the listwise 
removal of the prospective donors with missing data, the final dataset utilized for this analysis 
included data from 744 prospective donors.  
Descriptors and Frequencies 
Results from the overall prospective donor screening program were evaluated to better 
understand the sample population and data utilized in this study. Of the 744 prospective donors 
included in this study, a total of 610 (82.0%) prospective donors were deferred from donating 
upon completion of the prospective screening program (Table 3). 
Table 3.  
Overall results of OpenBiome’s prospective FMT donor screening 
Outcome Total (n=744) 





Screening (n=610)  
Defer 610 (82.0%) 531 (87.0%) 73 (12.0%) 6 (1.0%) 
Pass 134 (18.0%)    
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Of the prospective donors who were deferred, the majority of donors (n=531, 87.0%) 
were deferred during the clinical assessment. Donors were predominantly deferred due to a 
qualifying event related to mental health and well-being (n=95, 17.9%), which included a 
positive history for depression, anxiety, and other mental health related diagnoses (Table 4). A 
history of health diagnoses related to atopy, asthma, and allergies was the second most frequently 
reported rationale for deferral (n=92, 17.3%), followed by a history of a relevant infectious 
disease (n=58, 10.9%). In total, these top categories accounted for 46.1% (n=245), nearly half of 
the prospective donor deferrals. Further explanation of the deferral criteria utilized during the 
clinical assessment can be found in Appendix C. 
Table 4.  
Primary rationale for donor deferral during clinical assessment (n=531) 
Rank Rationale Total n (%) 
1 Mental Health and Well-Being 95 (17.9) 
2 Atopy, Asthma, Allergies 92 (17.3) 
3 Infectious Disease History 58 (10.9) 
4 Sexual Behavior and History 53 (10.0) 
5 Medications and Supplements 44 (8.3) 
6 Social History 40 (7.5) 
7 Gastrointestinal Conditions 30 (5.5) 
8 Family History 26 (4.9) 
9 Other 21 (4.0) 
10 Travel History 21 (4.0) 
11 Autoimmune Conditions 16 (3.0) 
12 Vital Signs 14 (2.6) 
13 Surgical and Other Medical History 5 (0.9) 
14 Neurological Conditions 4 (0.8) 
15 Cancer History 3 (0.6) 
16 Cardiovascular and Metabolic Conditions 3 (0.6) 
17 Diet and Exercise 2 (0.4) 
18 Women's Health 2 (0.4) 
19 Current Health Status 1 (0.2) 
20 Musculoskeletal Conditions 1 (0.2) 
 
During the stool and serological screening assessment, a total of 79 (13.0%) prospective 
donors were deferred. Health related deferrals were predominantly due to abnormal laboratory 
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findings (n=46, 58.2%), of which 42 (91.3%) were due to the identification of a known 
infectious pathogen in an otherwise asymptomatic prospective donor and 4 (8.7%) due to 
abnormal non-infectious serological results (Table 5). The remaining 33 prospective donors 
(n=33, 41.8%) were deferred during the laboratory screening phase as a result of a loss to follow-
up. These prospective donors passed the clinical assessment phase but failed to complete either 
the blood or stool sections of the laboratory screening phase for the prospective donor screening 
program. The final 134 (18.0%) prospective donors who passed all steps of the prospective donor 
screening program were allowed to donate fecal material for use in FMT. 
Table 5.  
Primary rationale for donor deferral during stool and blood screening 
Rank Rationale Total (n=79) 
1 Infectious Disease 42 (53.2%) 
2 Non-Infectious Serologic Test Result 4 (5.1%) 
3 Lost to Follow-up 33 (41.8%) 
 
Descriptive statistics including mean, range, standard deviation, and variance were 
calculated for all four continuous variables to further describe the sample population and 
variables of interest (Table 6). On average, prospective donors were approximately 28 years of  
Table 6.  
Statistical summary of continuous variables 
Predictor Variable Mean Range Min Max Std.  Deviation Variance Statistic Std. Error 
Age (years) 28.1 0.23 31.0 18.0 49.0 6.19 38.25 
Body Mass Index 
(kg/m²) 




1.7 0.02 4.5 0.5 5.0 0.67 0.45 
Alcohol Use (per 
week) 
2.9 0.10 20.0 0.0 20.0 2.71 7.33 
 
age, had a healthy BMI of 23.6, passed between one to two bowel movements per day (1.7 bowel 
movement per day on average), and consumed fewer than three alcoholic beverages per week 
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(2.9 beverages per week on average). In addition, data for all four categorical variables were 
summarized into proportions (Table 7). In general, prospective donors were found to be 
predominantly male (68.1%), consumed a meat-based diet (86.7%), and never smoked (81.3%). 
Most prospective donors were screened in the fall (29.2%) or winter (29.2%), with a notable 
drop in screenings observed during spring (18.6%) and moderate recovery in prospective donor 
screenings during summer (23.0%).  
Table 7.  
Statistical summary of categorical variables 
Predictor Variable Frequency % Cumulative % 
Gender Male 507 68.1 68.1 
 Female 237 31.9 100.0 
Diet Meat Based 645 86.7 86.7 
 No Meat 99 13.3 100.0 
Tobacco Use Never 605 81.3 81.3 
 Former 87 11.7 93.0 
 Current 52 7.0 100.0 
Seasonality Winter 217 29.2 29.2 
 Spring 139 18.6 47.8 
 Summer 171 23.0 70.8 
 Fall 217 29.2 100.0 
 
Statistical Analysis and Data Management 
All eight variables selected a priori for the logistic regression in Aim 1 were evaluated to 
confirm model inclusion and assess for violations of the regression assumptions. Four of the 
variables selected a priori were continuous (age, BMI, frequency of bowel movements, and 
alcohol use) and four were categorical (gender, diet, tobacco use, and seasonality). The following 
section outlines the evaluation of the variables, testing of the logistic regression assumptions, and 
any data management steps taken.  
Measures of central tendency and variance for each continuous variable were reviewed 
for any trends. Frequency distribution histograms and corresponding probability plots (P-P plot) 
for all four continuous variables were generated and evaluated for normality and skewness 
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(Appendix D). Data for age were predominantly normally distributed but demonstrated a slight 
positive skew in both the histogram and P-P plot. Data from BMI generally appeared to be 
normally distributed in both the histogram and P-P plot. The histograms and P-P plots for both 
the frequency of bowel movements and alcohol use demonstrated an obvious positive skew 
indicating a clustering of the data toward the low end of the scale and possible significant 
outliers.  
Findings of skewness were further evaluated using Fisher’s measure of skewness, which 
was calculated by dividing the skewness statistic by its standard error (Table 8).  
Table 8.  
Evaluation of continuous variables for skewness  





Age (years) 1.113 0.090 12.367 
Body Mass Index (kg/m²) 0.077 0.090 0.856 
Frequency of Bowel Movements 
(per day) 
1.130 0.090 12.556 
Alcohol Use (per week) 1.380 0.090 15.333 
 
Due to the sufficiently large sample size and previous observations from evaluation of the 
distribution histograms (Appendix D), a higher criterion level of p <0.001 (+/- 3.29) was utilized 
to assess significance in order to account for small errors inherently found in larger samples 
(Field, 2009; Plitchta & Kelvin, 2013). Despite the limitations observed with Fisher’s measure, 
skewness was significant at p <0.001 for the continuous variables age, frequency of bowel 
movements, and alcohol use. These results were consistent with the visual observation that the 
variables age, frequency of bowel movements, and alcohol use contained a significant number of 
absolute values that were three standard deviations from the mean (+/- 3.29). As such, these 
variables were flagged for further evaluation of outliers and consideration for recoding or log 
transformation.  
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Scatterplots for all four continuous variables were generated against the outcome variable 
and evaluated for nonlinearity and need to address outliers (Appendix E). Visual assessment of 
the scatterplots for each continuous variable demonstrated linearity throughout and independence 
of the error given the binary outcome variable (pass or defer). Further, fit lines indicated that as 
the value of each continuous variable increased, prospective donors were more likely to be 
deferred. While no outliers were noted for age and BMI, several outliers were observed for 
frequency of bowel movements and alcohol use. As such, boxplots were generated for all four 
continuous variables and evaluated (Appendix F). Data for BMI were similar across the two 
groups and did not identify any outliers. For the continuous variables age, frequency of bowel 
movements, and alcohol use demonstrated several data points outside the upper quartile 
supporting the previous finding of skewness observed with these variables.  
Notably, the boxplot for alcohol use identified one potentially problematic outlier. The 
original source documentation for this prospective donor was reviewed to assess any 
discrepancies of which there were none. Further, the impact on the regression line of removing 
this prospective donor from the analysis was assessed and found to be minimal. Lastly, a binary 
logistic regression with casewise diagnostics was run for all four variables against the dependent 
variable. Casewise analysis for all four continuous variables revealed that there were no outliers 
outside the +/- 3.0 standard deviation cut off and there did not appear to be any particular pattern 
to the data. Given these observations and because the data from the outlier was found to be valid, 
the decision was made to retain the donor in the model to preserve the integrity of the original 
sample population and assumptions of the model.  
Based on the problematic findings of skewness associated with three of the continuous 
variables (age, frequency of bowel movements, and alcohol use), options were evaluated to 
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ensure a more equal distribution of the data across the groups. Both recoding of variables and log 
transformation were considered. Review of the data for the continuous variable, alcohol use, 
revealed that a large number of prospective donors reported zero values (n=120, 16.1%) 
indicating that the prospective donors did not regularly consume any alcoholic beverages each 
week. Because log transformation is problematic when variables contain large numbers of zero 
values, the decision was made to recode the variables.  
The continuous variable age was distributed into four clusters based on a modified 
version of the United States (U.S.) Census Bureau’s age distribution (United States Census 
Bureau, 2011). The average number of bowel movements per day (1.7 bowel movements) was 
rounded to a whole number (two bowel movements) and used to distribute the continuous 
variable frequency of bowel movements into two primary clusters in order to account for outliers 
and skewness observed in this variable. Lastly, the U.S. Department of Health and Human 
Services dietary guidelines on alcohol consumption was used as a template to code the variable 
alcohol use (United States Department of Health and Human Services, 2015). Based on these 
guidelines, alcohol use was distributed into three clusters ranging from zero consumption to 
moderate consumption (greater than one but less than seven drinks per week) to high 
consumption (seven drinks or greater per week). Differences in alcohol consumption guidelines 
between genders were not considered for this recoding in order to maintain homogeneity of the 
distribution. Because this study focused on the impact of alcohol on the intestinal microbiome 
and not its impact on gender differences, the decision was made to ensure alcohol exposure was 
consistently measured. Table 9 demonstrates how these three variables were recoded for analysis 
purposes.  
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Table 9.  
Recoded continuous variables 
Predictor 
Variable Initial Measurement Recoded Measurement Groups 
Age • Age (discrete) of FMT donor at 
the time of study participation 
o Mean= 28.1 
o Range= 31.0 
o SD= 6.19 
• Recoded into four primary clusters as 
follows: 
o 1= 18 to 24 years of age (n=226, 
30.4%) 
o 2= 25 to 29 years of age (n=272, 
36.6%) 
o 3= 30 to 34 years of age and greater 
(n=146, 19.6%) 





(per day)  
• The average number (discrete) 
of bowel movements a donor 
self-reports as passing each 
day, rounded to the first 
decimal. 
o Mean= 1.7 
o Range= 4.5 
o SD= 0.67 
• Recoded into two primary clusters as 
follows: 
o 1= Fewer than two bowel movements 
per day (n=465, 62.5%) 
o 2= Two or more bowel movements per 




• An average (continuous) of the 
prospective donor’s self-
reported weekly consumption 
of alcoholic beverages, 
rounded to the first decimal 
place. 
o Mean= 2.9 
o Range= 20.0 
o SD= 2.71 
• Recoded into three primary clusters as 
follows: 
o 1= None; 0 drinks per week (n=120, 
16.1%) 
o 2= Moderate; < 7 drinks per week 
(n=549, 73.8%) 
o 3= High; 7 drinks or greater per 
week (n=75, 10.1%) 
 
The assumption of linearity in regression models asserts that the data points for 
continuous variables share a consistent and specific linear relationship throughout. Nonlinearity 
of the data points could result in a regression model that over- or under-estimates the value of the 
predictor. As such the estimator or regression must be linear. Prior to evaluating plots of the 
residuals, a logistic regression was run to test the assumption of linearity by evaluating for any 
interaction between the remaining continuous variable predictor, BMI, and its log (Table 10). 
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Review of the regression output demonstrated that the interactions were not significant at the p 
<0.05 level, indicating that the assumption of linearity was met for BMI.  
Table 10.  
Test for linearity of the logit* 
 B S.E. Wald df p Exp(B) 
Body Mass Index 2.508 2.291 1.199 1 0.274 12.279 
Body Mass Index by Natural Log 
Transformation for Body Mass Index 
-0.610 0.551 1.224 1 0.269 0.544 
Constant -15.141 12.892 1.379 1 0.240 0.000 
*Variable(s) entered on step 1: Body Mass Index, Body Mass Index * Natural Log 
Transformation for Body Mass Index. 
 
Linearity was further assessed through visual evaluation of the residuals for the 
continuous variable BMI (Appendix G). Despite the limitations of evaluating scatterplots of 
residuals when a binary outcome variable is utilized, visual evaluation of the plots did not 
demonstrate any obvious abnormalities from what would otherwise be anticipated within a 
logistic regression model. As such, it was concluded that the plots concurred with the results 
observed for the regression test for linearity of the logit and supported the assumption that 
linearity had been met. To assess normality, a histogram of standardized residuals was generated 
and reviewed (Appendix H). Although one group clearly contained a higher number of data 
points, the data appeared to be grouped normally. Observations presented in the histogram were 
consistent with findings anticipated when using a binary logistic regression model. As such, 
normality of the data was assumed. 
Chi-square testing was conducted to allow for group comparisons among the predictor 
variables to evaluate for differences and any relationship among the variables. Both a priori and 
recoded categorical variables were used in this analysis. The predictor variables were first 
examined through a correlation matrix for values greater than 0.80, which, if found, would 
suggest the variables could be interrelated and require further evaluation (Munro, 2000). 
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Correlations among several study variables were observed to be significant at the p <0.01 and p 
<0.05 (2-tailed) levels (Table 11). The variables gender and frequency of bowel movements were 
observed to have the highest potential correlation suggesting further inquiry was required. 
Similarly, alcohol use and tobacco use were noted to be significant at the p <0.01 levels. Despite 
these findings, none of the initial correlations assessed at the 2-tailed level of significance were 
found to be highly correlated with correlation values greater than an absolute value of 0.80 
suggesting the correlations were low (Field, 2009).  
Table 11.  
Correlations for predictor variables included in logistic regression 





Gender 1       




-0.172** -0.050 1     
Diet 0.055 0.008 -0.001 1    
Alcohol Use -0.072 -0.073* 0.048 -0.094* 1   
Tobacco Use -0.059 -0.011 0.036 -0.003 0.117** 1  
Seasonality -0.079* -0.038 0.062 -0.065 0.014 -0.017 1 
* Correlation is significant at the 0.05 level (2-tailed). 
** Correlation is significant at the 0.01 level (2-tailed). 
 
Collinearity statistics were subsequently run to further evaluate the relationships among 
the continuous variables (Table 12). The average variance inflation factor (VIF) of the group was 
calculated as 1.024, which was marginally above 1.0. This indicated that multicollinearity had a 
low likelihood of introducing bias into the logistic regression. Similarly, this appeared to be 
predominantly driven by the variables, gender and frequency of bowel movements. However, 
evaluation of the tolerance levels and percent of variance demonstrated a low amount of variance 
shared by other variables, 4.3% for gender and 3.5% for frequency of bowel movements. As 
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such, based on the results of these analyses and taking into consideration the large sample size 
utilized in this study, the risk from multicollinearity was considered to be minimal. 
Table 12.  
Collinearity statistics 
 VIF Tolerance Statistic % 
Gender 1.045 0.957 4.3 
Age 1.009 0.991 0.9 
Frequency of Bowel Movements 1.037 0.965 3.5 
Diet 1.015 0.985 1.5 
Alcohol Use 1.033 0.968 3.2 
Tobacco Use 1.018 0.982 1.8 
Seasonality 1.014 0.986 1.4 
 
Aim 1 Logistic Regression 
A backward elimination logistic regression was conducted to test the hypothesis that 
there is a statistically significant association between one or more prospective FMT donor 
characteristic (predictor variables) and passing the FMT donor screening program (outcome 
variable). Predictor variables were entered in one block and a backward stepwise elimination 
approach using likelihood ratio was selected. Categorical predictors were set to indicator status 
for coding the standard dummy variable. The first category of each categorical variable was 
selected as the baseline value for coding purposes. The outcome variable was coded as “0” for 
deferral of a prospective donor and “1” for when a prospective donor passed the screening. The 
alpha level of significance was set at p <0.05 for the analysis. Hosmer and Lemeshow Goodness 
of Fit statistic, residuals, and classification plots were further selected to evaluate how well the 
model fit the data. Casewise listings was set to two standard deviations. Finally, a confidence 
interval of 95% was used to calculate the odds ratios for significant predictors. Results of the 
logistic regression analysis are provided in Appendix I. All selected cases were utilized in the 
analysis and there were no missing cases.  
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The log-likelihood value of the baseline model where only the constant was included was 
701.68 (Block 0: Beginning Block), which represented the most basic fit of the model to the data. 
For the backward stepwise elimination model with likelihood ratio, a total of eight iterations 
were performed using a 0.001 threshold as the parameter estimate before arriving at the final 
model. The eighth and final iteration of the backward elimination model included the variable 
frequency of bowel movements of two or more per day and reported a log-likelihood value of 
695.66. The log-likelihood for the final model was reduced in comparison to the baseline model, 
suggesting that when donor frequency of bowel movements was included, the model was better 
at predicting whether a prospective donor would pass or be deferred. Analysis of the model chi-
square statistic of 6.017 taken from the Omnibus tests of the model coefficients was significant 
with a p value of 0.014 (p >0.05) providing further support for the that the results of the 
regression model was significantly different from the baseline model. 
Notably, the classification table for the final model remained unchanged from the 
baseline model, with the model chosen that predicted donor outcome based on the majority of 
observations. Based on this approach, the model predicted that prospective donors who had a 
frequency of bowel movements of two or more per day would be more likely to be deferred. A 
cross tabulation table was generated for the predictor variable frequency of bowel movement and 
the outcome variable FMT donor status, defined as defer or pass upon completion of the 
screening program (Table 13). A total of 279 prospective donors with a frequency of bowel 
movements of two or more per day were deferred. Of these 279 donors, the model correctly 
predicted that 241 (86.4%) of these donors were deferred and misclassified 38 (13.6%) of the 
prospective donors.  
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Table 13.  
Cross tabulation of FMT donor status and frequency of bowel movements 
  Frequency of Bowel Movements Total Fewer than two Two or more 
FMT Donor Status Defer 369 (79.4%) 241 (86.4%) 610 (82.0%) 
 Pass 96 (20.6%) 38 (13.6%) 134 (18.0%) 
 Total 465 279 744 
 
The value of the beta coefficient (B) for the final model was -0.501 (Table 14), which had an 
associated Wald statistic of 5.73 and was significant at a p value of 0.016 (p >0.05). As such, 
inclusion of the predictor frequency of bowel movements in the model was a significant 
predictor of whether a donor was deferred upon completion of the prospective donor screening 
program. The negative beta coefficient indicated that prospective donors with a frequency of 
bowel movements of two or more per day were less likely to pass the screening than donors with 
a frequency of bowel movements of fewer than two per day. Review of the final model log 
likelihood statistic reported a change of 6.017, which was significant with a p value of 0.014 (p 
<0.05). As such, removal of the variable frequency of bowel movements of two or more per day 
would have a significant effect on the predictability of the model. The residual chi-square overall 
statistic for the final model was 11.703 but was not significant with a p value of 0.552 (p >0.05) 
supporting the conclusion that addition of the other variables would not increase the model’s 
predictive power. This was further supported by absence of any significant Roa’s efficient score 
statistic values provided by the table for variables not included in the model.  
Table 14.  
Results of final logistic regression analysis 
Variable Beta S.E. Wald p Exp(B) 95% CI for Exp(B) 
Lower Upper 
Frequency of BM  
Two or more (per day) -0.501 0.209 5.753 0.016 0.606 0.403 0.913 
Constant -0.846       
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The odds ratio, labeled Exp (B), is an indicator for the change in odds as a result of a one-
unit change in the predictor. For the final model predictor, frequency of bowel movements of 
two or more per day, the odds ratio was 0.606 with an associated confidence interval of 0.403 to 
0.913 (Table 14). Given the value of 0.606 change in odds was less than one, the model 
suggested that the odds of the outcome occurring, decreased with an increase in the value of the 
predictor. Namely, the odds of a donor passing the prospective donor screening with a frequency 
in bowel movements of two or more per day was lower at 0.606. Probabilities were also 
calculated to evaluate the odds for each outcome (Table 15). In summary, the odds of a donor 
having a frequency of bowel movements of two or more per day and passing the prospective 
donor screening were 13.6%. These odds were lower as compared to the 20.6% odds for donors 
who reported a frequency of bowel movements of fewer than two per day. The predicted 
probabilities concurred with the probabilities supplied in the Case summaries table resulting 
from the final model. 
Table 15.  
Final model probabilities 
 Frequency of Bowel Movements 
Fewer than two (%) Two or more (%) 
Pass 20.6 13.6 
Defer 79.4 86.4 
 
Evaluation of Cook’s Distance (range 0.001 to 0.023) for the model found that all the 
variables were less than one, indicating that no specific case had an undue influence on the 
model. Similar findings were observed by evaluation of the Centered Leverage value (range 
0.002 to 0.004) providing further evidence that there were no influential cases within the model. 
DFBeta statistics for the model were evaluated to assess whether any cases had a large influence 
on the regression parameters. The review found no absolute values greater than one for either 
DFBeta statistics for the constant (range 0.000 to 0.010) or frequency of bowel movements 
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(range 0.003 to 0.026), suggesting that no cases exerted undue influence on the regression 
parameters utilized in this model. Finally, a forced entry logistic regression model was rerun with 
the predictor variable, frequency of bowel movements, to remove any influence that the non-
significant predictors may have had on the model. Results of the forced entry logistic regression 
concurred with the findings from the backwards elimination logistic regression analysis. 
Similarly, forced entry simple logistic regression models were performed for each non-
significant variable (Appendix J). Results of these logistic regression analyses concurred with the 
findings from the backward elimination logistic regression analysis. 
For the Aim 1 logistic regression, all predictor variables were entered into the model and 
evaluated stepwise to see if they contributed to the regression equation (Table 16). Predictor 
variables found not to contribute statistically to the model (reporting a p value equal to or greater 
than 0.05) were dropped until only statistically significant predictors remained. The final model 
contained the predictor, frequency of bowel movements two or more per day, and accounted for 
0.8% (0.008 Cox & Snell R Square) to 1.3% (0.013 Nagelkerke R Square) of the variance.  
Table 16.  
Results of the logistic regression analysis 
 Variables  





Gender        
Female -0.341 0.224 2.311 0.128 0.711 0.459 1.104 
Age        
18 to 24 years of age   1.477 0.688     
25 to 29 years of age -0.251 0.24 1.095 0.295 0.778 0.487 1.245 
30 to 34 years of age -0.115 0.276 0.173 0.678 0.892 0.519 1.533 
35 to 50 years of age -0.322 0.341 0.895 0.344 0.724 0.371 1.413 
Body Mass Index -0.028 0.039 0.509 0.475 0.973 0.902 1.049 
Frequency of BM        
Two or more per day -0.509 0.215 5.592 0.018* 0.601 0.394 0.917 
Diet        
No Meat -0.461 0.322 2.054 0.152 0.631 0.336 1.185 
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Table 16. (continued) 
 Variables  
(Step 1) Beta S.E. Wald p 
Odds 
Ratio CI 95% 
Alcohol Use        
None   0.459 0.795     
Moderate -0.027 0.267 0.01 0.921 0.974 0.577 1.645 
High -0.249 0.405 0.378 0.539 0.78 0.353 1.724 
Tobacco Use        
None   1.121 0.571     
Former -0.11 0.319 0.119 0.730 0.896 0.480 1.673 
Current -0.438 0.428 1.048 0.306 0.645 0.279 1.493 
Seasonality        
Winter    4.244 0.236     
Spring -0.491 0.309 2.528 0.112 0.612 0.334 1.121 
Summer -0.297 0.277 1.148 0.284 0.743 0.432 1.279 
Fall 0.045 0.243 0.035 0.852 1.047 0.650 1.685 
Constant 0.341 0.997 0.117 0.732 1.406    
* Significant at the p value level of <0.05 
 
Overall, the final model was found to be more predictive of donor passage or deferral 
when the variable frequency of bowel movements was included. However, despite the 
statistically significant finding, further evaluation of the model parameters supported that the 
overall model was not a good fit or very good at predicting the outcome. Evaluation of Hosmer 
and Lemeshow Goodness of Fit test was not feasible due to inherent constraints resulting from 
the use of a binary predictor in the final model (degrees of freedom equal to 0). In summary, 
frequency of bowel movements, while found to be a significant predictor, did not explain most of 
the variability in the outcome. Most notably, the remaining seven predictors including gender, 
age, BMI, diet, alcohol use, tobacco use, and seasonality were not statistically significant 
predictors of donor passage or deferral based on the logistic regression despite the theoretical 
underpinnings suggesting that these variables may play a role in overall donor health. 
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Aim 2 Description of Sample and Results of Analysis 
 Data were collected from a subset of screened prospective donors for the analysis 
associated with the second aim of this study. The sample included prospective donors who had 1) 
passed the FMT donor screening program; 2) submitted a fecal sample for 16S ribosomal 
ribonucleic acid (rRNA) sequencing; and 3) donated material that was used in a FMT to treat 
patients with recurrent Clostridium difficile infections (CDI). Although a total of 134 prospective 
donors passed the screening, only 87 donors (64.9%) contributed fecal material for which 
clinical efficacy data were available. The clinical efficacy rate for each of the sample donors was 
entered into a Microsoft Excel© spreadsheet as a cumulative percentage rate (rounded to the 
nearest tenth), verified for accuracy, and subsequently uploaded into an IBM® SPSS version 25 
database for analysis.  
 One copy of 16S rRNA sequencing data for each of the sample donors was requested and 
retrieved from the data repository. Fecal microbiome 16S rRNA sequencing data were available 
for all 87 of the requested donors. A compressed file containing de-multiplexed paired strands 
was downloaded onto an Apple Macintosh® computer capable of processing the raw sequencing 
data using QIIME 2© version 2018.8 microbiome data analysis software (Caporaso et al., 2011; 
QIIME 2 development team, 2018). De-multiplexed paired strands for all sample donors were 
imported into the QIIME 2 software without error. A summary table was generated to visualize 
the data for sequencing quality control (Appendix K). Based on visual inspection, the quality of 
the sequence data observed was high and no data trimming was required at the beginning or end 
of the sequences. As such, a right trim point at 200 bases was selected based on an observed 
decrease in quality reads past this point. This information was used to run the Divisive Amplicon 
Denoising Algorithm 2 (DADA2) pipeline to detect and filter out biological variations in the 
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sequencing data associated with amplicon sequencing errors, including phiX reads and chimeric 
sequences (Callahan et al., 2016). The results of this quality filtering were used to construct the 
Feature Table and Feature Data files needed to evaluate the donor fecal microbiome data. No 
errors or issues were observed in the sequencing data upon completion of the quality control 
measures executed in QIIME 2.  
Descriptors and Frequencies 
 Descriptive statistics were calculated using the same variables utilized during Aim 1 to 
better understand and evaluate the sample population used in the analysis for Aim 2 (Table 17). 
On average, the donors included in the sample for Aim 2 were approximately 27 years of age, 
had a healthy BMI of 23.2 kg/m2, passed fewer than 2 bowel movements per day (1.6 bowel 
movements per day on average), and consumed approximately 3 alcoholic beverages per week 
(3.1 beverages per week on average).  
Table 17.  
Statistical summary of continuous variables 
Predictor Variable Mean Range Min Max Std.  Deviation Variance Statistic Std. Error 
Age (years) 27.3 0.6 26.0 19.0 45.0 5.48 30.00 
Body Mass Index 




1.6 0.1 3.0 0.5 3.5 0.67 0.45 
Alcohol Use (per 
week) 3.1 0.3 10.0 0.0 10.0 2.47 6.12 
 
 Data for all four categorical variables were summarized into proportions and evaluated 
for trends (Table 18). In general, the sample population used in Aim 2 was predominantly male 
(72.4%), consumed a meat-based diet (90.8%), and never smoked (83.9%). 
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Table 18.  
Statistical summary of categorical variables 
Predictor Variable Frequency % Cumulative % 
Gender Male 63 72.4 72.4 
 Female 24 27.6 100.0 
Diet Meat Based 79 90.8 90.8 
 No Meat 8 9.2 100.0 
Tobacco Use Never 73 83.9 83.9 
 Former 8 9.2 93.1 
 Current 73 83.9 100.0 
Seasonality Winter 29 33.3 33.3 
 Spring 11 12.6 46.0 
 Summer 17 19.5 65.5 
 Fall 30 34.5 100.0 
 
Descriptive statistics for both the continuous variables (Appendix L) and categorical 
variables (Appendix M) utilized in the sample population for Aim 2 were compared with the 
sample population utilized in Aim 1 to evaluate for any obvious patterns or discrepancies. 
Despite the notably smaller sample size in Aim 2, comparison of the tables found similar results 
between the two sample populations used in Aim 1 and Aim 2.  
Microbiome Analysis 
 A metadata file was generated and imported to QIIME 2, which included the identifier, 
sequence information, and cumulative clinical efficacy for each donor. The variable found to be 
significant from Aim 1, frequency of bowel movements, was included in the metadata file. The 
information contained within the metadata, Feature Table, and Feature Data files were used to 
explore the fecal microbiome composition and characteristics for the total sample and by 
individual donor fecal material. This information was further used to evaluate the beta and alpha 
diversity of the total sample and by individual donor. 
Characteristics of the fecal microbiome for the overall sample. Descriptive statistics 
were calculated at the bacterial phylum level to evaluate the frequency of features e.g., bacterial 
operational taxonomic units (OTU), present within the sample (Table 19). Bacterial phyla were 
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organized in descending order from most to least frequent. The total frequency of bacterial OTUs 
observed for the entire sample, all 87 donors, was 2,769,977 with a per donor frequency rate 
ranging from a low of 5,705 OTUs to a high of 71,173 OTUs. The average frequency of OTU 
bacterial features for the sample was 31,839 for the sample. Within the total sample population, 
the most abundant bacteria represented belonged to the Firmicutes phylum (n=1,632,950, 59.0%) 
followed by bacteria from the Bacteroidetes phylum (n=897,287, 32.4%). Overall, bacteria from 
the Firmicutes and Bacteroidetes phyla contributed 91.3% of the frequency of bacterial OTU 
features observed within the sample. 
Table 19.  
Statistical summary of sample frequencies or OTUs by phylum 
Phylum N % Mean Range Min Max 
Firmicutes 1,632,950 59.0 18,770 41,865 3,990 45,855 
Bacteroidetes 897,287 32.4 10,314 43,477 1,134 44,611 
Actinobacteria 127,813 4.6 1,469 9,933 62 9,995 
Proteobacteria 68,874 2.5 792 10,532 74 10,606 
Verrucomicrobia 19,481 0.7 224 2,969 0 2,969 
Euryarchaeota 11,230 0.4 129 1,558 0 1,558 
Cyanobacteria 5,062 0.2 58 715 0 715 
Fusobacteria 4,746 0.2 55 2,768 0 2,768 
Tenericutes 1,860 0.1 21 253 0 253 
Lentisphaerae 393 0.0 5 65 0 65 
Bacteria, unclassified 220 0.0 3 198 0 198 
Synergistetes 58 0.0 1 19 0 19 
Spirochaetes 3 0.0 0 3 0 3 
Total 2,769,977 100.0 31,839 65,468 5,705 71,173 
 
The next nearest phylum, Actinobacteria, was notably lower contributing only 4.6% (n=127,813), 
while the Proteobacteria phylum contributed an additional 2.5% of the bacterial OTU features. 
In total, the four aforementioned bacterial phyla, Firmicutes, Bacteroidetes, Actinobacteria, and 
Proteobacteria contributed 98.4% of the feature OTUs found in the overall sample.  
Characteristics of the fecal microbiome by individual donor. Descriptive statistics 
were generated at the individual donor level to evaluate and better understand the fecal 
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microbiome composition contributed by each donor and to observe for any differences. A 
histogram presenting the frequency in number of bacterial OTU features provided by each donor 
sample demonstrated a predominantly normal shaped distribution across the sample (Appendix 
N). A summary table containing descriptive statistics at the phylum level was generated using 
these data to visually evaluate community richness by donor (Table 20). Consistent with the 
overall observations for the sample, the most prominent phylum, Firmicutes, ranged between 
22.3% to 83.6% of the composition of the fecal microbiome of each donor and, on average, 
composed 59.2% of a donor’s fecal microbiome. The second most abundant bacterial phylum, 
Bacteroidetes, ranged in composition from 10.9% to 62.7% of the fecal microbiome for each 
donor and, on average, comprised 32.0% of a donor’s fecal microbiome.  
Table 20.  
Summary of percentage composition of bacterial phylum by donors 
Predictor Variable Mean Range Min Max Std.  Deviation Variance Statistic Std. Error 
Firmicutes 59.2 1.015 61.3 22.3 83.6 9.470 89.689 
Bacteroidetes 32.0 0.979 51.8 10.9 62.7 9.131 83.380 
Actinobacteria 4.6 0.346 14.8 0.2 15.0 3.230 10.435 
Proteobacteria 2.5 0.287 23.8 0.3 24.1 2.680 7.184 
Verrucomicrobia 0.8 0.170 8.8 0.0 8.8 1.586 2.516 
Euryarchaeota 0.4 0.102 3.9 0.0 3.9 0.950 0.902 
Cyanobacteria 0.2 0.063 3.1 0.0 3.1 0.588 0.346 
Fusobacteria 0.2 0.127 10.5 0.0 10.5 1.188 1.412 
Tenericutes 0.1 0.021 1.0 0.0 1.0 0.200 0.040 
Lentisphaerae 0.0 0.004 0.2 0.0 0.2 0.038 0.001 
Bacteria, unclassified 0.0 0.006 0.5 0.0 0.5 0.054 0.003 
Synergistetes 0.0 0.000 0.0 0.0 0.0 0.000 0.000 
Spirochaetes 0.0 0.000 0.0 0.0 0.0 0.000 0.000 
 
An OTU taxonomy bar chart was generated to visually evaluate the per donor 
observations summarized in the table (Appendix O). Consistent with the previous findings, 
bacteria from the phyla Firmicutes and Bacteroidetes were predominantly observed in the 
compositions for each donor. On the low end of the scale, bacteria from the combined groups, 
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Firmicutes and Bacteroidetes, composed 72.2% of the donor’s fecal microbiome. For this donor, 
bacteria from the Proteobacteria phylum contributed 24.1% of the remaining fecal microbiome. 
In contrast, the fecal microbiome of the donor with the second lowest combined percentage 
composition of Firmicutes and Bacteroidetes (80.6%) was comprised primarily of bacteria from 
the Actinobacteria phylum, which composed 15.0% of the donor’s fecal microbiome. On the 
high end of the table, bacteria from the combined group Firmicutes and Bacteroidetes comprised 
98.2% of the donor’s fecal microbiome. One donor had a notably higher percentage composition 
of bacteria from a less common phylum, Fusobacteria (10.5%). Bacteria from this phylum were 
otherwise not well represented elsewhere in the sample population.  
 A heatmap based on donor 16S rRNA data can be useful to explore for any unusual 
patterns in donor contribution and corroborate the observations with those presented by the OTU 
taxonomy bar chart. As such, a heatmap was generated at the phylum level to further evaluate the 
donor sample (Appendix P). Generally, most donors were observed to contribute similar OTU 
frequencies across all phyla. However, bacteria from the phyla Verrucomicrobia and 
Euryarchaeota comprised higher portions of the intestinal composition for a select subset of 
donors. When compared with the taxonomy bar chart, this same observation was also noted in 
OTUs (Appendix O). On further exploration, these two phyla groups combined 
(Verrucomicrobia and Euryarchaeota) contributed less than 10% of the overall frequency of 
OTUs for any of the donors.  
 A Principal Coordinate Analysis plot (PCoA) was generated using the QIIME 2 software 
platform to visually evaluate the microbiome diversity between donors, referred to as beta 
diversity. Beta diversity is utilized to evaluate how different two or more microbiome 
communities are from each other and represents a between samples analysis. Using a Bray-Curtis 
STOOL DONOR CHARACTERISTICS 
 
96 
approach and taxonomic data provided by the16S rRNA donor data, relative distance matrices 
for donors included in the sample were calculated using the QIIME 2 software platform and 
plotted on a three-dimensional emperor plot (Appendix Q). Each data point in the PCoA plot 
represented an individual donor. The resulting PCoA plot demonstrated an overall clustering of 
the donor samples within a large data cloud, indicating that most donors shared similar 
microbiome habitats. Variance explained by the three axes in the PCoA plot ranged from 5.6% to 
11.3%. Despite the low values, overall observation suggested that donors included in the sample 
did not differ significantly (Goodrich et al., 2014; Kuczynski et al., 2010). Two donors in 
particular, however, appeared to be notably different from the remainder of the donors. Despite a 
review of these donors’ data, there were no apparent dissimilarities in the donor characteristics, 
nor were any data observed that could account for the differences observed in microbial habitat.  
 The Shannon diversity index was utilized to evaluate how diverse each donor sample was 
independently, referred to as alpha diversity. Alpha diversity as measured by the Shannon 
diversity index provides a measure of both the abundance and evenness of the taxa that are 
present within a specific donor sample (Shannon, 1997). This approach demonstrates a within 
sample evaluation and tends to vary across different sampled sites. In general, fecal samples tend 
to be more diverse and present higher alpha diversity levels than other sampled human 
microbiome sites (J. Peterson et al., 2009). The QIIME 2 software platform provides several 
measures of alpha diversity. However, for this study the data represented by the Shannon 
diversity index were selected for further evaluation (Table 21). On average, the alpha diversity of 
the donor sample was 5.5 and ranged from a low of 2.6 to a maximum of 6.4. No apparent 
variations were noted in the data results and overall observations were consistent with donor data 
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reported in the literature on FMT donors (Kelly et al., 2016; Seekatz et al., 2014; van Nood, 
Dijkgraaf, et al., 2013).  
Table 21.  
Statistical summary of continuous variable, alpha diversity 
Predictor Variable Mean Range Min Max Std.  Deviation Variance Statistic Std. Error 
Alpha Diversity 5.5 0.055 2.6 3.8 6.4 0.509 0.259 
 
Shannon’s diversity index for each donor was used to generate a box and whisker plot to 
evaluate for any difference in alpha diversity among the categorical variable, frequency of bowel 
movements (Appendix R). This variable was found to be predictive of a donor passing the FMT 
donor screening program. Visual observation demonstrated that donors who passed fewer than 
two bowel movements per day did appear to have a higher level of alpha diversity as compared 
with donors who had two or more bowel movements per day. Descriptive statistics were 
calculated to further explore for any differences between the groups (Table 22). More than half 
of all donors who passed fewer than two bowel movements per day had an alpha diversity 
greater than 5.6 as compare to the 5.3 mean alpha diversity for donors who passed two or more 
bowel movements per day. The difference in mean alpha diversity between groups, however, 
was marginal and concurred with observations demonstrated by Vandeputte and colleagues’ 
(2016) assessment of alpha diversity based on stool consistency using the Bristol stool scale.  
Table 22.  
Statistical summary of alpha diversity by donor frequency of bowel movements per day  
 n Mean Range Min Max Std.  Deviation Variance Statistic Std. Error 
Fewer than two 
BM per day 
63 5.6 0.052 2.6 3.8 6.4 0.416 0.173 
Two or more 
BM per day 
24 5.3 0.133 2.4 3.9 6.3 0.649 0.422 
 
One outlier was noted in the group of donors who passed fewer than two bowel 
movements per day. This donor was removed from the subgroup of donors and descriptive 
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statistics were repeated to evaluate any changes in the data (Table 23). After excluding the 
potential outlier, donors who passed two or more bowel movements per day demonstrated a 
much wider degree of alpha diversity (range of 2.6) ranging from a minimum of 3.9 to a high of 
6.3 as compared to a range of 1.6 for donors who passed fewer than 2 bowel movements per day. 
Despite the limited impact that removing this donor had on a change in the mean alpha diversity 
(5.6 pre-removal versus 5.7 post-removal), this donor was flagged for further evaluation during 
the linear regression analysis portion of this study. 
Table 23.  
Revised statistical summary of alpha diversity by donors who passed fewer than two bowel 
movements per day 
 n Mean Range Min Max Std.  Deviation Variance Statistic Std. Error 
Fewer than two 
BM per day 
62 5.7 0.043 1.6 4.8 6.4 0.342 0.177 
 
Statistical Analysis and Data Management 
A simple linear regression approach was chosen for Aim 2 to evaluate the relationship 
between the a priori selected continuous predictor variable, alpha diversity, and the donor’s 
FMT clinical efficacy rate recorded as an overall percentage. Prior to the analysis, the regression 
variables, alpha diversity and efficacy rate, were plotted in a simple scatterplot to assess the 
general relationship between the two variables (Appendix S). Based on the scatterplot, alpha 
diversity appeared to be positively correlated with the rate of efficacy, suggesting that as alpha 
diversity of the donor fecal microbiome increased, the efficacy rate of the fecal material in 
preventing Clostridium difficile recurrence also increased. The two aforementioned potential 
outliers observed during the visual evaluation of the sample and donor microbiome were also 
evaluated against the scatterplot to verify if the trend continued when the efficacy rate was 
included. Despite the findings observed in the descriptive analysis of the donor microbiome, the 
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two potential donor outliers were found to reside within the large data cloud, suggesting that for 
the linear regression analysis, these donors were not significant outliers.  
The independent variable, alpha diversity, was further evaluated to confirm the choice of 
the model and assess for any violations of the regression assumptions. A frequency histogram 
and P-P plot were generated to assess the predictor variable, alpha diversity, and evaluate 
measures of central tendency (Appendix T). Both figures demonstrated an obvious negative 
skew to the data with a large clustering of the data at the upper end of the scale. Fisher’s measure 
was subsequently run to further evaluate the observation (Table 24). Despite the limitations of 
Fisher’s measure, the results were consistent with a negative skewing of the data. The measure 
was noted to be significant at p <0.001 (+/- 3.29). Based on these results, the decision was made 
to perform a reverse score log transformation on the predictor, alpha diversity, to address the 
negative skewing. 
Table 24.  
Evaluation of continuous variable for skewness  





Alpha Diversity -1.226 0.258 -4.752 
 
A frequency histogram and P-P plot were rerun utilizing the reverse score log-
transformed predictor variable, renamed alpha diversity log-transformed, to evaluate the impact 
of the reverse score log transformation on the variable’s skewness (Appendix U). Both figures 
demonstrated a notable decrease in the level of skewness observed. Evaluation of the histogram 
for the log-transformed alpha diversity variable was consistent with trends that would be 
anticipated when utilizing a reverse score approach, namely the reversal of scores, where big 
scores become smaller and vice versa (Field, 2009). Although the histogram of the log-
transformed variable continued to demonstrate some skewing, the skew was less prominent than 
STOOL DONOR CHARACTERISTICS 
 
100 
what had been observed in the previous, non-transformed histogram. Visual evaluation of the P-
P plot provided similar findings with a continued, yet notably reduced skewing in the data. 
Fisher’s measure was rerun to further evaluate the findings (Table 25). Results of the analysis 
demonstrated that despite the slight positive skewing, the observations were no longer significant 
at the p <0.001 (+/- 3.29). 
Table 25.  
Evaluation of transformed continuous variable for skewness  







0.314 0.258 1.217 
 
A post-transformation scatterplot of the predictor variable, alpha diversity, against the 
outcome variable, efficacy rate, was constructed to reassess the relationship between the 
variables, identify any new outliers, and assess for nonlinearity (Appendix V). Visual assessment 
of the scatterplots demonstrated linearity throughout and supported independence of the error. 
Further, the scatterplot continued to demonstrate a positive relationship between alpha diversity 
and efficacy rate. As such, the same relationship was observed between the pre- and post-
transformed scatterplots of the predictor variable alpha diversity and efficacy rate. Otherwise, 
there did not appear to be any particular pattern to the data cloud present in the post-transformed 
scatterplot indicating that a violation of the assumption of linearity was unlikely. Confidence 
intervals at 95% were added to the post-transformed scatterplot to assess for potential outliers 
that may exert an undue influence on the regression analysis (Appendix W).  
Several outliers not previously flagged during the analysis were observed and marked for 
further evaluation. Casewise diagnostics were run and confirmed the presence of one donor 
residing outside the +/- 3.0 standard deviation cut off of particular concern (Appendix X). This 
donor had a high alpha diversity score with corresponding low clinical efficacy rate. Source 
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documents were requested and queried for this donor and were found to be valid. The impact to 
the dataset and regression line of removing this suspected donor outlier was assessed by plotting 
the pre- and post-removal regression lines on a scatterplot (Appendix Y). Although a shift in the 
regression line was observed, the change was noted to be small. Based on these findings, the 
decision was made to retain the donor’s data within the dataset in order to maintain the integrity 
of the data and assumptions of the regression model. 
Plots of the residuals with the predicted values for the independent variable alpha 
diversity log-transformed was generated to further evaluate for violations in the regression 
assumption (Appendix Z). The assumption of linearity was assessed through a plot of the 
residuals versus the predicted values. Although the graph demonstrated a dense data cloud and 
one suspected data point outside +/-3.0 standard deviation, there did not appear to be a particular 
pattern to the data indicating that a violation of the assumption of linearity was unlikely. 
Scatterplots demonstrated data that were generally well spread throughout the plots. A P-P plot 
of the standardized residuals demonstrated some bowing out of the data particularly in the 
middle and towards the upper end, closer to 1.0. However, the bowing did not appear to be 
significant, indicating that while some level of violation of constant variance might have been 
present, this was not likely to notably impact the regression analysis. Analysis of the residual 
scatterplots for the independent variable, alpha diversity log-transformed, did not demonstrate 
any particular pattern to the data. As such, it was assumed that independence of the error was not 
violated. To assess normality, a histogram of standardized residuals was generated and reviewed 
(Appendix AA). Although the data were predominantly normally distributed, the histogram did 
demonstrate some skewing to the left with a number of variables lying beyond the -4.0 point. 
However, this appeared to be a small portion of the overall residual.  
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Aim 2 Linear Regression 
 A simple linear regression assessing the relationship between the clinical efficacy rate 
and alpha diversity of the donor fecal material as measured by Shannon’s diversity was used to 
evaluate if there was any level of predictability between the two variables. Because only one 
predictor variable was considered, alpha diversity, the model was set to enter all variables at 
once. The results of the regression analysis were calculated in model 1 as part of the test for 
interaction (Appendix BB). For this analysis, the alpha level of significance was set at p <0.05. 
Residuals and classification plots were further selected to evaluate how well the model fit the 
data. Casewise listing was set to two standard deviations. Lastly, a confidence interval of 95% 
was set in order to calculate the odds ratios if the predictor, alpha diversity, was found to be 
significant. All cases in the sample were utilized in the regression analysis and there were no 
missing cases from the analysis.  
On average, the efficacy rate for the overall sample of 87 donors was 78.9%, suggesting a 
CDI recurrence rate of 21.1%. Evaluation of the reported correlation value (R) of 0.159 observed 
between the two variables used in the simple regression model, alpha diversity and efficacy 
(Table 26), was not significant with a p value of 0.07 (p >0.05). The proportion of variance (R2) 
explained by the simple linear regression model was reported as 0.025, indicating that 
approximately 2.5% of the variability in the efficacy rate could be explained by changes in the 
alpha diversity of the donor’s fecal microbiome. In total, 97.5% of the variability in the efficacy 
rate could not be explained by the predictor, alpha diversity, indicating that other variables not 
included in the model were likely more influential of the outcome. The adjusted R2 value 
provided a more conservative estimate of 0.014 or 1.4% of explained variance in the efficacy 
rate. However, this was not notably different from the R2 of 2.4% indicating that the R2 value 
STOOL DONOR CHARACTERISTICS 
 
103 
was generally reflective of the model. Because this model only utilized one predictor variable, 
this similarity between the statistics was not unexpected.  
Table 26.  
Model summaryb 
Model R R Square 
Adj R 
Square 








1 0.159a 0.025 0.014 11.405 0.025 2.217 0.140 
a Predictors: (Constant), Alpha Diversity log transformed 
b Dependent Variable: Efficacy % 
 
The standard error of the estimate associated with the reported R2 value in the model was 
11.405 and provided an estimate of the accuracy of the predictions made by the regression line. 
Approximately 68.0% of the scores in the model were 11.67 points above and below the 
predicted value. This wide spread was not surprising given the number of observations that were 
not explained by the model (97.5%). The observed F change statistic for the R2 value in the 
model was reported as 2.217 with an associated level of significance p value of 0.14 (p >0.05). 
Based on these results, it was concluded that the variable alpha diversity was not a significant 
predictor of the efficacy rate of FMT.  
Analysis of the overall fit of the model was presented in the analysis of variance 
(ANOVA) table. The regression model’s Sum of Squares statistic was reported as 288.3 and had 
an F-ratio statistic of 2.22. This statistic was found to not be significant with a p value of 0.14 (p 
>0.05). Based on this result, the ANOVA table supported the conclusion that the model, efficacy 
rate regressed on the predictor alpha diversity, was not significantly correlated. In summary, the 
model found that the degree of alpha diversity of the donor’s fecal material was not a predictor 
of the efficacy of the FMT procedure in preventing CDI recurrence.  
Per the coefficients table, the regression beta coefficient value (B) obtained for the simple 
regression model was -16.3. This suggested that for a unit change in alpha diversity, the efficacy 
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rate increased by 16.3%, keeping in consideration the reversal of values resulting from the 
reverse log transformation of the alpha diversity data points. However, the t observed value of  
-1.49 for the regression coefficient had an associated level of significance p value of 0.14, which 
was not significant (p >0.05). As such, this finding suggested that the regression coefficient 
value likely occurred by chance. Odds ratios were not generated because the results of the simple 
linear regression were found not to be significant.  
Cook’s Distance for the data used in the model were observed to all be less than one, 
ranging from 0.000 to 0.165, indicating that no specific case had an undue influence on the 
model. Similar findings were observed by the Centered Leverage value (range 0.000 to 0.088). 
DFBeta statistics for the model was predominantly less than one, though three points were noted 
to be slightly above the cut-off value (range 0.001 to 1.222). Evaluation of these cases 
demonstrated corresponding Cook’s Distance and Centered Leverage values that were less than 
0.165, suggesting that these cases were not likely to have significantly influenced the results of 
the regression analysis. A simple linear regression was run with these cases excluded to further 
evaluate the findings. This analysis demonstrated similar results as those observed in the final 
model (model 1). As such, it was concluded that no cases exerted a substantial or undue 
influence on the regression parameters utilized in the final model (model 1). 
For the Aim 2 simple linear regression, the predictor variable alpha diversity was entered 
into the model and evaluated to see if it contributed to the regression equation. The final model 
(model 1) accounted for only approximately 2.5% of the variance in the outcome variable. 
Efficacy rate and was found to not be significant with a p value of 0.14 (p >0.05) (Table 27). As 
such, it was determined that the level of alpha diversity of a donor’s fecal microbiome was not 
predictive as to whether the material was efficacious in preventing the recurrence of CDI.  
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Table 27.  
Results of the simple linear regression analysisa 
Model Beta S.E. Std. Coefficients Beta t p 
CI 95% 
Lower Upper 
(Constant) 83.095 3.050  27.245 0.000 77.031 89.159 
Alpha Diversity -16.337 10.973 -0.159 -1.489 0.140 -38.154 5.481 
a Dependent Variable: Efficacy % 
  
Overall, evaluation of the donor microbiome for Aim 2 demonstrated a predominantly 
homogenous sample comprised of bacteria from the Bacteroidetes and Firmicutes phylum (70% 
or greater). Despite indications of some variability observed in the beta analysis, the simple 
regression analysis was not significant, indicating that the observed variability did not impact the 
clinical efficacy of the donor material. Additionally, the non-significant result of the regression 
analysis suggested that any observed relationship between donor alpha diversity and clinical 
efficacy of the material might have occurred by chance.  
  
STOOL DONOR CHARACTERISTICS 
 
106 
Chapter 5. Discussion 
There is a paucity of research on ideal healthy stool donor characteristics and the 
microbiome of donor fecal material. Because of the lack of consensus-based data to support a 
correlation between donor characteristics and passing the prospective donor screening, nurses 
and other clinicians face multiple hurdles and operational challenges in finding stool donors to 
treat recurrent Clostridium difficile infections (CDI) patients with consistently efficacious fecal 
microbiota transplant (FMT) material. This research set out to build knowledge about an 
emerging area of science and clinical care. Two hypotheses aimed at improving the process of 
finding suitable donors with consistently efficacious intestinal microbiomes were tested. The first 
aim evaluated eight variables for any correlation with passing OpenBiome’s prospective FMT 
donor screening program. The second aim evaluated a subset of donors who passed the screening 
to determine any correlation between the stool donor’s intestinal microbiome composition (as 
measured by 16S ribosomal ribonucleic acid [rRNA] based Shannon’s alpha diversity index) and 
the clinical efficacy of FMT. The results, along with study limitations, implications for clinical 
practice, and recommendations for future research are discussed in this chapter. 
Sample Representation of Stool Donor Population 
 Prior to conducting the analyses, the characteristics of the sample were compared with 
information about stool donors reported in the literature. Overall, the study sample was similar to 
samples described in the literature. However, in this study, 18.0% (n=134) of the donors passed 
OpenBiome’s prospective FMT donor screening program, a rate that was notably higher than 
those reported for other screening programs, which ranged from 4% (L. J. Burns et al., 2015) to 
10% (Paramsothy et al., 2015). This difference may be explained by the fact that donors in this 
study had already been prescreened using a targeted online questionnaire, whereas in other 
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studies, stool donors were recruited directly from the general population. The online tool used by 
OpenBiome had been tailored to capture common deferral criteria prior to scheduling an in-
person assessment, such as a high body mass index (BMI), recent use of antibiotics, and age 
outside the inclusion range. As such, the prescreening may have prospectively deferred a number 
of donors prior to the more rigorous in-person clinical and laboratory screenings and account for 
the difference in passage rates observed in the literature. Despite this difference, the sample 
cohort utilized in this study did not appear to be notably different from those reported in the 
literature (L. J. Burns et al., 2015; Paramsothy et al., 2015) and thus was considered to be a 
representative sample of the pool of stool donors. Although the online prescreening was not 
evaluated as part of this study, these results suggested that the use of a short online survey 
utilizing targeted questions might be a quick and economic approach to improving the FMT 
prospective donor pass rates.  
Discussion of the Findings 
 The following section provides a discussion of the observations resulting from the 
analyses of both aims as they pertain to each of the FMT donor characteristics selected a priori 
based on a review of the existing literature. The discussion is organized by the statistical 
regression approach and variables utilized within those analyses, which were pre-identified in the 
theoretical framework, namely host, environmental, and microbiome features.  
Analysis of Donor Characteristics Predictive of Passing 
The purpose of the logistic regression utilized in the first aim was to explore and identify 
donor characteristics that were predictive of passing the FMT prospective donor screening 
program. Significant results from this analysis would be used to inform clinical and nursing 
practice on methods to help identify healthy donors earlier during the prospective donor 
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screening process. Eight variables were evaluated to determine whether the prospective 
consideration of these donor characteristics by nurses and other clinicians would reduce deferral 
rates and improve program efficiency. While the final model was significant at the 0.05 level, 
most of the variables considered for inclusion were found not to be predictive of the outcome. 
Specifically, gender, age, BMI, diet, alcohol and tobacco use, and seasonality were not predictive 
of whether a prospective donor passed or was deferred upon completion of the donor screening 
program. Only one donor related variable, frequency of bowel movements, was observed to be 
significant at the p <0.05 level (p value of 0.018) and was included in the final model. The 
details of the results for each variable and the related implications for the stool donor screening 
process are discussed in the following section. 
Host Features.  
 Gender. OpenBiome’s FMT donor screening program encouraged participation by both 
genders. Despite this policy, 68.1% of prospective stool donors used in this study were male. 
This finding was notably different from trends in gender participation observed for blood 
donation, which report more equal representation (Greinacher, Fendrich, Brzenska, Kiefel, & 
Hoffmann, 2011). Analysis of the data demonstrated that the overall pass rate reported by male 
stool donors (18.9%) was marginally higher than for female stool donors (16.0%). Results from 
the logistic regression analysis confirmed that there was no relevant predictive relationship 
between gender and passing the prospective stool donor screening. This finding appeared to be 
contrary to existing literature that suggests women may be diagnosed with gastrointestinal 
disorders at higher rates and possibly more likely to be deferred (Bakken et al., 2011; Houghton 
et al., 2016; Lo et al., 2003). However, the results of this study did not support the assumption 
that gender predicts stool donor health or FMT suitability. Rather, the finding suggests that 
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prospective stool donor screening programs should remain agnostic as to gender and support 
equal participation by both genders in stool donation. Various factors may have contributed to 
the imbalance in gender participation observed in this study. Research to evaluate potential 
influences on individual gender motivations for donating stool could provide strategies for 
increasing participation by female stool donors. 
Age. The age range for inclusion in OpenBiome’s stool donor screening program was 
limited to donors between the ages of 18 and 50 years. Review of the study data demonstrated a 
progressive decrease in the pass rate as donor age increased, consistent with observations 
supported by the literature that suggest younger adults are generally healthier (Niccoli & 
Partridge, 2012). As such, the data suggested that younger adults may be more likely to pass the 
screening and may be less likely to be diagnosed with disorders that are generally found to 
increase in prevalence as one ages, such as high blood pressure and metabolic syndrome (Niccoli 
& Partridge, 2012). Results from the logistic regression analysis however, did not support age as 
predictive of a donor passing the screening. Rather, the study finding suggested that overall 
health for adults between the ages of 18 and 50 years remained relatively stable. These findings 
concur with results reported in the literature from studies evaluating the intestinal microbiome in 
healthy younger to middle aged adults (Odamaki et al., 2016). As such, this study did not support 
the need to further restrict the range in age for inclusion that is currently utilized by stool banks. 
Rather, it suggested that research to evaluate whether the age range can be broadened beyond the 
existing recommendation of 18 to 50 is warranted. This research may lead to greater access and a 
larger pool of suitable stool donors, which currently are deferred based on age alone.  
 Body Mass Index. Seminal research published in the past decade suggests a link between 
obesity, as measured by one’s BMI, and the intestinal microbiome composition (Ley et al., 2005; 
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Turnbaugh et al., 2008; Turnbaugh et al., 2009). More recently, anecdotal case reports of post-
FMT weight gain in recipients receiving material from obese donors were similarly reported 
(Alang & Kelly, 2015). For this reason, prospective stool donors with a BMI in the obese range 
of 30.0 kg/m² or greater are deferred from donating. Excess weight has been found to be 
associated with an increased risk and prevalence for chronic conditions, many of which are 
considered to be reasons for donor deferral i.e., metabolic syndrome and certain cancers (Guh et 
al., 2009; Kent et al., 2017). As such, this study sought to determine whether being in the 
overweight range of 25.0 kg/m² to 29.5 kg/m² affects prospective stool donors’ general health 
and likelihood of being deferred. No correlation between an increase in BMI and donor deferral 
was found however. The results appear to support more recent literature that has introduced 
uncertainty regarding the link between stool donor BMI and post-procedure recipient weight gain 
(Fischer et al., 2018; Steevens, Roto, & DeCross, 2017), suggesting that factors other than donor 
BMI account for the development of obesity after FMT. As such, the results of this study did not 
support the need to change current BMI deferral recommendations. However, based on the 
conflicting results presented by this study and recent literature, re-evaluation of BMI as a metric 
for assessing stool donor health and suitability may be warranted. Further research would be 
useful to determine whether there are limitations in using BMI to evaluate stool donor health and 
suitability for donating fecal material. Such research could warrant the use of more precise 
clinical tools for identifying healthy FMT donor weight compositions and could result in 
improvements to the donor screening process.  
Frequency of Bowel Movements. Most prospective donors included in this study sample 
reported daily bowel movements at a frequency considered by the literature and medical 
community to be within a healthy range of one to four (Connell, Hilton, Irvine, Lennard-Jones, 
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& Misiewicz, 1966; Heaton et al., 1992). However, findings from the logistic regression 
supported a predictive relationship between frequency of bowel movements and passing the stool 
donor screening. More specifically, the analysis revealed that donors with a frequency of bowel 
movements of two or more per day were more likely to be deferred during the screening, 
suggesting that there may be a possible connection between stool donor health and one’s 
frequency of bowel movements. Although evidence for a correlation between intestinal 
microbiome composition and disease in asymptomatic individuals varies in the literature (Budree, 
Rao, et al., 2017; Vandeputte et al., 2016), further research on the impact of frequency of bowel 
movements and stool donor health may provide additional metrics to help nurses and other 
clinicians more readily identify suitable stool donors for use in FMT.  
Based on the findings of this study, stool donor frequency of bowel movements may be a 
suitable proxy for assessing stool donor suitability in healthy people. The current standard for 
assessing donor health based on stool quality presented in the literature is the Bristol stool scale, 
which depends on visual inspection of a donor’s stool (Budree, Rao, et al., 2017). While the 
Bristol stool scale has been shown in the literature to be associated with unique intestinal 
microbiome compositions (Vandeputte et al., 2016), the ability of the scale to accurately assess 
stool efficacy for use in FMT is inconclusive (Budree, Rao, et al., 2017; Budree, Wong, et al., 
2017). Further, visual inspection of donor stool to evaluate donor health occurs continuously 
throughout the donation period and only after a prospective donor has been cleared to donate for 
FMT use. Measuring donor frequency of bowel movements may be an easier approach for nurses 
and other clinicians to proactively evaluate donor health in comparison to the Bristol stool scale. 
Inquiring about one’s frequency of bowel movements is easily measured via a survey and can be 
conducted by nurses and other clinicians earlier in the screening process. This may allow nurses 
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and other clinicians to prioritize donor screening and defer donors who are not suitable earlier in 
the process, thus reducing costs and time to screen prospective stool donors.  
 Environmental Features. 
 Diet. Most prospective donors included in this study (86.7%) reported consuming an 
animal-based diet. Despite reports in the literature that certain diets promote unique bacterial 
intestinal compositions (De Filippo et al., 2010; Wu et al., 2011; Zimmer et al., 2012), the 
literature is inconclusive when it comes to identifying an optimal diet for stool donors. Some 
studies suggest that individuals who consume meat may be at higher risk for certain diseases that 
meet deferral criteria in the donor screening process, perhaps due to decreased dietary fiber or 
consumption of undercooked meat (Aiken et al., 2013; J. Slavin, 2013; J. L. Slavin, 2008). As 
such, there is an assumption that these donors may be more likely to be deferred during the 
prospective donor screening process. However, this was not supported by the logistic regression 
results, which demonstrated that diet was not predictive of passing or being deferred from the 
stool donor screening program. As such, selecting donors based on diet was not supported by this 
study and may not be informative in determining stool donor health or suitability for donating 
stool. Rather, this finding suggested that an evaluation of the use of deferral criteria based on 
donor dietary preferences may be warranted. Evidence supporting the value of including healthy 
stool donors despite their consumption of less common but increasingly popular fad diets, such 
as paleo or low carbohydrate diets, may increase the availability of healthy stool donors and the 
overall pass rate for prospective stool donor screening programs.  
Alcohol Use. Current literature is lacking in evidence to support a relationship between 
low to moderate alcohol intake on donor health and suitability for stool donation. As such, there 
is value in evaluating whether regular low to moderate alcohol consumption is predictive of stool 
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donor health and suitability as a first step toward generating knowledge in this area. Although 
most prospective donors reported no alcohol consumption, the results of this study indicated that 
there was no relationship between the level of alcohol intake and passage of the donor screening. 
This finding suggests that low to moderate alcohol consumption may not have the same impact 
on donor health and passing the prospective donor screening or on the intestinal microbiome 
composition as has been observed in research on long-term, heavy alcohol use (Bode et al., 1984; 
P. Chen & Schnabl, 2014; Y. Chen et al., 2011; Mutlu et al., 2012). As such, the results of this 
study did not support the inclusion of alcohol consumption as a criterion for determining donor 
health and suitability for donating stool. However, given potential biases that can be introduced 
by donor self-report, the evaluation of other measures for quantifying the effects of regular, 
heavy alcohol consumption, such as binge drinking, on donor suitability may be warranted to 
ensure these donors continue to be identified and deferred.  
 Tobacco Use. Prospective donors who reported regular use of tobacco over the allowable 
threshold were deferred from donating stool due to the long-term effects of tobacco use on donor 
health as demonstrated by the literature (Giovannucci, 2001; Giovannucci & Martinez, 1996; N. 
Morgan, 1996). Infrequent and former tobacco users, however, were not deferred, citing a lack of 
research to support the deferral of this population. While the literature is limited in regard to the 
impact of infrequent tobacco use on the health and suitability of stool donors, there is some 
evidence to suggest that periodic and past tobacco use continue to negatively impact health for 
certain gastrointestinal related diseases long-term (Kuenzig et al., 2016). As such, evaluating 
donors for a possible dosage effect for tobacco use with passing the prospective donor screening 
program was warranted. Results of the logistic regression, however, demonstrated that there was 
no predictive difference in the pass rates for donors regardless of whether they reported zero, 
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past, or infrequent tobacco use, suggesting that stool donor healthy and suitability were not 
influenced by the reported levels of donor tobacco use. This finding provided further evidence to 
support the research of Tu and colleagues (2017), who reported that there was no difference in 
the intestinal microbiome of non-smoking donors and donors who smoked occasionally. As such, 
this evidence supported the continued use of current screening guidelines to evaluate tobacco use 
and donor suitability. 
Seasonality. Evaluation of prospective donors occurred throughout the year with the 
majority of donors screened during the fall and winter months (29.2% per season). Trends in 
seasonality are not factored into OpenBiome’s prospective donor screening program. However, 
the rates of donor deferral resulting from infectious diseases such as influenza and rotavirus may 
coincide with the peak incidence reported in the literature during the fall and winter months 
(Fisman, 2007). As such, this study aimed to assess whether there would be a similar uptick in 
donor deferral during the fall and winter months. Despite the sources to support this assumption 
in the literature, deferral rates across the seasons were similar and seasonality was found not to 
be predictive of donor deferral in the logistic regression analysis. This finding appeared to be in 
contrast to what has been reported in the literature and trends observed with the incidence for 
infectious disease. However, because no particular season was identified as predictive or optimal 
for screening donors, this study did not support consideration of seasonality during the 
evaluation of prospective donors nor that changes be made as to the frequency of donors 
screened throughout the year.  
Impact of Alpha Diversity on Clinical Efficacy 
The purpose of the second aim of this study was to assess whether donor 16S rRNA 
microbiome composition, as measured by Shannon’s alpha diversity, was correlated with FMT 
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clinical efficacy in the treatment of patients with recurrent CDI. Results of the simple regression 
were used to evaluate the utility of including alpha diversity as a screening tool during the FMT 
donor screening process. Most studies to date have focused on evaluating the recipient’s fecal 
microbiome to address engraftment of the donor material (Kelly et al., 2016; Seekatz et al., 2014; 
van Nood, Dijkgraaf, et al., 2013). Taking a different approach, this study evaluated the 16S 
rRNA intestinal microbiome of stool donor material for efficacy in treating patients with 
recurrent CDI. Available data about stool donor intestinal microbiome compositions reported as 
part of the aforementioned research literature were used to evaluate the findings of this study.  
Microbiome Features. While the donor intestinal microbiome composition from this 
sample demonstrated some variability among individual donors, overall the sample cohort was 
comprised of generally healthy donors with diverse microbiome compositions consistent with a 
healthy gut (Cresci & Bawden, 2015; Dave, Higgins, Middha, & Rioux, 2012). Bacteria from 
nine different phyla predominantly colonize the healthy human gut (Gillilland, Young, & 
Huffnagle, 2012). Phyla are top level operational taxonomic units (OTU) representing the major 
lineages of bacteria and are comprised of numerous unique bacterial species. For this study’s 
sample, bacteria from the Firmicutes and Bacteroidetes phyla comprised 91.4% of the total 
sequenced 16S rRNA microbiome data utilized in the analysis. In healthy adults, bacteria from 
these two aforementioned phyla have been shown to represent around 90% or greater of the 
bacterial composition of the intestinal microbiome (Rajilic-Stojanovic, Smidt, & de Vos, 2007). 
As a group, the intestinal microbiome composition sequenced for the entire sample cohort was 
consistent with observations found in the literature on the healthy human intestinal microbiome 
(Human Microbiome Project Consortium, 2012). This trend was similarly reflected at the 
individual donor level, with 55 (63.2%) of the donors having a 90% or greater intestinal 
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microbiome composition comprised of bacteria from the Firmicutes and Bacteroidetes phyla and 
most of the remaining donors (n=31, 35.6%) having at least 80%. Similar observations 
pertaining to bacterial richness were observed as part of the beta diversity analysis, further 
supporting the assumption that prospective donors who passed OpenBiome’s stool donor 
screening program had an intestinal microbiome composition consistent with that observed in 
healthy individuals as reported in the literature.  
Alpha Diversity. Alpha diversity of the donor samples provided a numerical metric of the 
level of diversity observed at the bacterial species level for each donor’s intestinal microbiome 
composition. While reference thresholds for the range of alpha diversity associated with a 
healthy stool donor intestinal microbiome composition are not currently available in the literature, 
the range observed by this study was consistent those reported in similar research conducted on 
patient recipients of FMT (Kelly et al., 2016; Seekatz et al., 2014). Analysis of the scatterplot of 
alpha diversity against FMT clinical efficacy using the sample cohort demonstrated a positive 
relationship between the two variables. This observation suggested that, while donors in the 
sample were considered to be otherwise healthy, a correlation might exist between the bacterial 
diversity of the donor’s fecal material and increased likelihood of preventing CDI recurrence in 
recipients. Despite these observations, the simple linear regression was not significant at the p 
<0.05 level. As such, it could not be concluded that alpha diversity was correlated with any 
observed change in clinical efficacy resulting from the use of the stool donor material. This 
finding was consistent with results from similar studies on smaller donor cohorts presented in the 
literature (Budree, Wong, et al., 2017). As such, the results of this study provided additional 
evidence to support conclusions made by prior research that the intestinal microbiome 
composition among donors who pass the stool donor screening is predominantly homogenous in 
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regard to alpha diversity and generally efficacious in preventing recurrent CDI. Although the 
results of this study did not support the evaluation of donor alpha diversity during prospective 
donor screening, further research on donor and non-donor related characteristics might provide 
greater insight into factors that more directly contribute to increased FMT clinical efficacy rates.  
Implications for Practice 
The current process for identifying and selecting healthy stool donors that are suitable for 
donating fecal material for use in FMT presents many challenges for nurses and other clinicians 
who are tasked with leading this process on behalf of their patients. Although the results of this 
study did not definitively support the routine deferral of donors who pass two or more bowel 
movements per day, the findings can be used by nurses and other clinicians to prioritize the 
screening of specific donor populations that are more likely to pass. Stool donor screening does 
not currently utilize information regarding bowel habits as part of the triage or decision-making 
process. Inquiring about bowel habits at the initial online prescreening process could lead to 
increased program efficiency by reducing the number of in-person donor screening appointments. 
As such, targeted recruitment may prove to be more cost-effective when performing the in-
person donor assessment by increasing the overall pass rates. While the results did provide 
suggestions on first steps that can be taken to improve the program, additional research would be 
needed to further evaluate whether donor frequency of bowel movements could serve as a proxy 
for some of the questions asked during the in-person screening process and possibly lead to 
additional improvements in the program.  
The ability to target a specific donor profile may lead to a reduction in the delay to 
patient treatment in those who chose to use a directed donor approach. Nurses and other 
clinicians could counsel patient recipients to inquire about daily bowel habits with family and 
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friends. This conversation may be perceived as less obtrusive for both patient recipients and 
prospective donors. As such, this approach may be preferential to questioning prospective donors 
about other more private health related factors that increase one’s risks for infectious or 
transmissible diseases, such as use of alcohol or drugs, previous diagnoses, and sexual behavior. 
This new information may decrease the time it takes for a patient to identify a suitable directed 
donor without having to disclose personal information about his or her own health.  
The current process for evaluating stool donors is complex, costly, and time consuming. 
Thus, there is increased interest from the healthcare community for a rapid stool-based test to 
assess donor microbiome composition at the onset of screening to reduce delays, risks for 
transmitting an infectious organism, and increase clinical efficacy. Although the results of the 
analysis did not support the utility of incorporating alpha diversity as a biomarker during the 
stool donor screening process, the analysis indicated that there is value in further exploring the 
role of the intestinal microbiome in preventing CDI recurrence to identify different metrics and 
intestinal compositions that may be more efficacious.  
Limitations 
A shortfall of this study was the use of retrospective donor data for the analysis. The 
retrospective approach restricted the ability of the researcher to influence the way data about the 
variables were collected in a manner that would be most informative to the study. Several of the 
donor characteristics included in this study were presented as open-ended questions, for example 
diet and tobacco use. As such, this created an aspect of ambiguity in the answers and decision-
making that may not have been consistently applied across the donors. Further, reliance on donor 
self-reporting introduced a potential bias. For example, a diet history collected with an accepted 
diet recall instrument may have been more informative and accurate than open-ended responses. 
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Ultimately, this study relied on data that may not have fully or accurately captured the donor 
characteristics, thus increasing the risk for insignificant findings. 
The characteristics of the population from which the study sample was drawn also limit 
generalizability of the findings from this study. Evaluation of the non-significant prospective 
stool donor characteristics suggested that the overall population characteristics and study 
logistics might have influenced the sample demographics. In particular, the donor sample was 
heavily skewed toward younger individuals. Further, a notable percentage of donors were 
deferred due to logistics, despite being deemed healthy and suitable during the clinical 
assessment. These donors were unable to complete the entire screening process, which may have 
skewed the final pass or deferral outcome. The high density of young college students in the 
population from where the sample was drawn, and limitations imposed due to logistics of 
needing to travel often to the donation site suggest that caution be taken when applying these 
results to differing settings.  
Recommendations for Future Research 
The use of FMT to treat infectious and chronic diseases is a rapidly expanding field of 
medicine. However, the procedure is highly dependent on the availability of healthy stool donors 
and technological advancements. This study provided an evaluation of the health and 
microbiome characteristics of prospective stool donors in order to inform our understanding of 
how donor fecal material can be harnessed most efficiently and effectively by nurses and other 
clinicians to treat patients with recurrent CDI. As such, the results of this study serve as a 
platform for further inquiry in a program of research aimed at improving the outcomes of 
patients through the use of FMT from healthy stool donors. The success of this approach, 
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however, will depend on multidisciplinary research from the fields of nursing, microbiology, and 
medicine. 
While this study identified donor frequency of bowel movements as predictive of passing 
the FMT donor screening program, additional opportunities exist to better understand the 
characteristics of optimal stool donors. This study did not evaluate deferral rationales to assess 
for any correlations with donor characteristics and behavior, which may be informative to the 
program. Other donor characteristics that were not captured by the prospective FMT donor 
screening program may have also contributed to the deferral of prospective donors. These 
include factors such as stress, exercise, and specific dietary habits, such as regular consumption 
of probiotics, dietary fiber, and vitamin D supplements. These may be informative to the 
screening process and donor outcomes. More research is needed to explore stool donor 
characteristics that were not captured by this study to evaluate whether these factors may or may 
not be predictive of passing the donor screening and could be utilized to improve the process. 
Additional research is also needed to assess the value that each step in the lengthy and 
time-consuming prospective stool donor screening program provides to identifying optimal 
donors. Understanding donor characteristics that can serve as a proxy for infectious disease risk 
and a healthy microbiome composition, such as the frequency of bowel movements, could be 
utilized to shorten the steps during the clinical and laboratory screening. Evaluation of the 
frequency of bowel movements during screening could determine whether an infectious disease 
or microbiome-mediated risk was more likely to result in donor deferral. This information could 
be used to distinguish between real versus perceived risks and further build the literature and 
rationale for utilizing or removing barriers to stool donor screening in order to streamline the 
process while also maintain patient safety.  
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This study was not able to evaluate the stool donor characteristics in relation to intestinal 
microbiome composition. Though in-depth analysis of alpha diversity and donor characteristics 
was beyond the scope of this study, scatterplots of alpha diversity generated against donor 
frequency of bowel movements suggested trends in alpha diversity worth evaluating. This level 
of inquiry between additional intestinal microbiome markers with stool donor characteristics 
may be valuable in identifying whether specific donor characteristics are associated with unique 
and more efficacious intestinal microbiome compositions. This information may provide a 
platform for further study on the intestinal microbiome composition of stool donors and the 
clinical efficacy of FMT. 
As an emerging area of science, there are many opportunities for future research on 
bacteria that colonize the intestines both at the phylum and species levels to better understand 
how they behave within different intestinal ecosystems. This research could generate information 
that assists nurses and other clinicians to expeditiously evaluate prospective donors to procure 
fecal material with consistently high rates of clinical efficacy and reduce further barriers to 
patient access. Despite the observation that bacteria from the Firmicutes and Bacteroidetes phyla 
predominantly comprise the intestinal microbiome of healthy donors, the efficacy of FMT 
material is likely to reside within the nuances of the species in the microbiome and how they 
interact with each other. Factors not evaluated as part of this study were the patient recipient 
comorbidities and medications and their influences on bacterial expression and engraftment. 
Understanding predictive factors for clinical efficacy that are external to the stool donors may 
provide a secondary approach to improving outcomes and increasing the likelihood of 
microbiome engraftment in the recipients.  
  




The findings from this study were helpful in generating new knowledge and supporting 
existing literature on stool donor characteristics. These results were used to suggest changes that 
nurses and other clinicians could implement into the current process for screening stool donors to 
increase the pass rate, reduce costs and treatment delays, and potentially improve clinical 
efficacy. Results from the logistic regression identified donor reported frequency of bowel 
movements as informative in predicting whether a donor would be more likely to pass or be 
deferred. The findings of this study suggested that the ideal FMT donor candidates are donors 
who report passing fewer than two bowel movements per day on average. These donors may 
inherently have a lower risk for infectious or transmissible disease and possess a healthier 
microbiome. The remaining donor characteristics (gender, age, BMI, diet, tobacco and alcohol 
use, and seasonality) were not found to be predictive and thus supported maintaining the current 
criteria for screening stool donors. Similarly, the level of diversity observed by the stool donor 
intestinal microbiome was not found to be associated with a higher rate of FMT clinical efficacy. 
Despite the clinical interest in utilizing this tool during the prospective donor screening process, 
alpha diversity was not informative and thus not recommended as a potential biomarker for 
assessing the efficacy of donor stool or identifying more optimal stool donors. Additional 
research on factors not evaluated as part of this study could provide more evidence to better 
understand the factors that impact stool donor suitability and FMT clinical efficacy and lead to 
further improvements in the stool donor screening process.  
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Appendix A. Change in descriptive statistics for continuous variables pre- and post-listwise 
removal 
 
  N Range Minimum Maximum 
Age Pre-Removal 767 31.0 18.0 49.0  
Post-Removal 744 31.0 18.0 49.0  
Change 23 0.0 0.0 0.0 
Body Mass 
Index 
Pre-Removal 751 13.5 16.3 29.8 
Post-Removal 744 12.9 16.9 29.8 




Pre-Removal 758 4.5 0.5 5.0 
Post-Removal 744 4.5 0.5 5.0 
Change 14 0.0 0.0 0.0 
Alcohol Use Pre-Removal 744 20.0 0.0 20.0  
Post-Removal 744 20.0 0.0 20.0 
  Change 0 0.0 0.0 0.0 
 
    Mean Std. Deviation Variance Statistic Std. Error 
Age Pre-Removal 28.1 0.22 6.13 37.63  
Post-Removal 28.1 0.23 6.19 38.25  
Change 0.0 0.00 -0.10 -0.63 
Body Mass 
Index 
Pre-Removal 23.6 0.10 2.71 7.32 
Post-Removal 23.6 0.10 2.69 7.22 




Pre-Removal 1.7 0.02 0.67 0.45 
Post-Removal 1.7 0.02 0.67 0.45 
Change 0.0 0.00 0.00 -0.01 
Alcohol Use Pre-Removal 2.9 0.10 2.69 7.26  
Post-Removal 2.9 0.10 2.71 7.33 
  Change 0.0 0.00 0.00 -0.07 
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Appendix B. Change in descriptive statistics for categorical variables pre- and post- listwise 
removal 
 
    Frequency % Cumulative % 
Gender Male Pre-Removal 521 67.7 67.7 
  Post-Removal 507 68.1 68.1 
   Change 14 -0.5   
 Female Pre-Removal 249 32.3 100.0 
  Post-Removal 237 31.9 100.0 
   Change 12 0.5   
 Total Pre-Removal 770   
  Post-Removal 744   
    Change 26 3.4   
Diet Meat Based Pre-Removal 668 86.8 86.8 
  Post-Removal 645 86.7 86.7 
  Change 23 0.1  
 No Meat Pre-Removal 102 13.2 100.0 
  Post-Removal 99 13.3 100.0 
   Change 3 -0.1   
 Total Pre-Removal 770   
  Post-Removal 744   
    Change 26 3.4   
Tobacco Use Never Pre-Removal 621 81.4 81.4 
  Post-Removal 605 81.3 81.3 
  Change 16 0.1  
 Former Pre-Removal 89 11.7 93.1 
  Post-Removal 87 11.7 93.0 
   Change 2 0.0   
 Current Pre-Removal 53 6.9 100.0 
  Post-Removal 52 7.0 100.0 
  Change 1 0.0  
 Subtotal Pre-Removal 763     
  Post-Removal 744   
   Change 19 2.5   
 Missing Pre-Removal 7 0.9  
  Post-Removal 0 0.0  
   Change 7 0.9   
 Total Pre-Removal 770   
  Post-Removal 744   
    Change 26 3.4   
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    Frequency % Cumulative % 
Seasonality Winter Pre-Removal 226 29.4 29.4 
  Post-Removal 217 29.2 29.2 
  Change 9 0.2  
 Spring Pre-Removal 140 18.2 47.5 
  Post-Removal 139 18.7 47.8 
   Change 1 -0.5  
 Summer Pre-Removal 178 23.1 70.6 
  Post-Removal 171 23.0 70.8 
  Change 7 0.1   
 Fall Pre-Removal 226 29.4 100.0 
  Post-Removal 217 29.2 100.0 
   Change 9 0.2  
 Total Pre-Removal 770     
  Post-Removal 744   
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Appendix C. Clinical assessment deferral categories utilized to assess prospective donor 
qualifications 
 
Atopy, Asthma, or Allergies. Donors deferred for a positive diagnosis of two or more 
conditions related to atopy, asthma, or allergies e.g., atopic dermatitis, drug allergies, asthma, 
etc. 
 
Autoimmune Conditions. Donors deferred for a positive history of an autoimmune related 
diagnosis e.g., psoriasis, or other recurrent skin condition. 
 
Cancer History. Donors deferred for a positive history of a cancer diagnosis e.g., colon cancer. 
 
Cardiovascular and Metabolic Conditions. Donors deferred for a positive diagnostic history of 
a cardiovascular of metabolic condition e.g., hypertension, diabetes type 1 or 2.  
 
Current Health Status. Donors deferred if symptomatic for gastrointestinal or respiratory 
related illness during the screening or in the two weeks prior.  
 
Diet and Exercise. Donors deferred for reporting a fad diet e.g., gluten-free, recent elimination 
diet, or regular avoidance of a specific food due to food intolerance.  
 
Family History. Donors deferred for reporting a positive family history of a gastrointestinal 
related diagnosis where a risk for inheritance is suspected e.g., inflammatory bowel disease.  
 
Gastrointestinal Conditions. Donors deferred for a positive history of gastrointestinal diagnosis 
e.g., inflammatory bowel disease, or for consulting with a gastroenterologist for treatment of a 
recurrent gastrointestinal symptom or gastrointestinal related medical concern. 
 
Infectious Disease History. Donors deferred for a positive history of a diagnosis with a chronic 
communicable disease e.g., Human immunodeficiency virus or recent exposure that placed the 
donor at increased risk for contracting an infectious or communicable disease e.g., recent tick 
bite. 
 
Medications and Supplements. Donors deferred for reporting regular use of a prescription or 
over-the-counter medication e.g., laxatives, antibiotics, etc., regular use of a supplement 
suspected of impacting the intestinal microbiome e.g., probiotics, or recent immunization with a 
vaccination utilizing an attenuated organism.  
 
Mental Health and Well-Being. Donors deferred for a positive history of a mental health 
related diagnosis related e.g., generalized anxiety.  
 
Musculoskeletal Conditions. Donors deferred for reporting a positive history of a 
musculoskeletal diagnosis that results in chronic pain e.g., fibromyalgia.  
 
Neurological Conditions. Donors deferred for a positive history of a neurological diagnosis e.g., 
multiple sclerosis. 




Sexual Behavior and History. Donors deferred for reporting recent sexual behavior associated 
with an increased risk for infectious or communicable disease transmitted through sexual contact 
e.g., anonymous sexual contact. 
 
Social History. Donors deferred for reporting active or regular volunteer work in an 
environment at high risk for exposure to an infectious or communicable disease e.g., hospital 
workers, use of illicit drugs, or recent tattoo or piercing.  
 
Surgical and Other Medical History. Donors deferred for major surgeries e.g., transplantation 
or other procedures or medical diagnosis requiring frequent or increased hospital exposure. 
 
Travel History. Donors deferred for recent travel to areas considered high risk for infectious or 
communicable disease. 
 
Vital Signs. Donors deferred for a finding of abnormal vital signs e.g., repeated hypertensive 
measurements, Body Mass Index greater than or equal to 30, etc.  
 
Women’s Health. Donors deferred for being pregnant or actively breast-feeding. 
 
Other. Donors deferred for logistical reasons or other, not previously reported infectious or 
communicable diagnosis or medical conditions that may impact the intestinal microbiome. 
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Appendix D. Histograms and P-P plots for continuous variables (age, body mass index, 
frequency of bowel movements, and alcohol use) 
 
Histogram of Age 
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Histogram of Alcohol Use 
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Appendix E. Scatterplots for continuous variables (age, body mass index, frequency of 
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Appendix F. Boxplots for continuous variables (age, body mass index, frequency of bowel 
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Appendix I. Results from initial model for Aim 1 backward elimination logistic regression 
 








Categorical variables codings     
    Frequency Parameter coding     -1 -2 -3 
Seasonality  Winter 217 0 0 0 
  Spring 139 1 0 0 
  Summer 171 0 1 0 
  Fall 217 0 0 1 
Age 18 to 24 years 226 0 0 0 
  25 to 29 years 272 1 0 0 
  30 to 34 years 146 0 1 0 
  35 to 50 years 100 0 0 1 
Tobacco Use  Never 605 0 0   Former 87 1 0   
  Current 52 0 1   
Alcohol Use  None 120 0 0   
  Moderate 549 1 0   
  High 75 0 1   
Frequency of 
Bowel Movements 
Fewer than two 465 0     
Two of more 279 1     
Diet  Meat Based 645 0    
  No Meat 99 1     
Gender  Male 507 0    
  Female 237 1     
 
Block 0: Beginning Block 
 
Iteration historya,b,c    
Iteration     -2 Log likelihood  
Coefficients 
Constant 
Step 0 1 708.108 -1.280 
  2 701.703 -1.500 
  3 701.676 -1.516 
  4 701.676 -1.516 
a Constant is included in the model   
b Initial -2 Log Likelihood: 701.676   
c Estimation terminated at iteration number 4 because parameter estimates changed by less than 
0.001 
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Result of Screening  Percentage 
Correct Defer Pass 
Step 0 Result of Screening  Defer 610 0 100 
    Pass 134 0 0 
  Overall Percentage       82 
a Constant is included in the model     
b The cut value is 0.500      
 
Variables in the equation       
    B S.E. Wald df Sig. Exp (B) 
Step 0 Constant -1.516 0.095 252.372 1 0.000 0.220 
 
Variables not in the equation     
      Score df Sig. 
Step 0 Variables Gender (1) 0.921 1 0.337 
    Age  1.524 3 0.677 
    Age (1) 0.351 1 0.554 
    Age (2) 0.168 1 0.682 
    Age (3) 0.709 1 0.400 
    Body Mass Index 0.503 1 0.478 
    Frequency of BM (1) 5.828 1 0.016 
    Diet (1) 1.841 1 0.175 
    Alcohol Use  0.229 2 0.892 
    Alcohol Use (1) 0.059 1 0.808 
    Alcohol Use (2) 0.228 1 0.633 
    Tobacco Use  1.128 2 0.569 
    Tobacco Use (1) 0.246 1 0.620 
    Tobacco Use (2) 0.784 1 0.376 
    Seasonality  4.954 3 0.175 
    Seasonality (1) 2.965 1 0.085 
    Seasonality (2) 0.742 1 0.389 
    Seasonality (3) 2.108 1 0.147 
  Overall Statistics   17.501 14 0.230 
 
  
STOOL DONOR CHARACTERISTICS 
 
152 
Block 1: Method = Backward Stepwise (Likelihood Ratio) 
 
Iteration historya,b,c,d,e    
Iteration     -2 Log likelihood 
Coefficients 
Constant 
Step 1 1 694.403 -0.205 
  2 683.756 0.223 
  3 683.550 0.338 
  4 683.550 0.341 
  5 683.550 0.341 
Step 2 1 694.749 -0.221 
  2 684.225 0.188 
  3 684.027 0.296 
  4 684.026 0.299 
  5 684.026 0.299 
Step 3 1 695.841 -0.215 
  2 685.611 0.210 
  3 685.424 0.323 
  4 685.423 0.326 
  5 685.423 0.326 
Step 4 1 696.728 -0.224 
  2 686.801 0.199 
  3 686.631 0.311 
  4 686.631 0.314 
  5 686.631 0.314 
Step 5 1 697.482 -0.736 
  2 687.800 -0.634 
  3 687.642 -0.588 
  4 687.641 -0.586 
  5 687.641 -0.586 
Step 6 1 700.711 -0.776 
  2 692.009 -0.691 
  3 691.894 -0.649 
  4 691.894 -0.648 
  5 691.894 -0.648 
Step 7 1 702.075 -0.863 
  2 693.769 -0.828 
  3 693.668 -0.794 
  4 693.668 -0.793 
  5 693.668 -0.793 
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Iteration historya,b,c,d,e (continued) 
Iteration     -2 Log likelihood 
Coefficients 
Constant 
Step 8 1 703.537 -0.893 
  2 695.736 -0.876 
  3 695.660 -0.846 
  4 695.660 -0.846 
a Method: Backward Stepwise (Likelihood Ratio) 
b Constant is included in the model. Model too large to include all coefficient values 
c Initial -2 Log Likelihood: 701.676 
d Estimation terminated at iteration number 5 because parameter estimates changed by less than 
0.001 
e Estimation terminated at iteration number 4 because parameter estimates changed by less than 
0.001 
 
Omnibus tests of model coefficients    
    Chi-square df Sig. 
Step 1 Step 18.126 14 0.201 
  Block 18.126 14 0.201 
  Model 18.126 14 0.201 
Step 2a Step -0.477 2 0.788 
  Block 17.650 12 0.127 
  Model 17.650 11 0.090 
Step 3a Step -1.397 3 0.706 
  Block 16.253 9 0.062 
  Model 16.253 9 0.062 
Step 4a Step -1.207 2 0.547 
  Block 15.045 7 0.035 
  Model 15.045 6 0.020 
Step 5a Step -1.011 1 0.315 
  Block 14.035 6 0.029 
  Model 14.035 4 0.007 
Step 6a Step -4.252 3 0.235 
  Block 9.782 3 0.021 
  Model 9.782 3 0.021 
Step 7a Step -1.774 1 0.183 
  Block 8.008 2 0.018 
  Model 8.008 2 0.018 
Step 8a Step -1.992 1 0.158 
  Block 6.017 1 0.014 
  Model 6.017 1 0.014 
    




Step -2 Log likelihood 




1 683.550a 0.024 0.039 
2 684.026a 0.023 0.038 
3 685.423a 0.022 0.035 
4 686.631a 0.020 0.033 
5 687.641a 0.019 0.031 
6 691.894a 0.013 0.021 
7 693.668a 0.011 0.018 
8 695.660b 0.008 0.013 
a Estimation terminated at iteration number 5 because parameter estimates changed by less than 
0.001 
b Estimation terminated at iteration number 4 because parameter estimates changed by less than 
0.001 
 
Hosmer and Lemeshow test   
Step Chi-square df Sig. 
1 8.234 8 0.411 
2 2.52 8 0.961 
3 7.597 8 0.474 
4 4.47 8 0.812 
5 6.118 8 0.634 
6 0.808 4 0.937 
7 1.244 2 0.537 
8 0.00 0 . 
 
Contingency table for Hosmer and Lemeshow test 
     
  
   
Result of Screening = Defer Result of Screening = Pass Total Observed Expected Observed Expected 
Step 1 1 67 67 7 7 74 
  2 67 65 7 9 74 
  3 68 64 6 10 74 
  4 58 63 16 11 74 
  5 62 62 12 12 74 
  6 60 60 14 14 74 
  7 60 60 15 15 75 
  8 59 57 15 17 74 
  9 50 56 24 18 74 
  10 59 55 18 22 77 
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Contingency table for Hosmer and Lemeshow test (continued) 
  
   
Result of Screening = Defer Result of Screening = Pass Total Observed Expected Observed Expected 
Step 2 1 68 67 6 7 74 
  2 66 65 8 9 74 
  3 67 65 8 10 75 
  4 61 63 13 11 74 
  5 62 62 12 12 74 
  6 58 60 16 14 74 
  7 61 60 14 15 75 
  8 58 58 17 17 75 
  9 53 56 21 18 74 
  10 56 53 19 22 75 
Step 3 1 67 68 8 7 75 
  2 68 65 6 9 74 
  3 66 64 8 10 74 
  4 59 63 15 11 74 
  5 65 61 9 13 74 
  6 60 60 14 14 74 
  7 58 59 16 15 74 
  8 58 58 16 16 74 
  9 50 56 24 18 74 
  10 59 56 18 21 77 
Step 4 1 66 67 8 7 74 
  2 67 65 7 9 74 
  3 63 64 11 10 74 
  4 62 63 12 11 74 
  5 63 62 11 12 74 
  6 64 60 10 14 74 
  7 57 58 16 15 73 
  8 55 58 20 17 75 
  9 53 56 21 18 74 
  10 60 57 18 21 78 
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Contingency table for Hosmer and Lemeshow test (continued) 
  
  
Result of Screening = Defer Result of Screening = Pass Total Observed Expected Observed Expected 
Step 5 1 47 48 6 5 53 
  2 70 67 6 9 76 
  3 65 68 14 11 79 
  4 65 64 11 12 76 
  5 69 66 11 14 80 
  6 65 61 9 13 74 
  7 43 46 15 12 58 
  8 68 69 19 18 87 
  9 56 57 20 19 76 
  10 62 63 23 22 85 
Step 6 1 76 77 10 9 86 
  2 23 23 4 4 27 
  3 165 164 28 29 193 
  4 28 29 7 6 35 
  5 125 122 25 28 150 
  6 193 194 60 59 253 
Step 7 1 35 33 2 4 37 
  2 206 208 36 34 242 
  3 51 53 11 9 62 
  4 318 316 85 87 403 
Step 8 1 241 241 38 38 279 
  2 369 369 96 96 465 
 
  
STOOL DONOR CHARACTERISTICS 
 
157 









Result of Screening  Percentage 
Correct Defer Pass 
Step 1 Result of Screening  Defer 610 0 100 
    Pass 134 0 0 
  Overall Percentage     82 
Step 2 Result of Screening  Defer 610 0 100 
    Pass 134 0 0 
  Overall Percentage     82 
Step 3 Result of Screening  Defer 610 0 100 
    Pass 134 0 0 
  Overall Percentage     82 
Step 4 Result of Screening  Defer 610 0 100 
    Pass 134 0 0 
  Overall Percentage     82 
Step 5 Result of Screening  Defer 610 0 100 
    Pass 134 0 0 
  Overall Percentage     82 
Step 6 Result of Screening  Defer 610 0 100 
    Pass 134 0 0 
  Overall Percentage     82 
Step 7 Result of Screening  Defer 610 0 100 
    Pass 134 0 0 
  Overall Percentage     82 
Step 8 Result of Screening  Defer 610 0 100 
    Pass 134 0 0 
  Overall Percentage       82 
a Constant is included in the model 
b The cut value is 0.500  
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  B S.E. Wald df Sig. 
Exp 
(B) 
95% C.I. for 
Exp(B) 
Lower Upper 
Step 1a Gender (1) -0.341 0.224 2.311 1 0.128 0.711 0.459 1.104 
  Age    1.477 3 0.688     
  Age (1) -0.251 0.24 1.095 1 0.295 0.778 0.487 1.245 
  Age (2) -0.115 0.276 0.173 1 0.678 0.892 0.519 1.533 
  Age (3) -0.322 0.341 0.895 1 0.344 0.724 0.371 1.413 
  Body Mass Index -0.028 0.039 0.509 1 0.475 0.973 0.902 1.049 
  Frequency of BM (1) -0.509 0.215 5.592 1 0.018 0.601 0.394 0.917 
  Diet (1) -0.461 0.322 2.054 1 0.152 0.631 0.336 1.185 
  Alcohol Use    0.459 2 0.795     
  Alcohol Use (1) -0.027 0.267 0.01 1 0.921 0.974 0.577 1.645 
  Alcohol Use (2) -0.249 0.405 0.378 1 0.539 0.78 0.353 1.724 
  Tobacco Use    1.121 2 0.571     
  Tobacco Use (1) -0.11 0.319 0.119 1 0.730 0.896 0.48 1.673 
  Tobacco Use (2) -0.438 0.428 1.048 1 0.306 0.645 0.279 1.493 
  Seasonality    4.244 3 0.236     
  Seasonality (1) -0.491 0.309 2.528 1 0.112 0.612 0.334 1.121 
  Seasonality (2) -0.297 0.277 1.148 1 0.284 0.743 0.432 1.279 
  Seasonality (3) 0.045 0.243 0.035 1 0.852 1.047 0.65 1.685 
  Constant 0.341 0.997 0.117 1 0.732 1.406    
Step 2a Gender (1) -0.326 0.223 2.139 1 0.144 0.722 0.466 1.117 
  Age    1.397 3 0.706     
  Age (1) -0.242 0.239 1.027 1 0.311 0.785 0.491 1.254 
  Age (2) -0.112 0.276 0.164 1 0.686 0.894 0.52 1.537 
  Age (3) -0.313 0.338 0.854 1 0.356 0.732 0.377 1.42 
  Body Mass Index -0.028 0.039 0.534 1 0.465 0.972 0.901 1.049 
  Frequency of BM (1) -0.507 0.215 5.56 1 0.018 0.602 0.395 0.918 
  Diet (1) -0.447 0.32 1.948 1 0.163 0.64 0.342 1.198 
  Tobacco Use    1.238 2 0.538     
  Tobacco Use (1) -0.127 0.317 0.16 1 0.690 0.881 0.473 1.64 
  Tobacco Use (2) -0.454 0.427 1.13 1 0.288 0.635 0.275 1.467 
  Seasonality    4.208 3 0.240     
  Seasonality (1) -0.485 0.309 2.474 1 0.116 0.615 0.336 1.127 
  Seasonality (2) -0.294 0.277 1.127 1 0.288 0.745 0.433 1.283 
  Seasonality (3) 0.049 0.243 0.041 1 0.839 1.051 0.652 1.692 
  Constant 0.299 0.967 0.095 1 0.758 1.348    
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  B S.E. Wald df Sig. 
Exp 
(B) 
95% C.I. for 
Exp(B) 
Lower Upper 
Step 3a Gender (1) -0.333 0.222 2.249 1 0.134 0.717 0.464 1.108 
  Body Mass Index -0.036 0.038 0.928 1 0.335 0.964 0.896 1.038 
  Frequency of BM (1) -0.498 0.214 5.401 1 0.020 0.608 0.4 0.925 
  Diet (1) -0.444 0.319 1.935 1 0.164 0.641 0.343 1.199 
  Tobacco Use    1.132 2 0.568     
  Tobacco Use (1) -0.159 0.315 0.257 1 0.612 0.853 0.46 1.58 
  Tobacco Use (2) -0.413 0.425 0.945 1 0.331 0.662 0.288 1.521 
  Seasonality    4.308 3 0.230     
  Seasonality (1) -0.481 0.308 2.439 1 0.118 0.618 0.338 1.131 
  Seasonality (2) -0.294 0.276 1.131 1 0.287 0.745 0.434 1.281 
  Seasonality (3) 0.06 0.242 0.062 1 0.803 1.062 0.661 1.708 
  Constant 0.326 0.955 0.116 1 0.733 1.385    
Step 4a Gender (1) -0.321 0.222 2.1 1 0.147 0.725 0.47 1.12 
  Body Mass Index -0.038 0.038 1.007 1 0.316 0.963 0.894 1.037 
  Frequency of BM (1) -0.502 0.214 5.515 1 0.019 0.605 0.398 0.92 
  Diet (1) -0.441 0.319 1.909 1 0.167 0.644 0.345 1.203 
  Seasonality    4.248 3 0.236     
  Seasonality (1) -0.474 0.308 2.375 1 0.123 0.622 0.34 1.138 
  Seasonality (2) -0.283 0.275 1.059 1 0.303 0.754 0.44 1.291 
  Seasonality (3) 0.068 0.242 0.08 1 0.777 1.071 0.667 1.719 
  Constant 0.314 0.956 0.108 1 0.743 1.369    
Step 5a Gender (1) -0.268 0.215 1.554 1 0.213 0.765 0.502 1.166 
  Frequency of BM (1) -0.517 0.213 5.888 1 0.015 0.596 0.392 0.905 
  Diet (1) -0.41 0.317 1.671 1 0.196 0.664 0.356 1.236 
  Seasonality    4.096 3 0.251     
  Seasonality (1) -0.464 0.307 2.284 1 0.131 0.628 0.344 1.148 
  Seasonality (2) -0.255 0.273 0.87 1 0.351 0.775 0.454 1.324 
  Seasonality (3) 0.082 0.241 0.114 1 0.735 1.085 0.677 1.74 
  Constant -0.586 0.334 3.083 1 0.079 0.556    
Step 6a Gender (1) -0.282 0.214 1.731 1 0.188 0.754 0.496 1.148 
  Frequency of BM (1) -0.548 0.212 6.69 1 0.010 0.578 0.381 0.876 
  Diet (1) -0.409 0.316 1.674 1 0.196 0.665 0.358 1.234 
  Constant -0.648 0.31 4.377 1 0.036 0.523    
Step 7a Frequency of BM (1) -0.502 0.209 5.773 1 0.016 0.605 0.402 0.912 
  Diet (1) -0.427 0.315 1.839 1 0.175 0.652 0.352 1.21 
  Constant -0.793 0.291 7.458 1 0.006 0.452    
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  B S.E. Wald df Sig. 
Exp 
(B) 
95% C.I. for 
Exp(B) 
Lower Upper 
Step 8a Frequency of BM (1) -0.501 0.209 5.753 1 0.016 0.606 0.403 0.913 
  Constant -0.846 0.288 8.62 1 0.003 0.429     
a Variable(s) entered on step 1: Gender, Age, Body Mass Index, Frequency of BM, Diet, Alcohol 
Use, Tobacco Use, Seasonality 
 
Model if term removed     
Variable   Model Log Likelihood 
Change in -2 
Log Likelihood df 
Sig. of the 
Change 
Step 1 Gender  -342.96 2.37 1 0.124 
  Age  -342.514 1.477 3 0.688 
  Body Mass Index -342.03 0.51 1 0.475 
  Frequency of BM (1) -344.686 5.823 1 0.016 
  Diet  -342.888 2.226 1 0.136 
  Alcohol Use  -342.013 0.477 2 0.788 
  Tobacco Use  -342.379 1.209 2 0.546 
  Seasonality  -343.978 4.407 3 0.221 
Step 2 Gender  -343.11 2.193 1 0.139 
  Age  -342.712 1.397 3 0.706 
  Body Mass Index -342.281 0.535 1 0.465 
  Frequency of BM (1) -344.908 5.79 1 0.016 
  Diet  -343.067 2.108 1 0.147 
  Tobacco Use  -342.682 1.337 2 0.513 
  Seasonality  -344.197 4.368 3 0.224 
Step 3 Gender  -343.865 2.307 1 0.129 
  Body Mass Index -343.178 0.932 1 0.334 
  Frequency of BM (1) -345.524 5.624 1 0.018 
  Diet  -343.759 2.094 1 0.148 
  Tobacco Use  -343.315 1.207 2 0.547 
  Seasonality  -344.946 4.468 3 0.215 
Step 4 Gender  -344.392 2.152 1 0.142 
  Body Mass Index -343.821 1.011 1 0.315 
  Frequency of BM (1) -346.189 5.746 1 0.017 
  Diet  -344.348 2.065 1 0.151 
  Seasonality  -345.518 4.405 3 0.221 
Step 5 Gender  -344.615 1.589 1 0.207 
  Frequency of BM (1) -346.894 6.147 1 0.013 
  Diet  -344.721 1.8 1 0.180 
  Seasonality  -345.947 4.252 3 0.235 
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Model if term removed (continued)     
Variable   Model Log Likelihood 
Change in -2 
Log Likelihood df 
Sig. of the 
Change 
Step 6 Gender  -346.834 1.774 1 0.183 
  Frequency of BM (1) -349.452 7.01 1 0.008 
  Diet  -346.85 1.805 1 0.179 
Step 7 Frequency of BM (1) -349.853 6.038 1 0.014 
  Diet  -347.83 1.992 1 0.158 
Step 8 Frequency of BM (1) -350.838 6.017 1 0.014 
 
Variables not in the equation     
      Score df Sig. 
Step 2a Variables Alcohol Use  0.461 2 0.794 
  Alcohol Use (1) 0.093 1 0.761 
  Alcohol Use (2) 0.451 1 0.502 
 Overall Statistics  0.461 2 0.794 
Step 3b Variables Age 1.401 1 0.705 
   Age (2) 0.044 1 0.834 
    Age (3) 0.353 1 0.552 
    Alcohol Use  0.384 2 0.825 
    Alcohol Use (1) 0.120 1 0.729 
    Alcohol Use (2) 0.384 1 0.536 
  Overall Statistics   1.861 5 0.868 
Step 4c Variables Age  1.271 3 0.736 
    Age (1) 0.483 1 0.487 
    Age (2) 0.047 1 0.828 
    Age (3) 0.321 1 0.571 
    Alcohol Use  0.487 2 0.784 
    Alcohol Use (1) 0.113 1 0.736 
    Alcohol Use (2) 0.482 1 0.487 
    Tobacco Use  1.142 2 0.565 
    Tobacco Use (1) 0.178 1 0.673 
    Tobacco Use (2) 0.882 1 0.348 
  Overall Statistics   3.002 7 0.885 
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Variables not in the equation (continued)     
      Score df Sig. 
Step 5d Variables Age  1.658 3 0.646 
    Age (1) 0.497 1 0.481 
    Age (2) 0.039 1 0.844 
    Age (3) 0.528 1 0.467 
    Body Mass Index 1.009 1 0.315 
    Alcohol Use  0.516 2 0.773 
    Alcohol Use (1) 0.157 1 0.692 
    Alcohol Use (2) 0.516 1 0.473 
    Tobacco Use  1.216 2 0.545 
    Tobacco Use (1) 0.193 1 0.661 
    Tobacco Use (2) 0.935 1 0.334 
  Overall Statistics   4.011 8 0.856 
Step 6e Variables Age  1.740 3 0.628 
    Age (1) 0.635 1 0.425 
    Age (2) 0.058 1 0.809 
    Age (3) 0.461 1 0.497 
    Body Mass Index 0.857 1 0.355 
    Alcohol Use  0.498 2 0.780 
    Alcohol Use (1) 0.185 1 0.667 
    Alcohol Use (2) 0.496 1 0.481 
    Tobacco Use  1.157 2 0.561 
    Tobacco Use (1) 0.202 1 0.653 
    Tobacco Use (2) 0.862 1 0.353 
    Seasonality  4.141 3 0.247 
    Seasonality (1) 2.453 1 0.117 
    Seasonality (2) 0.638 1 0.424 
    Seasonality (3) 1.789 1 0.181 
  Overall Statistics   8.121 11 0.702 
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Variables not in the equation (continued)     
      Score df Sig. 
Step 7f Variables Gender (1) 1.738 1 0.187 
    Age  1.735 3 0.629 
    Age (1) 0.513 1 0.474 
    Age (2) 0.055 1 0.815 
    Age (3) 0.575 1 0.448 
    Body Mass Index 0.345 1 0.557 
    Alcohol Use  0.300 2 0.861 
    Alcohol Use (1) 0.101 1 0.751 
    Alcohol Use (2) 0.300 1 0.584 
    Tobacco Use  1.004 2 0.605 
    Tobacco Use (1) 0.201 1 0.654 
    Tobacco Use (2) 0.719 1 0.396 
    Seasonality  4.324 3 0.229 
    Seasonality (1) 2.550 1 0.110 
    Seasonality (2) 0.635 1 0.425 
    Seasonality (3) 2.022 1 0.155 
  Overall Statistics   9.852 12 0.629 
Step 8g Variables Gender (1) 1.918 1 0.166 
    Age  1.679 3 0.642 
    Age (1) 0.422 1 0.516 
    Age (2) 0.052 1 0.820 
    Age (3) 0.638 1 0.424 
    Body Mass Index 0.197 1 0.657 
    Diet (1) 1.862 1 0.172 
    Alcohol Use  0.226 2 0.893 
    Alcohol Use (1) 0.124 1 0.725 
    Alcohol Use (2) 0.212 1 0.645 
    Tobacco Use  0.975 2 0.614 
    Tobacco Use (1) 0.240 1 0.624 
    Tobacco Use (2) 0.648 1 0.421 
    Seasonality  4.354 3 0.226 
    Seasonality (1) 2.580 1 0.108 
    Seasonality (2) 0.576 1 0.448 
    Seasonality (3) 2.198 1 0.138 
  Overall Statistics   11.703 13 0.552 
a Variable(s) removed on step 2: Alcohol Use 
b Variable(s) removed on step 3: Age 
c Variable(s) removed on step 4: Tobacco Use 
d Variable(s) removed on step 5: Body Mass Index 
e Variable(s) removed on step 6: Seasonality 
f Variable(s) removed on step 7: Gender 
g Variable(s) removed on step 8: Diet 
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Casewise listb        
Case Selected Statusa 
Observed 
Predicted Predicted Group 
Temporary Variable 
Result of 
Screening  Resid ZResid SResid 
20 S P** 0.136 D 0.864 2.518 2 
21 S P** 0.136 D 0.864 2.518 2 
42 S P** 0.136 D 0.864 2.518 2 
43 S P** 0.136 D 0.864 2.518 2 
46 S P** 0.136 D 0.864 2.518 2 
59 S P** 0.136 D 0.864 2.518 2 
61 S P** 0.136 D 0.864 2.518 2 
71 S P** 0.136 D 0.864 2.518 2 
85 S P** 0.136 D 0.864 2.518 2 
94 S P** 0.136 D 0.864 2.518 2 
97 S P** 0.136 D 0.864 2.518 2 
98 S P** 0.136 D 0.864 2.518 2 
103 S P** 0.136 D 0.864 2.518 2 
115 S P** 0.136 D 0.864 2.518 2 
119 S P** 0.136 D 0.864 2.518 2 
121 S P** 0.136 D 0.864 2.518 2 
419 S P** 0.136 D 0.864 2.518 2 
421 S P** 0.136 D 0.864 2.518 2 
444 S P** 0.136 D 0.864 2.518 2 
480 S P** 0.136 D 0.864 2.518 2 
519 S P** 0.136 D 0.864 2.518 2 
520 S P** 0.136 D 0.864 2.518 2 
548 S P** 0.136 D 0.864 2.518 2 
590 S P** 0.136 D 0.864 2.518 2 
592 S P** 0.136 D 0.864 2.518 2 
593 S P** 0.136 D 0.864 2.518 2 
595 S P** 0.136 D 0.864 2.518 2 
619 S P** 0.136 D 0.864 2.518 2 
624 S P** 0.136 D 0.864 2.518 2 
627 S P** 0.136 D 0.864 2.518 2 
628 S P** 0.136 D 0.864 2.518 2 
653 S P** 0.136 D 0.864 2.518 2 
685 S P** 0.136 D 0.864 2.518 2 
708 S P** 0.136 D 0.864 2.518 2 
713 S P** 0.136 D 0.864 2.518 2 
726 S P** 0.136 D 0.864 2.518 2 
728 S P** 0.136 D 0.864 2.518 2 
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Casewise listb (continued) 
Case Selected Statusa 
Observed 
Predicted Predicted Group 
Temporary Variable 
Result of 
Screening  Resid ZResid SResid 
731 S P** 0.136 D 0.864 2.518 2 
a S = Selected, U = Unselected cases, and ** = Misclassified cases      
b Cases with studentized residuals greater than 2.000 are listed       
 













1 1 Pass Fewer than two 0.20645 Defer 
2 4 Defer Fewer than two 0.20645 Defer 
3 5 Pass Fewer than two 0.20645 Defer 
4 11 Defer Fewer than two 0.20645 Defer 
5 13 Defer Two or more 0.13620 Defer 
6 14 Pass Fewer than two 0.20645 Defer 
7 18 Defer Fewer than two 0.20645 Defer 
8 19 Defer Fewer than two 0.20645 Defer 
9 21 Defer Fewer than two 0.20645 Defer 
10 23 Defer Two or more 0.13620 Defer 
11 24 Defer Two or more 0.13620 Defer 
12 25 Pass Fewer than two 0.20645 Defer 
13 26 Pass Fewer than two 0.20645 Defer 
14 27 Defer Two or more 0.13620 Defer 




STOOL DONOR CHARACTERISTICS 
 
166 
Appendix J. Results of forced entry simple logistic regression models 
 
Model Variables  





Gender        
Female 0.201 0.210 0.919 0.338 1.223 0.810 1.847 
Constant -1.656 0.177 87.47 0.000* 0.191     
Age        
18 to 24 years of age   1.518 0.678    
25 to 29 years of age 0.343 0.326 1.107 0.293 1.409 0.744 2.668 
30 to 34 years of age 0.143 0.323 0.195 0.659 1.153 0.612 2.174 
35 to 50 years of age 0.296 0.350 0.715 0.398 1.345 0.677 2.671 
Constant -1.735 0.280 38.363 0.000* 0.176   
Body Mass Index -0.025 0.036 0.503 0.478 0.975 0.909 1.046 
Constant -0.921 0.841 1.199 0.274 0.398   
Frequency of BM        
Two or more per day 0.501 0.209 5.753 0.016* 1.650 1.096 2.484 
Constant -1.847 0.175 112.003 0.000* 0.158   
Diet        
No Meat -0.424 0.314 1.818 0.178 0.655 0.354 1.212 
Constant -1.042 0.360 8.401 0.004* 0.353   
Alcohol Use        
None   0.229 0.892    
Moderate 0.164 0.394 0.174 0.676 1.179 0.545 2.549 
High 0.156 0.334 0.219 0.639 1.169 0.608 2.249 
Constant -1.658 0.315 27.717 0.000* 0.190   
Tobacco Use        
None   1.119 0.572    
Former 0.390 0.419 0.863 0.353 1.476 0.649 3.360 
Current 0.209 0.500 0.175 0.676 1.233 0.463 3.286 
Constant -1.861 0.406 20.974 0.000* 0.156   
Seasonality        
Winter    4.891 0.180    
Spring -0.085 0.238 0.127 0.721 0.919 0.576 1.464 
Summer -0.592 0.302 3.839 0.050 0.553 0.306 1.000 
Fall -0.361 0.268 1.820 0.177 0.697 0.413 1.177 
Constant -1.313 0.166 62.494 0.000* 0.269   
* Significant at the p value level of <0.05 
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The plot at position 200 was generated using a random sampling of 10,000 out of 3,048,790 
sequences without replacement. The minimum sequence length identified during subsampling 
was 248 bases. Outlier quality scores are not shown in box plots for clarity. 
 
Parametric seven-number summary for position 200 
Box Plot Feature Percentile Quality Score 
(Not shown in box plot) 2nd 12 
Lower Whisker 9th 12 
Bottom of Box 25th 24 
Middle of Box 50th (Median) 32 
Top of Box 75th 37 
Upper Whisker 91st 37 
(Not shown in box plot) 98th 38 
 
  






The plot at position 200 was generated using a random sampling of 10,000 out of 3,048,790 
sequences without replacement. The minimum sequence length identified during subsampling 
was 248 bases. Outlier quality scores are not shown in box plots for clarity. 
 
Parametric seven-number summary for position 200 
Box Plot Feature Percentile Quality Score 
(Not shown in box plot) 2nd 12 
Lower Whisker 9th 13 
Bottom of Box 25th 15 
Middle of Box 50th (Median) 31 
Top of Box 75th 37 
Upper Whisker 91st 38 







STOOL DONOR CHARACTERISTICS 
 
169 
Appendix L. Change in descriptive statistics for continuous variables between Aim 1 and 
Aim 2 
 
  N Range Minimum Maximum 
Age Aim 1 744 31.0 18.0 49.0  
Aim 2 87 26.0 19.0 45.0  
Change 
 
5.0 -1.0 4.0 
Body Mass 
Index 
Aim 1 744 12.9 16.9 29.8 
Aim 2 87 11.6 17.5 29.1 




Aim 1 744 4.5 0.5 5.0 
Aim 2 87 3.0 0.5 3.5 
Change 
 
1.5 0.0 1.5 
Alcohol Use Aim 1 744 20.0 0.0 20.0  
Aim 2 87 10.0 0.0 10.0 
  Change   10.0 0.0 10.0 
 
    Mean Std. Deviation Variance Statistic Std. Error 
Age Aim 1 28.1 0.23 6.19 38.25  
Aim 2 27.3 0.60 5.48 30.00  
Change 0.8 -0.40 0.70 8.25 
Body Mass 
Index 
Aim 1 23.6 0.10 2.69 7.22 
Aim 2 23.2 0.30 2.55 6.49 




Aim 1 1.7 0.02 0.67 0.45 
Aim 2 1.6 0.10 0.67 0.45 
Change 0.1 0.00 0.00 0.00 
Alcohol Use Aim 1 2.9 0.10 2.71 7.33  
Aim 2 3.1 0.30 2.47 6.12 
  Change -0.1 -0.20 0.20 1.21 
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Appendix M. Change in descriptive statistics for categorical variables between Aim 1 and 
Aim 2 
 
    Frequency Percent Cumulative Percent 
Gender Male Aim 1 507 68.1% 68.1% 
  Aim 2 63 72.4% 72.4% 
   Change 444 -4.3%   
 Female Aim 1 237 31.9% 100.0% 
  Aim 2 24 27.6% 100.0% 
   Change 213 4.3%   
 Total Aim 1 744   
  Aim 2 87   
    Change 657 88.3%   
Diet Meat Based Aim 1 645 86.7% 86.7% 
  Aim 2 79 90.8% 90.8% 
  Change 566 -4.1%  
 No Meat Aim 1 99 13.3% 100.0% 
  Aim 2 8 9.2% 100.0% 
   Change 91 4.1%   
 Total Aim 1 744   
  Aim 2 87   
    Change 657 88.3%   
Tobacco Use Never Aim 1 605 81.3% 81.3% 
  Aim 2 73 83.9% 83.9% 
  Change 532 -2.6%  
 Former Aim 1 87 11.7% 93.0% 
  Aim 2 8 9.2% 93.1% 
   Change 79 2.5%   
 Current Aim 1 52 7.0% 100.0% 
  Aim 2 6 6.9% 100.0% 
  Change 46 0.1%  
 Subtotal Aim 1 744     
  Aim 2 87   
   Change 657 88.3%   
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    Frequency Percent Cumulative Percent 
Seasonality Winter Aim 1 217 29.2% 29.2% 
  Aim 2 29 33.3% 33.3% 
  Change 188 -4.2%  
 Spring Aim 1 139 18.7% 47.8% 
  Aim 2 11 12.6% 46.0% 
   Change 128 6.0%  
 Summer Aim 1 171 23.0% 70.8% 
  Aim 2 17 19.5% 65.5% 
  Change 154 3.4%   
 Fall Aim 1 217 29.2% 100.0% 
  Aim 2 30 34.5% 100.0% 
   Change 187 -5.3%  
 Total Aim 1 744     
  Aim 2 87   
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9. Bacteria, unclassified OTU1492 
10. Bacteria, unclassified OTU16 
11. Bacteria, unclassified OTU443 
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Appendix Q. Principal coordinates of analyses (PCoA) utilizing bray-curtis, emperor plot 
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Appendix R. Box and whisker plot of alpha diversity per frequency of bowel movements 
per day category 
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Appendix X. Casewise diagnostics to evaluate for potential outliers 
 
Casewise Diagnosticsa 





72 -3.049 45.5 80.219 -34.7685 
a Dependent Variable: Efficacy %  
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Appendix BB. Results from model 1 for the Aim 2 simple linear regression 
 
Descriptive Statistics 
Variable N Mean Std. Dev. 
Efficacy % 87 78.9 11.5 
Alpha Diversity log-
transformed 
87 0.255 0.1 
 
Correlations     










Sig. (1-tailed) Efficacy %  0.07 
  Alpha Diversity log-transformed 
0.07 
 
N  Efficacy % 87 87 




Variables Entered / Removeda       
Model Variables Entered 
Variables 
Removed Method 
1 Alpha Diversity log-transformedb 
 Enter 
a Dependent Variable: Efficacy % 
b All requested variables entered. 
 
Model Summaryb       
Model R R Square 
Adj R 
Square 
Std. Error of 
the Estimate 
1 0.159a 0.025 0.014 11.405 
a Predictors: (Constant), Alpha Diversity log-transformed 
b Dependent Variable: Efficacy % 
 
Model Change Statistics 















 Model  Sum of Squares df 
Mean 
Square F Sig. 
1 Regression 288.3 1 288.3 2.217 0.14b 
 Residual 11,055.9 85 130.1   
 Total 11,344.2 86    
a Dependent Variable: Efficacy % 
b Predictors: (Constant), Alpha Diversity log-transformed 
 
Coefficientsa 




cients t Sig.  
95% C.I. for 
Exp(B) 
 B S.E. Beta Lower Upper 






-16.337 10.973 -0.159 -1.489 0.140 -38.154 5.481 
a Dependent Variable: Efficacy % 
 




Residual Efficacy % 
Predicted 
Value Residual 
72 -3.061 45.5 80.301 -34.851 
a Dependent Variable: Efficacy % 
 
Residuals Statisticsa 
 Minimum Maximum Mean Std. Dev. N 
Predicted Value 72.128 82.202 78.935 1.936 87 
Residual -34.851 21.638 0.000 11.321 87 
Std. Predicted 
Value -3.516 1.687 0.000 1.000 87 
Std. Residual -3.06 1.900 0.000 0.994 87 
a Dependent variable: Efficacy % 
 
 
 
 
 
